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MOLECULAR INTERVENTION IN MOUSE MODELS OF 
AMYOTROPHIC LATERAL SCLEROSIS AND 
ALZHEIMER’S DISEASE – NEUROPATHOLOGY AND BEHAVIOR 
 
 
Steven Prescott Bennett 
 
 
ABSTRACT 
 
 Neurodegeneration describes the progressive loss of structure and function of 
neurons, leading ultimately to cell and organism death.  Although the initiating factors of 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and 
Amyotrophic Lateral Sclerosis may be different, they share common pathophysiologies.  
Proteinopathies, as these diseases are now termed, are characterized by atypical deposits 
of proteins, often due to misfolding.  Associated with these deposits are dysfunctional 
mitochondria, oxidative stress, disrupted axonal transport, inflammation, and apoptotic 
cell death.  If this occurs in motor neurons, as in ALS, ataxia precedes death with little or 
no change in cognition.  On the other hand, if the deposits are found in cortical neurons, 
as in Alzheimer’s disease, the outcome is dementia and motor function remains largely 
intact.  Each disease is selective for particular types of neurons and brain regions.  
Although research has elucidated much of the molecular biology involved in these 
diseases, their initiating causes remain largely unknown.  
 Most of our current understanding originated with the identification of gene 
mutations that cause rare familial forms of these diseases.  As a result, numerous strains 
of transgenic animals have been developed to study neurodegenerative disease 
phenomena and were central to the studies presented in this body of work.  Novel routes 
of drug and gene delivery are described here as well as characterization of the mouse 
models studied.  In particular, this work demonstrates that the blood brain barrier is 
 xiv 
disrupted in ALS followed by the formation of autorosettes in ALS mice.  In various 
Alzheimer’s disease mouse models, it was demonstrated that the acute phase reactant 
alpha-1-antichymotrypsin (ACT) not only interacts with amyloid plaques, but also 
induces tau phosphorylation in vivo; tying together these disease hallmarks.  It was also 
shown that small fragments of Aβ (1-11) could disrupt the formation of mature amyloid 
plaques in these mice.  Lastly, it was demonstrated that mature plaques could also be 
decreased by intracranial delivery of granulocyte-macrophage stimulating factor (GM-
CSF).  My dissertation research goal was to understand and develop these treatment 
strategies based on protein disaggregation, neuroprotection, and inflammation, 
meanwhile developing novel methods for targeted delivery of molecules into the CNS of 
mice. 
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CHAPTER 1 – INTRODUCTION 
 
1.1.  Introduction to neurodegenerative disease      
                                   
 While all diseases, especially those that are fatal, are devastating, there is an 
additional sense of loss when those diseases affect our minds – often considered the core 
that makes us human.  Although the exact pathophysiology of different 
neurodegenerative diseases varies, they share certain commonalities, and all involve 
selective vulnerability of neurons in distinct brain regions.  For example, there are 
properties of motor neurons that make them selectively vulnerable to cell death in 
amyotrophic lateral sclerosis, and properties of cortical and hippocampal neurons that 
make these neurons susceptible to Alzheimer’s disease.  In either case, the outcome is 
progressive neuronal death that is terminal to the patient. 
 Collectively, neurodegenerative diseases are a leading cause of death in the U.S.  
There are currently over 5 million Alzheimer’s cases, 1.5 million Parkinson’s, 30,000 
ALS, and 30,000 Huntington’s patients.  In addition 150,000 people are annually 
diagnosed as “at risk” patients and about 300 cases of prion disease are counted annually 
(Centers of Disease Control and Prevention).  Despite decades of research dedicated to 
each of these diseases, there are no cures to date.  Indeed, those drugs currently 
prescribed provide modest, if any, alleviation of symptoms and may delay death for just 
weeks or months.  Therefore, novel therapies are urgently needed and strongly sought, 
some with the intent to be effective for multiple neurodegenerative disorders. 
 The most common molecular mechanism of neurodegenerative diseases, and a 
primary focus of my work, is the misfolding of proteins that leads to extracellular and/or 
intracellular proteinaceous aggregates.  Typically, these inclusions/plaques include 
molecular chaperones and polyubiquitinated proteins, indicating that the cellular 
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mechanisms for protein folding, quality control and protein degradation are overwhelmed 
in protein misfolding diseases (PMDs)/proteinopathies (reviewed in Soto and Estrada, 
2008). Another component of neurodegenerative diseases is inflammation, which is both 
a response to aggregates and contributes to their formation.  The activation of microglia 
and astrocytes and the subsequent release of various cytokines and chemokines induce a 
local, chronic state of inflammation in the affected brain regions (McGeer and McGeer, 
1995).  The involvement of astrocytes ties inflammation to another aspect of 
neurodegeneration: glutamate excitotoxicity (Abraham et al., 2001).  Astrocytes are 
known to surround glutaminergic synapses where they express GLT-1 (EAAT2) - 
glutamate transport molecules which function to rapidly clear this neurotransmitter.  
Failure to adequately clear glutamate can lead to abnormally elevated glutamate levels at 
the synapse, in turn causing surges of calcium into post-synaptic neurons (reviewed in 
Amara and Fontana 2002).  Although, Ca2+ entry partly underlies the process of synaptic 
plasticity, disruption of calcium homeostasis by excess Ca2+ has a pronounced deleterious 
impact on neurons and surrounding glia.  Calcium reacts within the cell, altering 
enzymatic activities, inducing damage to DNA and organelles, and negatively affecting 
axonal transport and cytoskeletal organization (Gennarelli et al., 1993).   
Excess intracellular calcium is also one of several conditions that lead to 
dysregulation of mitochondria.  Mitochondrial dysfunction is problematic because it 
burdens the cell with reactive oxygen species (ROS) and induces oxidative stress.  
Moreover, an intrinsic apoptotic pathway can be activated by the release of cytochrome c 
from the mitochondrial inner membrane, leading to programmed cell death (PCD) or 
apoptosis (reviewed by Onyango et al., 2006).  Indeed, neuronal apoptosis is a common, 
final event in virtually all neurodegenerative diseases. 
 While all neurodegenerative diseases have a genetic component, only 5-10% of 
patients represent cases where the genetic mutation leading to the autosomal dominantly 
inherited familial forms of both AD and ALS are known. Additional genetic and 
epigenetic components as well as environmental contributions still have to be determined.  
It is for this reason that most of the knowledge acquired about ALS and AD comes from 
the finding and analysis of genetic mutations throughout human populations.  Because 
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the phenotypes of familial and sporadic cases are so similar for each disease, those 
mutations have been the most useful means to study disease progression and develop 
possible therapeutic interventions for both familial and sporadic forms of the diseases.  
Protective as well as risk enhancing environmental or life style factors for each disease 
have also been described.  For example, educational/environmental “enrichment” and 
developing Alzheimer’s disease seem to be negatively correlated, i.e. these factors have a 
protective effect, while in ALS a positive correlation, a disease causing/enhancing impact 
of physical exertion as has been reported for example with soldiers and athletes (Belli and 
Vanacore, 2005; Haley, 2003). 
 Once mutations in the disease-related genes were identified and the genes were 
cloned, in vitro and in vivo models were developed to test various hypotheses on disease 
progression and therapy.  Cell culture and organotypic tissue culture have proven useful 
in answering very targeted scientific questions. However, for the study of protein 
aggregation in CNS tissues, a more systemic approach with animal studies was needed.  
Accordingly, several different lines of transgenic mice have been developed over the past 
15 years to analyze the formation of protein aggregates in vivo.  Such mouse models of 
AD and ALS were the main subjects of my work which investigated causes and 
treatments for Protein Misfolding Diseases in the brain. 
 
1.2.  Amyotrophic Lateral Sclerosis   
 
1.2.1.  ALS Pathology  
 
Amyotrophic Lateral Sclerosis (ALS) is currently the most common motor neuron 
disease, affecting roughly 30,000 people in the U.S. with a lifetime risk of 1 in 2000.   
Originally called Charcot’s disease after the French neurobiologist and physician Jean-
Martin Charot, who first characterized the disease in 1869, it has more recently been 
named Lou Gehrig’s disease after the famous Yankees baseball player who was 
diagnosed with ALS in 1939 and died 2 years later at the age of 37.  ALS is characterized 
by disruption of the cytoskeleton in motor neurons (Williamson et al., 1998), reactive 
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gliosis (Leigh and Swash, 1991), accumulation of intracellular proteinaceous inclusions 
(Bruijn et al., 1998), neurofilament abnormalities and formation of axonal spheroids 
(Carpenter, 1968; Gonatas et al., 1992; Hirano et al., 1984; Leigh et al., 1991), loss of 
myelinated fibers in the ventral roots of corticospinal tracts (Delisle and Carpenter, 
1984), and disruption of the blood brain barrier (Garbuzova-Davis et al., 2007c).  
Selective death of motor neurons occurs in the motor cortex, brainstem, and spinal cords 
of affected individuals (Rowland and Shneider, 2001b).  
 ALS is a devastating disease, causing spasticity, hyperreflexia, generalized 
weakness, muscle atrophy and paralysis (Mulder et al., 1986), all leading to death within 
2-5 years of onset, most commonly from respiratory failure.  ALS primarily targets the 
large caliber alpha motor neurons in the anterior horn of the spinal cord, 35-100μm in 
diameter (Ravits et al., 2007).  The average age of diagnosis varies, but generally 
symptoms occur between 40-60 years of age (Hirtz et al., 2007).  90-95% of ALS cases 
are sporadic, that is, there are no known genetic or environmental causes, despite the high 
prevalence of the disease in certain populations (Belli and Vanacore, 2005; Haley, 2003; 
Horner et al., 2003; Mulder and Kurland, 1987; Vanacore et al., 2006).  Most knowledge 
about the disease has so far been gained from mutations in 6 different genes that underlie 
ALS (Gros-Louis et al., 2006).  These genetic predispositions accounts for only 5-10% of 
all ALS cases, but because the phenotypes of familial and sporadic ALS are so similar, 
these mutations have been valuable tools in understanding the disease pathogenenesis. 
 
1.2.2.  Major Genes and Proteins in ALS  
 
 The most common gene that harbors mutations leading to familial ALS is 
superoxide dismutase (SOD1) (Rosen, 1993).  SOD1 functions as a 32 kD homodimer 
and each subunit of 153 amino acids is encoded by 5 exons on chromosome 21q22 
(Siddique et al., 1991).  The primary function of SOD1 is to convert toxic superoxide 
radicals, produced by mitochondria during oxidative phosphorylation, to molecular 
oxygen and hydrogen peroxide.  Appropriately, the protein is found in the cytosol, 
nucleus, mitochondrial inner membrane, and peroxisomes of cells to exert its antioxidant 
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effects (Bruijn et al., 2004b).  The precise role of SOD1 in the progression of ALS is not 
completely known. However, the prevalence and number of mutations in the human gene 
encoding SOD1 strongly indicated a role for the protein in the disease progression. 
 Although the protein is relatively small, there have been over 150 mutations 
identified in hSOD1 since the first was identified over 15 years ago (Rosen, 1993).  
Collectively, mutations in SOD1 account for about 3% of all ALS cases (Andersen, 
2006). SOD1 is a ubiquitously expressed Cu/Zn metalloenzyme with zinc providing 
structural stability and copper coordinating the alternating transfer of electrons to both 
oxidize and reduce superoxide (Beckman et al., 1993).  Each SOD1 monomer contains 
one Cu/Zn active site. However, mutations within this active site do not lead to any 
different ALS phenotype than mutations in other parts of the molecule (Borchelt et al., 
1994; Bowling et al., 1995).  Therefore it is likely not the activity of the enzyme itself 
that promotes the disease, but rather a structural change in the molecule with strong 
downstream effects. This information, together with the fact that SOD1 knockout mice do 
not develop disease symptoms, supports the hypothesis that the involvement of SOD1 in 
the pathogenesis of ALS is a result of a toxic-gain-of- function (Shaw, 2005).  This view 
leads to the conclusion that irrespective of the specific mutation, mutant SOD1 has taken 
on a new function, independent of its enzymatic activity, and that this function is toxic to 
the cell.  The inheritance pattern of SOD1 mutations, like most neurodegenerative 
diseases, is autosomal dominant (Siddique et al., 1996) 
 
1.2.3.  Genes and Major Mouse Models of ALS  
 
1.2.3.1.  SOD1 
 
 Currently 12 mouse models of ALS have been developed that harbor some of the 
indentified mutant forms of human SOD 1 and are used to study ALS and potential 
therapeutics.  The most intensely studied genetic variations are three point mutations 
leading to the single amino acid substitutions G93A (Gurney, 1994), G37R (Wong et al., 
1995), G85R (Bruijn et al., 1997), all of which are used to study disease progression at 
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different rates.  The G93A mouse model, for example, begins showing symptoms as early 
as 10 weeks and the animals die at 13-16 weeks.  The G85R model, on the other hand, 
begins showing symptoms at 5 months and the mice die by 8-9 months.  There are 
advantages to all different SOD1 mice, because some studies require longer therapeutic 
windows and others aim for fast responses.   
 The pathophysiology of SOD1 mutant mice is very similar to that of ALS 
patients, i.e. the primary pathological event is a progressive loss of both upper and lower 
motor neurons (Gurney, 1994) and mitochondrial vacuolization (Dalcanto and Gurney, 
1995) leading to severe hind limb weakness.  These events are accompanied by reactive 
microgliosis and astrocytosis and localized inflammation (Hall et al., 1998a), the 
formation of intracellular proteinaceous inclusions (Johnston et al., 2000), neurofilament 
positive inclusions (Tu et al., 1996), and fragmentation of the Golgi apparatus 
(Mourelatos et al., 1996).  Other events are glutamate excitotoxicity (Rothstein et al., 
1990), abnormal axonal transport (Williamson and Cleveland, 1999), and abnormal 
regulation of growth factors (Lambrechts et al., 2003). Importantly, in all cases the 
pathological cascade culminates finally in the activation of caspase 3 (Li et al., 2000; 
Pasinelli et al., 2000; Vukosavic et al., 2000), and the induction of cell death.  Although it 
is generally disputed if aggregate formation is the cause, a byproduct, or even a protective 
mechanism in neurodegenerative disease, there is no doubt that the presence of inclusions 
in ALS and the downstream effects of mutant SOD1 on subcellular organelles as well as 
the activation of programmed cell death (PCD) make SOD1 a very attractive molecule 
for the investigation of this disease. 
 
1.2.3.2.  ALS2 
 
 In another ALS related gene, ALS2 (alsin) some disease related mutations have 
been identified. ALS2 is located on chromosome 2 and was recently shown to cause rare, 
juvenile onset forms of motor neuron disease which progress slowly, and strongly 
resemble the symptoms of ALS (Hadano et al., 2001; Yang et al., 2001).  The ALS2 
encoded protein, alsin, is a 184-kD protein that has been shown to have 3 putative 
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guanine-nucleotide-exchange factor domains (GEFs).  Alsin binds to the periphery of 
endosomes and is involved with the Ras superfamily of G protein receptors (Yamanaka et 
al., 2003).  Specifically, GEFs catalyze the dissociation of GDP from G-proteins and act, 
in vitro, as an exchange factor for Rab5 (Otomo et al., 2003), a molecule known to be 
involved in endosomal trafficking.  Alsin is enriched in nervous tissue and the mutations 
that have been identified so far are very unstable (Yamanaka et al., 2003), suggesting a 
loss of activity in one or more of the GEF domains.  Recently, animal models harboring 
mutations in alsin (ALS2) have been generated for further investigation. 
 
1.2.3.3.  TDP-43   
 
Another protein that has drawn some attention over the past few years is TDP-43 
(TAR DNA Binding protein 43).  TDP-43 is a 43 kDa protein encoded by the TARDBP 
gene located on chromosome 1 and is expressed ubiquitously, including the CNS, where 
it is found in neuronal and glial nuclei and to a lesser extent in the cytoplasm (Geser et 
al., 2009).  The diverse functions of TDP-43 are not completely understood, but it is 
believed to stabilize low molecular weight neurofilaments (Strong et al., 2007), modulate 
cdk6 expression (Ayala et al., 2008a; Ayala et al., 2008b), act as a scaffold for nuclear 
bodies (Wang et al., 2004), and affect microRNA biogenesis (Gregory et al., 2004), cell 
cycle, apoptosis (Ayala et al., 2008b), and mRNA transport and regulation of its 
translation at synapses (Wang et al., 2004).  The protein, which can be abnormally 
phosphorylated and misfolded, was originally discovered in patients with Frontotemporal 
Dementia (FTD) and has recently been discovered in the inclusions of both familial and 
sporadic cases of ALS (Arai et al., 2006; Neumann et al., 2006).  Research results 
involving the role(s) of TDP-43 in neurodegenerative disease have been somewhat 
conflicting, but its presence in the inclusions of ALS patients has made it a very 
appealing target for therapeutic interventions. 
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1.2.4.  ALS and excitotoxicity  
 
The most convincing link between sporadic and familial forms of ALS involves 
glutamate excitotoxicity (Rothstein et al., 1990).  The neurotransmitter glutamate has 
been implicated in ALS because excess glutamate levels were discovered in the 
cerebrospinal fluid (CSF) of roughly half of the ALS patients sampled (Rothstein et al., 
1991; Rothstein et al., 1990; Shaw et al., 1995).  Excess glutamate induces repetitive 
firing of neurons leading to increases of intracellular calcium levels through increased 
permeability of calcium-permeable glutamate receptors (Beers et al., 2001).  A 
supporting phenomenon towards glutamate excess as a possible cause for the selective 
death of motor neurons in ALS is the fact that excess glutamate is cleared much less 
efficiently from synapses in sporadic and familial ALS cases and accordingly in most 
ALS cases, glutamate clearance is dysregulated.  Typically, finger-like projections from 
astrocytes rich in the glutamate transporter EAAT2 (GLT-1) surround synapses in order 
to rapidly clear glutamate (Rothstein et al., 1996; Tanaka et al., 1997).  This transport 
molecule, however, shows pronounced down-regulation in ALS (in response to caspase 
3), supporting glutamate excitotoxicity as a potential cause for ALS.  Riluzole, a drug 
that functions to deactivate NMDA receptors and reduce synaptic glutamate levels, is 
currently the only effective drug for ALS that is FDA approved (Gurney et al., 1998).  
Further studies revealed that glutamate may also be responsible for other 
neurodegenerative diseases, namely Alzheimer’s and Parkinson’s disease (Beal, 1998; 
Hynd et al., 2004). 
 
1.2.5.  ALS and the cytoskeleton  
 
 Most neurodegenerative proteinopathies, including both sporadic and familial 
ALS (Carpenter, 1968; Chou and Fakadej, 1971; Hirano, 1991; Hirano et al., 1984) show 
some disturbation of neurofilament content and assembly.   Neurofilaments are neuron-
specific intermediate filaments and are the most abundant structural proteins found in 
neurons.  They are thought to add rigidity, tensile strength and intracellular guidance for 
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transport along axons and dendrites.  Neurofilaments are cytoskeleton proteins that act 
together to form and maintain cell shape and facilitate the transport of various molecules 
and organelles within the cytoplasm of neurons.  Abnormal assembly of neurofilaments is 
of particular consequence in ALS as they are primarily responsible for establishing the 
proper diameter in axons (Lee and Cleveland, 1996).  Lower alpha motor axons are the 
thickest in the body and proper Neurofilament assembly are critical for adequate 
neurotransmission through these fibers.  Abnormal assembly is prevalent in sporadic ALS 
cases and in most mouse models.  Normally, Neurofilament assembly occurs between 
NF-L (light), NF-M (medium), and NF-H (heavy) chains (in order of molecular weight- 
68kDa, 160 kDA, and 200kDa, respectively) (Harris et al., 1991).  The first event is 
dimerization of NF-L filaments or dimerization of NF-L with either NF-M or NF-H 
filaments, followed by assembly of dimers in a staggered antiparallel fashion allowing 
NF-H and NF-M filaments to associate (Fuchs and Weber, 1994).  Elongation occurs by 
head to tail assembly of NF-L filaments and phosphorylation occurs on the NF-M and 
NF-H filaments, the latter of which is one of the most extensively phosphorylated 
proteins in neurons (Strong et al., 2005b).  In ALS, neurofilament assembly can be 
altered drastically due to reduced steady state levels of NF-L in affected motor neurons.  
Moreover, mutant SOD1 has recently been shown to destabilize NF-L, providing a 
potential connection between familial ALS mutations and alteration in NF ratios (Ge et 
al., 2005). 
 
1.2.6.  ALS and intracellular inclusions  
 
 The formation of intracellular inclusions has so far been the most prominent 
feature of ALS, even though there is still no clear understanding of their importance or 
contribution to the disease.  In familial cases of ALS, the inclusions are immunopositive 
for SOD1.  Otherwise, they are comprised mainly of Neurofilaments (Liu et al., 2004), 
ubiquitin (Bruijn et al., 1998; Jonsson et al., 2004; Mather et al., 1993), peripherin 
(Robertson et al., 2001), dorfin (Niwa et al., 2002), molecular chaperones (HSP 40 and 
HSP 90) (Namba et al., 1991; Shinder et al., 2001; Takeuchi et al., 2002) and other 
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proteins.  These inclusions, similar to the amyloid deposits in AD and the α-synuclein 
positive plaques found in Parkinson’s (Shimura et al., 2001), have been subject of 
intensive studies to elucidate the pathophysiolgy of this neurodegenerative disease.  
While the cause for these plaques/inclusions is still unknown, much emphasis has been 
placed on investigating those deposits and agents that can exacerbate or ameliorate 
plaque growth as well as their relative effects on behavior and pathology.  Intracellular 
deposits in ALS could negatively affect the cell in many ways.  They could contribute to 
the loss of protein function, thereby possibly enhancing further deposition and causing 
other downstream effects within the cell, such as mitochondrial dysfunction (Dal Canto 
and Gurney, 1994; Kong and Xu, 1998; Wong et al., 1995).  Another potential effect of 
protein aggregation might be the disruption of active sites and thereby enzymatic activity 
of the involved proteins.  In ALS, altering binding regions for copper and zinc in the 
active site of SOD1 was found to cause protein misfolding and aberrant activity regarding 
specific substrates (Wang et al., 2003).  It has been proposed, for example, that mutant 
SOD1 interacts with other molecules, such as nitric oxide (Estevez et al., 1999), and 
forms toxic byproducts, such as peroxynitrate.  Peroxynitrate can then react with tyrosine 
residues to form nitrotyrosine, and thereby block the activity of the nitrated protein 
(Beckman et al., 1993).   
Another consequence of protein aggregation is the binding of various chaperones, 
thereby leading to the depletion of, for example, of HSP 40 and HSP70.  A related 
observation describes evidence that in proteinopathies and inclusions/deposits the 
proteasome, the mayor protein degradation machinery in the cell, is overwhelmed by an 
overload of ubiquitinated proteins targeted  for degradation (Leigh et al., 1991).  
  
1.2.7.  ALS and inflammation  
 
 The activation of microglia and astrocytes has led researchers to the 
understanding that ALS is not a cell autonomous disease (Clement et al., 2003).  i.e. the 
disease does not progress solely within neurons, but is exacerbated by supporting glia in 
the brain.  Astrocytes and microglia have also been shown to express mutant SOD1 and 
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astrocytes even develop inclusions similar to those found in neurons.  Activated 
microglia are known to release proinflammatory cytokines such as TNFα, NO, Cox-2, 
and IL-1β and IL-6 (Sargsyan et al., 2005), all of which are a part of a localized immune 
response.  TNFα can drive peripherin expression in neurons (found in inclusions) 
(Robertson et al., 2001), again providing a link between non-neuronal cells and ALS. 
Transforming growth factor beta 1 (TGFβ-1) and Macrophage colony-stimulating factor 
(MCSF) are actually upregulated and released by microglia in presymptomatic mice 
(Elliott, 2001).  Initial studies involving administration of LPS into ALS mice, a known 
microglial activator, worsened the symptoms and shortened lifespan (Weydt et al., 2004).  
Studies have also shown that mutant SOD1 in microglia and astrocytes accelerates the 
release of these molecules and worsens the disease, whereas normal supporting cells 
surrounding a mutant SOD1 expressing neuron greatly slowed disease progression, but 
had no change on the onset of the disease.  Similarly, introducing mutant SOD1-
expressing microglia and astrocytes to normal neurons did not induce motor neuron death 
suggesting that the supporting cells play a role in the disease, but are not the cause 
(Boillee et al., 2006a; Boillee et al., 2006b).  Some current therapies are being used to 
target microglial activation.  Minocycline, a broad spectrum antibiotic, has been proven 
to inhibit microglial activation in vivo (Van Den Bosch et al., 2002; Zhu et al., 2002) and 
its use for treating ALS has been proposed for clinical investigation. 
 
1.2.8.   ALS and cellular respiration 
 
 The role of mitochondria in the pathology of ALS is not entirely clear, but the 
presence of vacuolated mitochondria in ALS patients and mouse models (Dalcanto and 
Gurney, 1995; Wong et al., 1995) and the concomitant interruption of cellular respiration 
in the presence of mutant SOD1 provides a strong indication that the organelle is 
involved in the disease process.  Specifically, cellular respiration is reduced significantly 
from both decreased activity of cytochrome oxidase, leading to decreased ATP 
production, and release of cytochrome c in response to oxidative stress and caspase 
activation (Jung et al., 2002).  Moreover, mutant SOD1 has been shown to bind within 
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the mitochondrial inner membrane space in spinal cord motor neurons (MNs) (Higgins et 
al., 2002).  Lastly, partial deficiency in the mitochondrial matrix manganese-containing 
SOD2 enzyme exacerbated ALS-like pathology in SOD1 mutant mice (Zimmerman et 
al., 2007).  Current therapies for ALS targeted to mitochondria include the non-protein 
amino acid creatine, to enhance mitochondrial energy storage (Adhihetty and Beal, 2008; 
Klivenyi et al., 1999), and the antibiotic minocycline.  Minocycline, a tetracycline 
derivative previously shown to inhibit microglial activation, has also been proven to 
inhibit the release of cytochrome c from mitochondria; a final step of programmed cell 
death (Kriz et al., 2002).  Despite promising effects in mice, neither therapy has provided 
patients with alleviation of symptoms or extended lifespan. 
 
1.2.9.   ALS and axonal transport  
 
 Another deficiency in ALS, impaired axonal transport, is common to 
neurodegenerative diseases.  Given the asymmetrical nature of motor neurons, an 
enormous metabolic load is placed on cell bodies to transport molecules as far as 1 meter 
(fast and slow transport) to and from synapses (Bruijn et al., 2004b).  The retrograde, 
dynein-mediated, transport of components such as multivesicular bodies and trophic 
factors (NGF, VEGF) back to the cell body is impaired by mutant SOD-1, leading to the 
conclusion that diminished transport correlates well with the development of motor 
neuron disease (Williamson et al., 1998).  Dynein has many roles, including positioning 
of the ER and Golgi, and the assembly of the mitotic spindle.  Two point mutations have 
been identified in dynein that cause motor neuron disease (Hafezparast et al., 2003).  
Moreover, the disruption of the dynactin complex, an activator of cytoplasmic dynein, 
inhibits retrograde axonal transport and leads to a late-onset progressive motor neuron 
disease (King and Schroer, 2000).  A single point mutation in the p150 subunit of 
dynactin has similarly been linked to a lower motor neuron disorder (Puls et al., 2003). 
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1.2.10.  ALS and the vascular system  
 
 Unexpected risk factors contributing to ALS have been revealed in growth and 
neurotrophic factors.  Since astrocytes and microglia are such important sources of these 
factors, damage to supporting cells and interruption of the trophic support provided by 
them is a primary underlying cause of motor neurodegeneration.  VEGF, a growth factor 
known to control the growth and permeability of blood vessels and to be protective of 
motor neurons, has been found to induce motor neuron disease following targeted 
deletion of the hypoxia-response element (Oosthuyse et al., 2001).  Under normal 
conditions, hypoxia will induce VEGF expression under transcription factors that respond 
to the oxygen tension in order to maintain or restore vascular perfusion and trigger the 
growth of blood vessels.  If this function is ablated in mice, however, classic ALS 
symptoms will ensue within 5 months of age (Lambrechts et al., 2003).   
Neurotrophic factors, on the other hand, though not shown to cause ALS 
pathology can ameliorate symptoms in mice.  The most prominent of these factors are 
CNTF (Anand et al., 1995), GDNF (Elliott and Snider, 1996), and IGF-1 (Oppenheim, 
1996), all of which have been used for retrograde AAV delivery from muscle to motor 
neurons, though the only positive effects seen on disease onset and survival were 
attributed to IGF-1 (Kaspar et al., 2003). 
 
1.2.11.  ALS and the blood brain barrier 
 
Recently, it was discovered that the blood brain barrier is compromised in ALS 
patients (Garbuzova-Davis et al., 2007c).  Indeed, impairment of the BBB occurs in most 
neurodegenerative diseases (Popescu et al., 2009).  Capillary endothelial cells are 
distributed along the length of the vessels, completely encircling the lumen and 
connected via adherents and tight junctions to form a diffusion barrier into the brain for 
most blood-borne substances (Ueno, 2007).  Increasing evidence points to immune 
system involvement in ALS pathogenesis.  In the spinal cord and brain of both ALS 
patients and animal models, the presence of T-cell lymphocytes (Alexianu et al., 2001; 
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Engelhardt et al., 1993a), deposits of IgG (Donnenfeld et al., 1984a; Engelhardt et al., 
2005b), complement components C3 and C4 (Engelhardt and Appel, 1990), and 
monocyte/macrophage and dendritic cells (Troost et al., 1990a) were observed that may 
have a critical role in motor neuron damage.  IgG was detected in the perikarya of motor 
neurons of the lumbar spinal cord in mice after intraperitoneal injection of IgG derived 
from sera of ALS patients.  Moreover, the uptake of IgG in multivesicular bodies in 
endothelial cells in the affected areas of the spinal cord was found in both ALS patients 
and mice injected with human ALS IgG.  Additionally, significantly increased levels of 
albumin, IgG, and C3c have been noted in the cerebrospinal fluid of ALS patients 
(Annunziata and Volpi, 1985a; Leonardi et al., 1984a). These findings suggest that 
barrier permeability is affected in ALS.   These phenomena were also identified in spinal 
cord microvessels of G93A mice at early (13 weeks of age) and late (17–18 weeks of 
age) stage disease, although more leakage, visible with Evans Blue dye, was found in 
lumbar spinal cords of mice at terminal stage disease. Additionally, basement membrane 
disruption was noted at both early and late stage disease, as shown by the loss of laminin 
staining in the G93A mice.  Down regulation of Glut-1 and CD146 expressions in spinal 
cord endothelial cells was also found in G93A mice at early and late stage disease, 
suggesting an altered endothelial lining leading to vascular leakage (Garbuzova-Davis et 
al., 2007c) 
 
1.2.12.  Environmental components of ALS  
 
 Although unexplained, there have been environmental links to acquiring ALS.  
First described by Mulder and Kurland in 1987, there are “clusters” of the disease in 
given populations that increase the chance of developing ALS.  In the 1950’s for 
example, there was a 50-fold increase in developing ALS on the island of Guam.  More 
recently there has been a 2 fold increase in ALS patients returning from duty in the Gulf 
Wars (Haley, 2003; Horner et al., 2003).  Additionally, it was reported that ALS was 
unusually common amongst Italian soccer players (Belli and Vanacore, 2005; Vanacore 
et al., 2006).  Factors such as length of time playing/fighting, intensity of exercise, and 
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use of drugs or supplements were taken into account, though nothing was conclusively 
identified as causing ALS. 
 
1.2.13.  ALS and neuronal death  
 
Apoptosis or PCD, is a common pathway for neuronal death in neurodegenerative 
disease and is the final event in ALS.  As a presymptomatic event, Caspase 1 was shown 
to be activated in neurons (Pasinelli et al., 2000; Vukosavic et al., 2000).  Activation of 
caspase 1 is later followed by activation of caspase 3 in astrocytes and motor neurons 
(Guegan et al., 2001).  Caspase 3 subsequently triggers the release of cytochrome C from 
the mitochondrial respiratory chain, which activates caspase 9, known as “intrinsic” 
caspase activation.  Caspase 9 may act as an effector for subsequent activation of caspase 
7 and increased release/activation of caspase 3 (executioner caspases), which are 
responsible for the degradation of cellular constituents and cell death.  Alternatively, 
apoptosis can be stimulated “extrinsically” by extracellular queues activating caspase 8 
followed by caspase 3 and then following the same path as the intrinsic pathway.  Further 
evidence to support apoptosis in ALS was determined by long-term, intrathecal delivery 
of the pan-caspase inhibitor (N-benzylocarbonyl-Val-Ala-Asp- fluoromethylketone) or 
zVAD-fmk, which significantly slowed the progression of the disease in G93A mice (Li 
et al., 2000).  Further support for apoptosis in ALS was demonstrated by BCL-2 
overexpression in this same model.  BCL-2 (B-cell lymphoma 2) is a known anti-
apoptotic factor that slowed onset and promoted survival of G93A mice to a similar 
extent as the pan-caspase inhibitor zVAD-fmk (Kostic et al., 1997). 
 
1.3.   Alzheimer’s Disease 
 
1.3.1.  Alzheimer’s Pathology 
 
 Alzheimer’s disease is currently the most common form of neurodegeneration, 
affecting over 5 million people nationwide.  Approximately 1 person in 8 will be 
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diagnosed with AD by the age of 65, and 1 in 2 by the age of 85 (National Institutes of 
Health U.S. Department of Health and Human Services).  The disease is characterized, 
initially, by loss of short term memory and attention span, although affected individuals 
function with relative normal capacity for up to 3 years following diagnosis.  Typically, 
individuals die within 7-10 years of AD diagnosis, during which time they gradually 
withdraw from daily life.  Slowly and inexorably, the inability to remember names and 
follow conversations culminates to the inability to carry out familiar tasks, to reason, and 
to exercise judgment.  It is a gradual, but severe cognitive decline, leading ultimately to 
dementia and death.  The cause of death, in most cases, is AD directly, but some AD 
patients die of cancer, stroke, heart disease, and pneumonia as their general health 
deteriorates. 
 Pathologically, AD is characterized by neuronal loss with extracellular deposits of 
amyloid and intracellular accumulation of neurofibrillary tangles in the hippocampus, 
amygdala, and cerebral cortex (Selkoe, 1986).  Curiously, these classical hallmarks of 
AD were already described in 1907 by Alois Alzheimer himself following an autopsy of 
a woman who had died with severe dementia.  It was not until 75 years later, however, 
that the biochemical tools were developed to determine the components of these 
proteinaceous aggregates (Glennar and Wong 1984)( reviewed by Avila et al., 2004).  
Moreover, it has since been discovered that other processes common to 
neurodegeneration including excitotoxicity, oxidative stress, inflammation, and apoptosis 
all have a role in the pathogenesis of AD. 
 
1.3.2.  Major Genes and Proteins in AD 
 
 Several proteins have been identified within the amyloid plaques including Aβ, 
apolipoprotein E (apoE) (Wisniewski and Frangione, 1992) and Alpha 1-
antichymotrypsin (ACT) (Abraham et al., 1988), LRP (low densitity lipoprotein receptor-
related protein), activated compliment, and numerous cytokines.  Aβ is the primary 
component of the plaques and is a 38-43 amino acid peptide proteolytically derived from 
the amyloid precursor protein (APP) (Glennar and Wong, 1984)(Hardy and Selkoe, 
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2002).  APP is a transmembrane protein of unknown function expressed in almost all 
tissues.  In mammals, there are three major isoforms, APP695, APP751, and APP770, 
which vary by the presence or absence of the Kunitz protease inhibitor (KPI) domain and 
a chondroitin sulfate glycosaminoglycan (CS GAG) attachment site (Sisodia and Price, 
1995).  In the brain, primarily APP695 is expressed on the surface of neurons.  
 APP is processed proteolytically by three enzymes, α, β, and γ-secretases to 
generate either amyloidgenic or non-amyloidogenic peptides.  During amyloidogenic 
processing, APP is cleaved first by β-secretase, releasing a large N-terminal ectodomain, 
sAPPβ, into the extracellular space.  The remaining C-terminal fragment of 99 amino 
acids still bound is then cleaved by γ-secretase in the cell membrane to yield Aβ at 39, 
40, or 42 amino acids in length.  γ-Secretase cleavage between Val637 (in the APP695 
isoform) and Ile638 generates Aβ40, and cleavage after Ala639 results in production of 
Ab42.  The C terminus remaining in the membrane would be expected to be 59 or 57 
amino acids in length, respectively, although only a 50 amino acid sequence has been 
identified.  This APP intracellular domain (AICD) presumably plays an important role in 
the regulation of multiple genes that are involved in the disease development (Słomnicki 
and Leśniak 2008).  Gamma-secretase has been discovered to exert further action by 
cleaving at the ε-site of APP (Leu646-Val647), followed by cleavage at the ζ-site 
(Val643 and Ile644).  Finally the peptide is cut at the γ-site, releasing both Aβ and AICD.  
In the non-amyloidgenic pathway, the production of Aβ peptides is precluded because the 
APP ectodomain is cleaved by α-secretase at the α-site of APP (Lys613-Leu614) which 
resides within the Aβ sequence. α-secretase cleaves APP into the released ectodomain 
(sAPPα) and a remaining membrane bound fragment, C83.  The remaining fragment is 
then processed by γ-secretase, similar to the amyloidgenic pathway, to generate AICD.   
 Some mutations in the APP gene result in an increased production of pathogenic 
forms of Aβ (Tanzi et al., 1991).  To date there are 160 known mutations in APP and 
related cleavage enzymes, presenilin 1 (PS1) and presenilin 2 (PS2), that lead to familial 
AD. In fact, most inherited forms of AD result from mutations in PS1. Together with 
APH-1 (anterior pharyx defective 1 protein ) and  nicastrin, the presenilins constitute an 
integral part of the γ-Secretase, an aspartyl protease with low specificity that cleaves 
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substrates within the sequence of their transmembrane domains.  PS1 has nine 
transmembrane spanning domains and is thought to harbor the active site of γ-secretase.  
Two highly conserved aspartate residues in PS1 (257 and 385) within the 6th and 7th 
transmembrane domains of PS1 comprise the catalytic core of the enzyme.  Nicastrin is 
necessary for the proper assembly of the γ-secretase complex and has been proposed to 
modulate the traffic of substrates to the active site, and to serve as a substrate receptor 
(Wolfe, 2008) . The functions of APH1 and PEN2 are not fully elucidated.  APH1 has 
been implicated in stabilizing PS1 and plays a role during assembly of the γ-Secretase 
complex, while PEN2 stabilizes the final complex and is involved in PS1 endoproteolysis 
(Spasic and Annaert, 2008). Because processing of APP is effected by secretase activity, 
mutations in individual components of this protein complex can lead to increases in Aβ 
similar to mutations in APP.  
        ApoE4 is the major genetic risk factor for Alzheimer’s disease.  While it serves 
systemically as a lipid transport protein, in the brain, ApoE is released by astrocytes and 
microglia as part of an immune response. It also plays a key role in the maintenance and 
repair of neurons.  The ε4 allele of ApoE confers the greatest risk of AD at the lowest age 
of onset.  ApoE2, on the other hand, is associated with the lowest risk and highest age of 
onset, and apoE3 with intermediate risk and age of onset (Strittmatter et al., 1993).  The 
exact mechanism behind the effect of ApoE isoforms as risk factors for AD remains 
under investigation. 
 
1.3.3.  Extracellular Aggregates in AD 
 
 Aβ is prone to aggregation under physiological conditions.  The C-terminal 12 
amino acid residues from the transmembrane region of the Aβ peptide are hydrophobic 
and promote self-aggregation and polymerization into amyloid fibrils.  The use of “β” in 
Aβ denotes its propensity to form cross β-sheet arrays and polymerize into amyloid 
fibrils.  Specifically, 1-42 has a stronger propensity for aggregation than the more 
common 1-40 peptide and is the key seed-forming Aβ species in amyloid fibrils and 
plaques.   
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 Aβ peptides behave aberrantly in AD, likely leading to a protein misfolding event 
that serves to nucleate further misfolding.  Because of the numerous ways that an amino 
acid sequence can orient in 3 dimensions, misfolding of proteins is a common event in 
cells.  The first line of defense against the formation of misfolded proteins is their 
prevention via the utilization of molecular chaperones.  Chaperones associate with 
nascent polypeptides during translation as they emerge from the ribosome and promote 
proper folding.  In the event that a protein is misfolded faster than a chaperone can 
prevent, a second line of defense, the ubiquitin/proteasome system, is employed.  
Misfolded proteins are ubiquitinylated and thereby (in most cases) labeled for 
degradation by the proteasome.  Both chaperones and ubiquitin are found in amyloid 
plaques (as well as intracellular tangles), suggesting that these systems were 
overwhelmed in affected cells (Pallares-Trujillo et al., 1998) 
 Alzheimer’s amyloid fibrils are filamentous structures comprised of Aβ about 10 
nm wide and 100-1000 nm long.  Previous studies using x-ray fiber diffraction analysis 
originally determined the presence of a β-sheet structure within fibrils.  These ribbon-like 
β sheets form when Aβ peptides align perpendicular to the length of the filament and are 
held together with hydrogen bonds that run parallel to the length of the fibril.  These 
fibrils then aggregate with themselves and other molecules, such as Apolipoprotein E 
(ApoE)(Wisniewski and Frangione, 1992) and ACT (Ma et al., 1994), to form insoluble 
amyloid plaques that average 50μm in diameter (Rambaran and Serpell, 2008). 
Amyloid plaques have been the focus of AD research for over 100 years. 
However, more recent data suggest that it might not be mainly the plaques that are 
neurotoxic, but the more soluble forms of Aβ.  Oligomers, trimers, and dimers of Aβ 
have been shown to be toxic to cultured neurons since they can readily pass through the 
cell membrane and cause neuronal damage (Walsh and Selkoe, 2007).  Moreover, it is 
unclear if disaggregation of plaques could possibly lead to an increase in soluble Aβ 
species.  In either view, however, it is clear that the toxic starter molecule is Aβ, whether 
in aggregates, oligomers or, most likely, both.  Therapies aimed at reducing monomeric 
Aβ would reduce the amount available for oligomers and fibrils alike. 
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1.3.4.  AD and the cytoskeleton (tau) 
 
 In addition to extracellular plaques, another central hallmark of Alzheimer’s 
disease is the accumulation of intracellular aggregates of hyperphosphorylated tau.  Tau 
is a cytosolic protein involved in the assembly and stability of microtubules.  In AD and 
other tauopathies, tau metabolism is altered by overexpression of tau, mis-sense 
mutations, and posttranslational modifications.  Upon phosphorylation, tau undergoes 
misfolding events, dissociates from microtubules, and aggregates into filaments 
(reviewed in Chung, 2009).  These filaments are the primary component of 
neurofibrillary tangles which disrupt the cytoskeleton and inhibit axonal transport, 
leading to cell death as reviewed (Gendron and Petrucelli, 2009). 
 Tau is encoded by 16 exons located on chromosome 17 and is primarily expressed 
in neurons.  Exons 2, 3, and 10 are alternatively spliced, leading to 6 isoforms of tau.  
Exon 10 encodes one of the regions involved in the binding of tau to microtubules, and 
alternative splicing of this exon produces tau isoforms containing either three (tau 3R 
without exon 10) or four (tau 4R with exon 10) microtubule binding domains (Andreadis, 
2005).  The contribution of the various tau isoforms to the development of tauopathies is 
evidenced by several tau mutations that cause frontotemporal dementia and parkinsonism 
linked to chromosome 17 (FTDP-17) (Kar et al., 2005).  In this disease, an increase in the 
splice variant of exon 10 leads to an elevated ratio of 4R with respect to 3R isoforms.  
This effect is mainly attributed to intronic mutations that result in the forced expression 
of exon 10.  In contrast, in Pick’s disease tau mutations have been identified that lead to 
decreased expression of exon 10.  Aggregates are predominantly tau filaments composed 
of the 3R isoform.  In AD, no mutations causing changes in tau isoforms have been 
identified, although increased expression of the 4R tau isoform has been detected in the 
affected brain region.  Imbalance among tau isoforms (3R:4R) and the types of neurons 
involved are distinct for each tauopathy (Hernandez and Avila, 2007). 
 Several phosphorylation sites have been identified in tauopathies and respective 
kinases are implicated in the disease pathogenesis.  Primarily, tau is phosphorylated by 
glycogen synthase kinase 3 (GSK 3), cdk5, CAMKII (Wang et al., 2007) and less 
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commonly by ERK1, CK1, and PKA (Li et al., 2004; Liu et al., 2006; Pei et al., 2002; 
Trojanowski et al., 1993).  In total, 45 phosphorylation sites have been identified that 
contribute to AD pathogenesis. They represent more than half of the total 85 
phosphorylation sites identified on tau.  Regulation of tau also occurs by 
dephosphorylation via PP2A and, to a lesser extent, PP1 and PP2B.  Pin-1, a member of 
the peptidyl-prolyl cis-trans isomerase family of proteins, is involved in the assembly, 
folding and transport of certain proteins, including tau.  Pin1 binds tau when it is 
phosphorylated at the AD-related thr 231 residue and facilitates its dephosphorylation by 
PP2A (Butterfield et al., 2006).  It is therefore through phosphorylation and 
dephosphorylation events that tau can be regulated in the CNS and effect aggregation.   
 
1.3.5.  Major Mouse Models of AD 
 
 In order to study Alzheimer’s disease, many different strains of transgenic mouse 
models have been developed over the past several years.  The animals have been 
generated following the identification of numerous genes involved in familial (early 
onset) AD, where the patient develops the disease before the age of 65.  In some studies, 
Tg2576 mice were used, which harbor the “Swedish” mutations in the Amyloid Precursor 
Protein (APP) gene (Mullan et al., 1992).  These mutations (K670D and M671L) lead to 
increased processing of the APP gene, resulting in the extracellular accumulation of 
peptides Aβ1-40 and Aβ1-42, the latter of which is more toxic.  One of the main 
pathological hallmarks of AD is the formation of neuritic plaques, termed amyloid, found 
primarily in the hippocampus and cortex and comprised predominantly of the Aβ 
peptides. Tg2576 mice also show cognitive impairment similar to that of AD patients.  
Typically, plaques are detectable in their brains at approximately 12 months of age and 
correlate with behavioral deficits (Dewachter et al., 2001). 
 Mouse models of Alzheimer’s disease have been generated for many of the APP 
and PS1 mutations identified in the human population.  Another common model is based 
on an APP gene in which valine is encoded instead of a phenylalanine at position 717, 
known as the “London” mutation (V717F) (Crawford et al., 1991). The PDAPP mouse is 
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used throughout the experiments presented here.  There are also mutations in PS1 and 
PS2 genes that give rise to altered processivity of APP and increased generation of Aβ 
peptides and correlating plaque load.  PS1 M146L is the model used in our laboratory.  
Double or triple transgenic mice harbor several of these mutated genes to determine the 
roles of these proteins in AD and aid in the design of therapeutics.  
 Additionally, transgenic mice have been generated to model the other hallmark of 
AD- tauopathy.  htau mice (B6.Cg-Mapttm1(GFP)Klt Tg(MAPT)8cPdav/J) are homozygous 
for knock out of the targeted endogenous mtau alleles and hemizygous for the transgene. 
Although no endogenous mtau is detected, all six isoforms (including both 3R and 4R 
forms) of human MAPT are expressed.  Hyperphosphorylated tau is detected in cell 
bodies and dendrites by three months of age.  Paired helical filaments of aggregated 
insoluble MAPT can be isolated from brain tissue as early as two months of age 
(Andorfer et al., 2003). 
 
1.3.6.  AD and inflammation 
 
 ApoE and ACT are a part of a local inflammatory process in the brain.  Aβ, in 
turn, has domains that bind ACT and ApoE, and these proteins serve to catalyze the 
conversion of Aβ into filaments in vitro (Ma et al., 1996; Wisniewski et al., 1994) and in 
vivo to form amyloid deposits in the formation of beta-pleated sheets (Bales et al., 1999; 
Nilsson et al., 2001). 
 ACT is a 68 kDa acute phase serum glycoprotein from the family of serine 
protease inhibitors (serpins).  Systemically, it is released by hepatocyes and monocytes in 
response to inflammation, and is released by neutrophils to function as a suicide inhibitor 
of cathepsin G (Kalsheker, 1996).  In the brain, ACT is known to be produced by and 
released from astrocytes in response to IL-1β stimulation by microglia, following trauma, 
infection, or amyloidoses (Abraham, 2001; Das and Potter, 1995).  ACT is highly 
upregulated in AD brain and is involved both in the formation of amyloid plaques 
(Abraham et al., 1988) and in the phosphorylation of tau (Padmanabhan et al., 2006). 
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 Microglia have been traditionally regarded as resident CNS macrophages.  They 
comprise about 10% of the adult CNS cell population (Pessac et al., 2001).  Microglia 
normally remain in a quiescent state in the healthy CNS, and are characterized 
morphologically by small cell bodies and elaborate processes.  However, upon 
“activation” in response to infection or CNS injury, microglia experience a change in 
morphology including shortening of cellular processes and enlargement of their somas.  
Activated microglia up-regulate a host of cell surface activation antigens (major 
histocompatibility complex (MHC) class I and II, B7.1, B7.2, and CD40) and produce 
innate cytokines and chemokines (e.g., tumor necrosis factor-α (TNF-α), interleukin 
(IL)-1, IL-6, IL-12, and IL-18 (Janeway and Medzhitov, 2002) (Medzhitov and Janeway, 
2000). 
 
1.3.7.  GM-CSF and Alzheimer’s disease 
 
Numerous studies have found Rheumatoid arthritis (RA) to be a negative risk 
factor for Alzheimer’s disease (AD) pathogenesis (Myllykangas-Luosujarvi and Isomaki, 
1994), but the mechanisms for RA’s protective effect are unknown. Although two 
decades of research have intensely focused on anti-inflammatory approaches against AD 
pathogenesis, NSAID clinical trials have failed to show therapeutic benefit in AD.  This 
suggests that cyclooxygenase 2 activation is not the causative agent for the inverse 
relationship between RA and AD (McGeer et al., 2006).  This outcome suggests that it 
might be intrinsic factors within RA pathogenesis that protect against AD.  Because RA 
is a peripheral disease that prevents the onset of a neurodegenerative disease, the most 
logical approach suggests immunological phenomena.  Keeping in mind that it seems 
unlikely for specific secreted factors to be produced in the synovial pannus and maintain 
sufficient concentrations during travel through the circulatory system and across the 
blood brain barrier to inhibit AD pathogenesis, we determined that up-regulation of local 
cellular populations in RA would have the highest potential to enter into the brain and 
inhibit the development of AD pathology and/or neuronal dysfunction. We therefore 
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focused our attention primarily on leukocytes involved in both diseases, and secondarily 
on their secreted inflammatory mediators.  
 
1.3.8.  Environmental components of AD  
 
Similar to ALS, sporadic AD cases are thought to have an environmental 
component in addition to genetic risk factors.  It is generally believed that individuals 
who remain physically and mentally active, maintain strong social ties, and have a history 
of higher education are less likely to develop AD.  Accordingly, groups that are isolated 
and have limited social interactions have a strong propensity to develop the disease.  
Studies with transgenic mice (PS/APP) in enriched environments (large cages, larger 
groups of animals, toys) compared to standard housing (individually caged), indicated 
that the enriched animals performed better in working memory tasks (RAWM) than 
controls (Costa et al., 2007).  In addition to lifestyle, nutritional components have also 
been implicated in conferring risks or benefits to the development of AD.  For example, 
Resveratrol, a polyphenol in red wine, epigallocatechin-3-gallate (EGCG) in green tea, 
caffeine, and moderate ethanol consumption have all been shown to decrease the 
likelihood of developing AD (Arendash et al., 2006; Marambaud et al., 2005; Rezai-
Zadeh et al., 2008).  However, their exact mechanisms of interference have still to be 
determined.  
 
1.3.9.  AD and the vascular system 
 
 The importance of environmental and medical components for the prevention and 
cure of Alzheimer’s disease leads to the question of how the blood brain barrier (BBB) is 
involved in the development and progression of Alzheimer’s disease.  It has been known 
that the BBB in AD, similar to ALS, is compromised.  In fact, vascular dysfunction has 
been implicated in the progression of AD patients for over 20 years (Kalaria, 1992).  
Cerebral hypoperfusion and impaired LRP or ApoE-mediated transport of Aβ across the 
BBB likely contribute to the progression of AD as well.  In cerebral amyloid angiopathy 
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(CAA), amyloid deposits are found lining the microvessels within the brain, potentially 
decreasing cerebral blood flow (CBF).  Recent data from clinical imaging experiments 
(MRI, SPECT) have shown that AD patients have a resting CBF that is significantly 
reduced when compared to healthy controls (Bell and Zlokovic, 2009).  The selective 
permeability of the BBB to certain molecules is of critical importance for maintaining 
homeostasis within the CNS.  Disruption of this barrier, as seen in ALS and AD, can 
inhibit normal transport of molecules to and from the brain, or deteriorate and allow 
indiscriminate interaction between the brain and periphery, exacerbating inflammation. 
 
1.3.10.  AD and oxidative stress  
 
Both fibrillar and oligomeric Aβ species stimulate the formation of reactive 
oxygen species, including free radicals, within neurons (Moreira et al., 2008).  Oxidative 
stress occurs when the antioxidant defense system is overpowered by free radicals.  
Oxygen and nitrogen based molecules with unpaired electrons are very unstable and 
highly reactive.  If they are not removed properly, they will react with lipids, proteins, 
and nucleic acids and disrupt membrane fluidity, enzymatic activity, and cause damage to 
organelles and DNA.  Alternatively, dysfunctional mitochondria could alter enzymatic 
activity in the antioxidant defense system.  Either way, there is a clear role of oxidative 
stress in AD pathogenesis as reviewed (Swerdlow, 2009).  
 
1.3.11.  Integration of many pathways  
 
Although it has been known for quite some time that both plaque and tangle 
pathologies exist in AD patients, it has not always been clear if the events occur 
independently or in close relationship.  It is now known that Aβ can interact with  
neurons to induce kinase activity and tau phosphorylation (Zheng et al., 2002).  
Moreover, Aβ has been shown to exert similar effects intracellularly (Laferla et al., 
2006).  Therefore, according to the amyloid cascade hypothesis of AD (Hardy, 2006), the 
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overproduction of Aβ leads directly to the formation of amyloid plaques and triggers 
intracellular aggregation of tau, leading to neuronal death. 
 Other evidence also supports the fact that amyloid and tau pathologies occur not 
completely independently.  ACT, a protein previously described to be upregulated in the 
CSF of AD patients and a component of amyloid plaques, has recently been shown to 
induce tau pathology.  Cortical neurons isolated from human embryos and neonatal mice 
treated with ACT showed increased tau phosphorylation at the AD relevant sites ser 202, 
thr 231, and thr 396/404 (PHF-1) that was triggered by the cellular kinases ERK1 and 
GSK3 (Padmanabhan et al., 2006).  Moreover, it has been shown that ACT expression is 
upregulated in other tauopathies (FTDB, PSP, CBD).  Collectively, these data support 
that ACT can induce the phosphorylation of tau, providing another pathological link 
between the seminal hallmarks of AD, namely plaques and tangles. 
 
1.3.12.  AD and neuronal death  
 
 Apoptosis is the last pathway activated in AD and other neurodegenerative 
diseases, other biochemical processes are activated earlier in the disease progression. 
Like ALS, apoptosis can be activated by the intrinsic and extrinsic pathways and is the 
final event in the disease progression.  
 
1.4.  Research Rationale- Amyotrophic Lateral Sclerosis 
 
As described above, Amyotrophic Lateral Sclerosis and Alzheimer’s disease are 
neurodegenerative diseases that share certain features and therefore might be prevented 
or cured with related procedures or medications.  It is with this perspective that I focused 
my research on the promotion and inhibition of protein aggregation in Amyotrophic 
Lateral Sclerosis and Alzheimer’s disease. 
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1.4.1.  Transmission and induction of ALS 
 
 Proteinopathies, i.e. diseases that are based on diverse forms of protein 
aggregation and misfolding or the secondary modifications that are based on those 
features, can be caused by environmental and/or genetic components.  For example, prion 
diseases involve the transformation of specific proteins into more aggregate-prone 
conformations, leading to the nucleation of beta-pleated sheet structures. 
Based on the transmissible nature of prion diseases after ingestion of a prion 
protein and given the aggressive and progressive nature of ALS, we sought to determine 
if the intracellular inclusions in ALS that contain SOD1, ubiquitin, and neurofilaments, 
could be isolated from the spinal cords of affected transgenic ALS mouse models and 
injected into young transgenic mice that do not yet carry the pathogenic form of SOD1.  
The goal was to assess if the disease could be induced in the host.  If these high 
molecular weight proteins could be isolated from ALS mice and delivered via a single 
bolus injection into the lateral ventricles of recipient mice, new avenues might be opened 
to study this devastating disease.   
 The literature on spinal cord diseases reported the route of protein delivery we 
had thought out for this experiment as rather problematic.  Because the CNS relies on 
passive diffusion and the animal‘s movement to circulate CSF, delivering small amounts 
of a test substance into the lateral ventricles was not likely to diffuse the substance in 
sufficient quantity to the lumbar cistern- the initial site of degeneration in ALS. 
Additionally, it was questionable if exposure to a single injection could trigger a response 
in the animals.  For these reasons, we preferred to develop a technique allowing chronic 
infusion of homogenates into the lumbar cistern at L3 and L4.  Catheters were fashioned 
to be placed directly into the intrathecal space, sutured into place, and attached to osmotic 
minipumps for 2 and 4 week delivery.  Changes in motor ability (rotarod, latency 
to/ability to turn over) as well as life-span and enhancement of pathology (increased 
inclusions and vacuolization of dysfunctional mitochondria) were investigated. 
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1.4.2.  Disruption of the blood brain barrier 
  
 The blood-brain barrier (BBB), blood-spinal cord barrier (BSCB), and blood-
cerebrospinal fluid barrier (BCSFB) control cerebral/spinal cord homeostasis by selective 
transport of molecules and cells..  In the spinal cord and brain of both ALS patients and 
animal models, infiltration of T-cell lymphocytes, monocyte-derived macrophages and 
dendritic cells, and IgG deposits have been observed that may have a critical role in 
motor neuron damage. Additionally, increased levels of albumin and IgG have been 
found in the cerebrospinal fluid in ALS patients. These findings suggest altered barrier 
permeability in ALS. Recently, using electron microscopy, we showed disruption of the 
BBB and BSCB in areas of motor neuron degeneration in the brain and spinal cord in 
G93ASOD1 mice modeling ALS at both early and late stages of disease (Garbuzova-
Davis et al., 2007c).  Examination of the capillary ultrastructure revealed endothelial cell 
degeneration, which, along with astrocyte alteration, compromised the BBB and BSCB.  
However, the effect of these alterations upon barrier function in ALS is still unclear.  The 
aim of this study was to determine the functional competence of the BSCB in G93A mice 
at different stages of disease 
 
1.4.3.  Neuroprotective effects of DTG (1,3-di-o-tolylguanidine) 
 
DTG (1,3-di-o-tolylguanidine) is a high affinity sigma receptor agonist that has 
often been reported to ameliorate stroke damage in rodents as reviewed (Willing and 
Pennypacker, 2007).  We therefore thought to investigate if DTG could serve as a 
potential treatment to reduce the robust pathology in ALS mouse models.  Because DTG 
was known to pass the blood brain barrier (BBB), direct delivery into the CNS was not 
required and subcutaneous release over a period of 28 days was expected to be sufficient.  
In mouse models of stroke, DTG had been reported to block the inflammatory response 
evoked by MCAO, as measured by the decreased number of reactive astrocytes and 
activated microglia (Ajmo et al., 2006).  Neuronal survival is specifically enhanced if 
DTG is administered 24 hours after an ischemic stroke. Because the efficacy of DTG for 
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stroke treatment was likely the result of combined neuroprotective and anti-inflammatory 
properties of sigma receptors, and because these receptors are found ubiquitously in the 
CNS, we hypothesized that enhancing the activity of sigma receptors might provide an 
effective means for the treatment of ALS as well. 
 
1.4.4.  Novel therapeutic laminin derivative, KDI  
 
Laminin is a heterotrimeric extracellular matrix glycoprotein involved in 
numerous biological processes including cell adhesion, differentiation, migration, and, 
most importantly, neurite outgrowth.  Our collaborator,  Paivi Liesi, elucidated that it is, 
in fact, the soluble tripeptide fragment composed of the amino acids lysine, aspartic acid 
and isoleucine (KDI) at the carboxy terminus of the laminin γ-chain that promotes neurite 
outgrowth (Liebkind et al., 2003).  They showed that KDI could protect the brain from a 
kainic acid induced lesion in a dose dependent manner (Wiksten et al., 2004a) and that 
local administration of KDI to a fully transected rat spinal cord would actually heal the 
tissue, promote the growth of neurons through the glial scar, and restore lower limb 
function to the animals (Wiksten et al., 2004a).  Because the pharmacokinetics of this 
tripeptide had not yet been established, direct delivery into the intrathecal space (lumbar 
cistern) via customized catheters instead of systemic application was desired.  Kainate is 
a glutamate analog and glutamate excitotoxicity (dysregulation) is a common feature of 
both sporadic and familial ALS.  The prospect of using KDI to treat ALS was therefore 
worthwhile for 2 reasons:  Neuroprotection from dysregulated glutamate excitotoxicity 
and re-growth of damaged motor neurons via laminins and integrins. 
 
1.5.  Research Rationale- Alzheimer’s Disease 
 
1.5.1.  Development of a bilateral infusion system in mice   
 
Many lines of transgenic mice harboring the gene for human amyloid precursor 
protein (APP) with different mutations causing familial Alzheimer’s disease have been 
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developed over the past decade to study plaque deposition and other aspects of AD.  
However, variations in size, density (fibrillar and dense core), plaque number, and total 
amyloid load between animals of the same age and genotype have been reported, and 
significant pathological analyses thus often require very large numbers of mice.  
Therefore, to study AD therapies for example, it was imperative to develop a technique 
that would allow each brain hemisphere to receive different infusions.  To this end, we 
developed a catheter technique that facilitates simultaneous bilateral infusion in mouse 
brains, thereby using the contralateral hemisphere of the same animal as an internal 
control.  The infusions occurred over a period of 28 days with less than 5% mortality. 
 
1.5.2.  Intracranial infusion of KDI, a glutamate receptor antagonist and electroporation 
of a KDI expressing plasmid  
 
A) Memantine was the first in a novel class of Alzheimer's disease medications that acts 
on the glutamatergic system by blocking NMDA glutamate receptors.  Blocking these 
receptors causes an upregulation in dormant AMPA receptors in post-synaptic neurons.  
In the dentate gyrus, this upregulation is part of the process of neurogenesis. 
Trying KDI as potential therapeutic for Alzheimer’s disease was based on the non-
competitive, ionotropic glutamate receptor antagonist properties of KDI.  KDI was 
infused intracranially to induce its effect while conferring general neuroprotection to 
increased glutamate levels.  
 
B) In vivo electroporation has proven to be an effective means of delivering plasmids to 
virtually any tissue or organ without the need for attenuated viral vectors.  The 
nucleotides encoding the six amino acids representing the longer c-terminus of γ-1 
laminin (EIIKDI) were successfully cloned into PCDNA 3.1+.  After optimizing the 
electroporation conditions with an EGFP expression vector, the plasmid encoding the 
KDI-peptide was introduced for sustained expression into the hippocampus of PS/APP 
mice via electroporation.  
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1.5.3.  Alzheimer’s Disease and α-1 antichymotrypsin 
 
1.5.3.1.  ACT and tauopathies 
 
 Recent work in our lab has shown, in vitro, that tau becomes phosphorylated at 
several AD-related sites when primary neuronal cultures are incubated with ACT 
(Padmanabhan et al., 2006).  In other, non-Alzheimer’s human tauopathies, ACT is also 
upregulated, suggesting that it may have a role in tying together the mayor players in 
Alzheimer’s pathology, i.e. amyloid and tau.  In this experiment, the same technique was 
employed as previously (bilateral infusions), but the infusions were performed in 
different transgenic animals.  Here I used mice expressing the human tau protein (htau), 
and knocked out for the endogenous mouse tau (mtau), to determine if ACT has a similar 
effect on the phosphorylation of tau in vivo as was shown in cell culture, potentially 
leading to NFTs. 
 
1.5.3.2.  Inhibition of the ACT-Aβ interaction 
 
 ACT is a serine protease inhibitor that has been show to act as a pathological 
chaperone for the development of Alzheimer’s disease.  ACT promotes the fibrillization 
of Aβ in vitro, is upregulated in the CSF of AD patients and is an integral part of amyloid 
plaques.  It is not known, however, how ACT reacts with existing plaques. While 
transgenic animals are useful for studying these phenomena, they have two 
disadvantages:  they are constructed to overexpress the transgene throughout their 
lifetime and show a strong variability in plaque load between animals.  To view ACT-
induced changes in plaque number, plaque size, and plaque morphology and to allow 
direct comparison in the same animal, ACT was infused unilaterally into the parenchyma 
of the (ipsilateral) hippocampus and CSF as control into the (contralateral) hippocampus 
of the same animal.  The purpose of this experiment, ultimately, is to test various 
compounds for their ability to inhibit the ACT-Aβ interaction.  Previous in vitro work 
showed that fragments of Aβ, when incubated with ACT or ApoE and full length Aβ, can 
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inhibit the formation of fibrils and increase survival of transfected cells (Ma et al., 1996).  
In this experiment, fragment 1-11 which is known to be the ACT binding fragment of Aβ, 
was co-infused with ACT into PS/APP mice to disrupt amyloid formation.  Other 
experiments entailed infusion of the 1-11 peptide alone to see if it might inhibit the 
endogenous “ACT-equivalent” in the mouse. 
 
1.5.4.  Colony stimulating factors and amyloid clearance and cognitive enhancement  
 
Numerous studies have found Rheumatoid arthritis (RA) to be a negative risk 
factor for Alzheimer’s disease (AD), but the mechanisms for RA’s protective effect are 
unknown.  Much research has proposed that medication with NSAIDs, which is common 
for RA patients, is protective against AD.  However most NSAID clinical trials have 
proven unsuccessful in AD patients and have therefore led to the hypothesis that intrinsic 
components of RA pathogenesis may be protective against AD.  In these experiments, we 
proposed that cytokines are upregulated in RA and confer neuroprotection to AD. 
Multiple colony stimulating factors that induce leukocyte populations and are involved in 
RA’s pathogenesis, such as GM-CSF, are upregualted in RA patients and were the 
natural target of our investigation.  First we performed bolus intrahippocampal 
administration of rmGM-CSF into one hemisphere and control aCSF into the other 
hemisphere to compare plaque load and reactive gliosis.  In a second approach we used 
sub-cutaneous rmGM-CSF injection into aged cognitively-impaired PS/APP mice in an 
attempt to reverse the cognitive impairment.  Both standard radial-arm water maze task 
and a novel Cognitive Interference task were employed to measure any cognitive 
enhancement.  
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CHAPTER 2 – TRANSMISSIBILITY OF MISFOLDED SUPEROXIDE 
DISMUTASE  INCLUSIONS IN A MOUSE MODEL OF ALS  
 
2.1.  Introduction 
 
 My first investigations related to ALS focused on the proteinaceous inclusions 
formed within neurons and astrocytes in the CNS of ALS patients.  Of  particular interest 
was the possibility that deposits of mutant or misfolded SOD1 might carry the capacity to 
transmit the disease in a prion like fashion.  In prion disease, the native prion protein, 
PrPc, (PrPc,= cellular prion protein) features a predominantly alpha-helical structure, 
while PrPSc, as in scrapie, a prion disease in sheep, features a predominantly beta-pleated 
sheet structure.  The only difference between these proteins is a conformational change 
and according to the “protein only” hypothesis, the agent responsible for misfolding 
native prion protein to the aggregate prone form is the misfolded protein itself (Prusiner, 
1998). PrPSc initiates and sustains the propagation of the pathogenic misfolding of the 
PrPc, molecule in vivo and causes neurodegeneration in a classic manner:  Progressive 
loss of neurons, local inflammation (microgliosis/astrocytosis), deposition of abnormally 
folded prion protein (PrPsc), and, notably, transmissibility in most forms of the disease 
(transmissible spongiform encephalopathy- TSE).     
 Seeded disease transmissibility/promotion has also been demonstrated in 
Alzheimer’s mouse models.  However, the diseases could only be induced if the mice 
were genetically predisposed to develop the disease.  In young APP transgenic mice, 
cerebral amyloidosis can be triggered with intracranial infusion of dilute cortical extracts 
from AD patients and they develop amyloid pathology within a few months.  Aβ-rich 
brain extracts from APP transgenic mice produce seeding similar to that from human 
extracts, indicating that the inducing agent is not uniquely present in the human brain 
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(Walker et al., 2002).  Infusion of brain extracts from WT or NTG mice into APP mice, 
or extracts from APP transgenic mice into Wt or NTG mice induced no phenotypic 
change, however, there is evidence that injecting brain homogenates from plaque 
producing mice induces tau pathology in tau transgenic mice (Bolmont et al., 2007).  
Moreover, direct infusion of Aβ 1-42 into AD transgenic mice, although sufficient to 
cause cognitive decline and neuronal death, will not form plaques.   
 Taken together, the data from a number of neurodegenerative diseases indicated 
that abnormal protein conformation could be acquired and induced in other animals.  I 
therefore sought to determine if a transmissible element could be identified within the 
motor neuron inclusions of ALS mice.  Spinal cord homogenates from symptomatic 
SOD1 G93A mice were homogenized, determined to contain high molecular weight 
species of SOD1, and injected into the lateral ventricles of SOD1 and NTG mice in an 
attempt to induce or speed the development of the ALS phenotype.  Additionally, the 
extracts were infused directly into the lumbar cistern of these animals.  Finally, spinal 
cord (SC) homogenates from symptomatic ALS mice were intrathecally infused into 
presyptomatic SOD1 transgenic mice with the intention to hasten the disease onset and/or 
progression. 
 
2.2.  Materials and Methods 
 
2.2.1.   Intrathecal Catheter Construction 
 
Recent work by our and other groups has shown that compounds that are injected 
into the cerebrospinal fluid (CSF) do not diffuse efficiently throughout the spinal cord 
(unpublished observations).  It was therefore necessary to infuse the peptide continuously 
into the CSF of the intrathecal space (lumbar cistern) of the spinal cord of the ALS 
models.  This approach turned out to be a very arduous task for many research groups, 
and successful long-term intrathecal catheterization in mice, particularly in conjunction 
with Alzet osmotic minipumps, had not been reported at this time.  Due to meticulous 
attention to surgical details and assistance from the ALS Therapy Development 
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Foundation, I succeeded in performing long-term intrathecal catheterization in mice.  To 
this end, intrathecal catheters were fashioned by first inserting a 10 cm, 0.005” diameter 
tungsten wire (Small Parts, Inc. Miramar, Fl) into a 3 cm length of polyethylene tubing 
(PE-10, Becton Dickinson, Sparks, MD.) with an internal diameter of 0.011” and 
stretching the material so it was snug with the wire.  The un-stretched portion of the PE-
10 (outer diameter 0.024”) was then inserted into a 4 cm long polyvinyl tubing (Durect 
Corp. Cupertino, Ca.) (internal diameter 0.027’’) with approximately 2 cm of overlap.  
The space difference of 0.003” in the step-up to the larger polyvinyl tubing is filled with 
Locktite 454 adhesive (Plastics One. Roanoke, VA.) and secured with a silk suture 
(figure 1).  After the assemblies were left to dry overnight, sterile water was forced 
through to assure that the lines were not occluded or damaged. 
 
2.2.2.  Spinal Cord Extracts 
 
After an overdose of sodium pentobarbital (~150mg/kg) (i.p.) 6 animals (4 
hSOD1 G93A mice and 2 hSOD1WT) were transcardially perfused with 0.9% saline.  
The spinal cords were microdissected from a group of 5 late disease stage animals and 2 
age-matched controls, immediately dounce homogenized in cold 300μM sucrose, 
aliquoted, and frozen at -80oC until use.  Equal amounts of protein from each sample 
were mixed with 2x sample buffer (Invitrogen, Carlsbad, CA), boiled for 5 min, and 
subjected to 10-20% Tris Tricine SDS gel electrophoresis (Invitrogen).  The 
electrophoresed proteins were wet transferred onto 0.2 µm nitrocellulose (Whatman, 
Dassel, Germany) and probed with a rabbit anti-mouse polyclonal antibody to SOD1 
(1:1000).  The secondary antibody was horseradish peroxidase-conjugated donkey anti-
rabbit IgG (Pierce, Rockford, IL).  The immuno-labelled proteins were visualized with an 
enhanced chemiluminesence detection kit (SuperSignal pico, Pierce, Rockford, IL).  
After different exposures, autoradiographs were developed with a Konica/Minolta 
SRX101A (Tokyo, Japan) and scanned using a Ricoh Aficio MP3010.  Homogenates that 
showed mostly higher weight SOD1 immunoreactivity were considered to be aggregates 
and used for subsequent infusions (figure 2). 
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2.2.3.  Osmotic Minipumps 
 
Sterile Alzet osmotic minipumps-model 2004 (Durect Corp. Cupertino, Ca.), with 
a flow rate of 0.25μL/hr were filled with 200μg of total protein from homogenates of 
G93A mutant and wt transgenic SOD1 mice, diluted in artificial CSF (Harvard 
Apparatus, Holliston, MA) and incubated at 37oC in sterile saline for 48 hours.  
Typically, catheters are attached and primed at this time, but the tungsten wire needed to 
remain in place for stability during insertion into the spine. 
 
2.2.4.  Mice 
 
Another 10 SOD1 G93A mice and 4 controls (C57/B6 background) were purchased from 
Jackson Labs (Bar Harbor, ME.).  These mice express 18 copies of mutant SOD1 and 
develop ALS pathology at approximately 100 days.  Their average lifespan is about 130 
days and the phenotype closely resembles a more aggressive familial form of the disease.  
This model was chosen because at the time it was widely accepted by ALS investigators 
and the therapeutic/pathological window was short enough to run multiple studies.   
 
2.2.5.  Intrathecal Infusions 
 
All procedures involving experimentation on animals were performed in 
accordance with the guidelines set forth by the University of South Florida Animal Care 
and Use Committee.  Animals (90 days old- 25g) were anesthetized with 1-2% isoflurane 
and shaved and scrubbed with 10% Betadine solution at the site of incision.  A small (3 
cm) incision was made, exposing the lumbar region of the vertebral column, and double 
bladed scissors were used to form a subcutaneous pocket along the back of the animal 
between the scapula and towards the head.  A puncture was then made between the L2 
and L3 vertebrae with a 23 gauge needle that allows the small, stretched portion of PE-10 
(stabilized with the tungsten wire) to be inserted 0.9 cm into the intrathecal space and 
being stopped by the silk suture used to adjoin the two different sized tubings.  Accurate 
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placement of the catheter was visualized in every instance by a brief tail flick or muscle 
twitch, at which point the tungsten wire was removed and an Alzet pump attached. 
Another silk suture was used to “anchor” the catheter into the superficial erector 
musculature dorsal the vertebral column.  The placement of the second suture into the 
musculature immediately caudal to the first “assembly” stitch on the catheter prevented 
them from being pulled out during the course of the experiment.  The pumps infused for 
28 days, around which time the animals were at the terminal stages of paralysis. 
 
2.2.6.  Histology and Immunohistochemistry 
 Mouse spinal cords were carefully removed and fixed in 10% formaldehyde 
(formalin) for 72 hours and then passed through a series of sucrose solutions (10-30%) 
over another 72 hours.  Tissues were frozen to the peltier stage (Physitemp, Clifton, NJ) 
of a histoslide (Leica, Heerbruug, Switzerland) and sectioned coronally at 25 μm. After 
incubating the sections with blocking buffer (Tris-buffered saline with 10% normal goat 
serum, 0.1% Triton X-100, and 0.02% sodium azide) for 60 min, primary antibodies 
against SOD1 (1:500) were applied and incubated at 4 o C overnight.  After thorough 
washing, the sections were incubated with secondary antibody, Alexa 488 and 594 
fluorophores (1:1000, 1:4000-Invitrogen) in the dark at ambient temperature for 2 hours.  
This incubation was followed by a Hoechst (1:10,000, Sigma, St. Louis, MO) nuclear 
stain, and the sections were washed and sealed with Gel-Mount (Electron Microscopy 
Sciences, Hatfield, PA).  Cresyl violet staining was used to analyze the general 
morphology of motor neurons and vacuolated mitochondria (figure 3).  The slides were 
first stained with cresyl violet (Sigma, St. Louis, MO- 1 gram/400mL water at pH 3.6) for 
3 minutes, rinsed in water, and placed in 95% ethanol, successively, 3 times, for 4 
minutes each.  Then they were placed into 100% ethanol twice for 2 minutes each and 
xylene twice for 2 minutes each before being coverslipped with Cytoseal (Electron 
Microscopy  Sciences, Fort Washington, PA) and left to dry at ambient temperature 
overnight. The images were analyzed on a Zeiss Imager Z1 microscope with a Zeiss 
Axiocam Mrm camera (Oberkochen, Germany) using Axiovision 4.7.   
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2.2.7.  Behavior 
 Motor deficits and the health of the animals were assessed throughout the 
experiment.  Body weights before and after a 28 day treatment were measured daily as 
well as the biweekly performance on a rotarod test.  The rotarod is designed to assess 
motor coordination, balance and equilibrium.  The test mouse is placed on the rod and the 
rotarod accelerates gradually to a pre-set maximum speed.  The mice’s performance 
abilities are recorded as latencies in falling from the rod.  The rotarod consists of a semi-
enclosed chamber which contains a beam made of ribbed plastic and flanked by round 
plates on either side to prevent any escape.  The rod is suspended at a height of 20 cm 
above the counter and the mouse is placed on top of the beam, facing in the orientation 
opposite to that of its rotation, so that forward locomotion is necessary to avoid falling 
(figure 4). The rotarod spins consistently at 1 of 10 pre-set speeds (#5 was chosen) during 
three 2-minute trials.  Latencies for the mice to fall from the rod are recorded 
automatically once the fallen animal interrupts a laser beam, thereby stopping the timer.  
Each mouse is given 3 trials with a 20 minute interval between trials.  Once it is evident 
that the mouse is unable to perform,the animal is removed from the study. 
 
2.3.  Results and Conclusions 
 
 Mating experiments in which mice harboring the wild type human SOD1 gene 
were mated with mice harboring the wild type human SOD 1 gene G85R resulted in 
offspring with a more aggressive phenotype than the G85R alone  (Wang et al., 2009).  
Disease onset time and age of death were both significantly reduced in the litter, 
suggesting that G85R’s interaction with WT SOD1 enhances its pathogenicity.  With 
similar rationale, we sought to determine if there was an element within the inclusions, if 
not mSOD1 itself, that could, similar to prion diseases induce a misfolding event, thereby 
accelerating the disease process.  
 In these experiments, we wished to determine if the induction of misfolding in the 
spinal cords of SOD1 G93A, another mutant human SOD1, was transmissible, i.e. if  a 
misfolded protein from a host can be introduced into a recipient to nucleate further 
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misfolding and cause neurodegeneration.  Transmissibility, not necessarily infectivity, of 
misfolded proteins might provide insight into how the process of nucleation occurs in 
proteinopathies.  Recent work with tau tangles, for example, in AD demonstrates that 
once the tangles are injected into the brain of a presymptomatic mouse, newly formed 
tangles form immediately, indicating that the first exposure to the tangles triggers a 
positive feedback loop of tangle formation (Clavaguera et al., 2009) 
 We sought to determine if exposure to mutant, aggregated SOD would nucleate 
the formation of characteristic intracellular inclusions in the spinal cord of ALS mice. 
This was approached first with intracerebroventricular bolus injections of homogenized 
spinal cords (figure 2) from symptomatic mice into WT and non-symptomatic mice in 
order to accelerate the phenotype.  We found, however, that this was an ineffective means 
of delivery in this model, since the pathology begins in the anterior spinal column and 
molecules travel in the CSF diffusely.  For this reason, customized catheters in 
combination with osmotic minipumps needed to be made in order to chronically and 
effectively deliver the homogenates directly to the target tissue and to infuse the 
homogenates for a month rather instead of single injections at a distal site.   
 Table 1 below shows that mutant mice receiving mutant homogenates lived an 
average of 129.6 days whereas mutant mice receiving WT homogenates lived an average 
of 124 days.  The average lifespan of animals in this colony was 128.  No significant 
change in disease onset (or time of death) were apparent between the groups behaviorally 
(data not shown- device figure 4), and histological examination of the spinal cords was 
not warranted.  Furthermore, no other group has reported transmissible elements of ALS 
since these experiments were conducted.  In sum, unlike AD and prion disease, SOD1 
inclusions cannot seed or nucleate the formation of new aggregates, suggesting a 
divergence in pathology from other neurodegenerative diseases.  At the same time 
intrathecal delivery of molecules into mice, at this time, a novel technique only practiced 
by a few researchers was proven to be a valuable tool for drug delivery. 
 
 
 
2.4.  Figures 
 
 
 
 
 
 
 
 
 
                        
 
    
 Figure 1.  Intrathecal catheter assembly 
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Figure 2.  Western Blot of spinal cord homogenates from nontransgenic, SOD1WT, and 
mSOD1 G93A mice which were subsequently used for chronic intrathecal infusions 
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SOD1 G93A Nontransgenic 
Figure 3. 20 μm sections from the lumbar region of spinal cords of nontransgenic (left) 
and SOD1 G93A mice (right) at 5x magnification.  Below is increased magnification 
(40x) from the ventral horn showing dying motor neurons with mitochondrial vacuoles in 
the SOD1 G93A mouse (right). 
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Figure 4.  A standard rotarod for individual mice (Med Associates Inc.) 
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Table 1. Comparing lifespan from SOD1 G93A mice infused with SOD1 G93A spinal 
cord homogenates (AGG-M) to animals infused with WT infusions (AGG-S) 
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CHAPTER 3 – EVIDENCE OF COMPROMISED BLOOD-SPINAL CORD 
BARRIER IN EARLY AND LATE SYMPTOMATIC SOD1 MICE MODELING 
ALS 
 
Svitlana Garbuzova-Davis a-d*, Samuel Saporta a,b,d, Edward Haller d , Irina Kolomey a, 
Steven P. Bennett f,g, Huntington Potter f,g, Paul R. Sanberg a-e 
 
3.1.  Abstract 
 
The blood-brain barrier (BBB), blood-spinal cord barrier (BSCB), and blood-
cerebrospinal fluid barrier (BCSFB) control cerebral/spinal cord homeostasis by selective 
transport of molecules and cells from the systemic compartment. In the spinal cord and 
brain of both ALS patients and animal models, infiltration of T-cell lymphocytes, 
monocyte-derived macrophages and dendritic cells, and IgG deposits have been observed 
that may have a critical role in motor neuron damage. Additionally, increased levels of 
albumin and IgG have been found in the cerebrospinal fluid in  
ALS patients. These findings suggest altered barrier permeability in ALS. Recently, we 
showed disruption of the BBB and BSCB in areas of motor neuron degeneration in the 
brain and spinal cord in G93A SOD1 mice modeling ALS at both early and late stages of 
disease using electron microscopy. Examination of capillary ultrastructure revealed 
endothelial cell degeneration, which, along with astrocyte alteration, compromised the 
BBB and BSCB. However, the effect of these alterations upon barrier function in ALS is 
still unclear. The aim of this study was to determine the functional competence of the 
BSCB in G93A mice at different stages of disease.  Methodology/Principal Findings:  
Evans Blue (EB) dye was intravenously injected into ALS mice at early or late stage 
disease. Vascular leakage and the condition of basement membranes, endothelial cells, 
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and astrocytes were investigated in cervical and lumbar spinal cords using 
immunohistochemistry. Results showed EB leakage in spinal cord microvessels from all 
G93A mice, indicating dysfunction in endothelia and basement membranes and 
confirming our previous ultrastructural findings on BSCB disruption. Additionally, 
downregulation of Glut-1 and CD146 expressions in the endothelial cells of the BSCB 
were found which may relate to vascular leakage. Conclusions/Significance: Results 
suggest that the BSCB is compromised in areas of motor neuron degeneration in ALS 
mice at both early and late stages of the disease.  
 
3.2. Introduction 
 
The central nervous system (CNS) is an immunologically privileged zone, which 
is normally protected from entry of immune cells and serum proteins by the blood-brain 
barrier (BBB), blood-spinal cord barrier (BSCB), and blood-cerebrospinal fluid barrier 
(BCSFB). These barriers are specialized structures of the CNS that control cerebral/spinal 
cord homeostasis by selective transport of molecules and cells from the systemic 
compartment (reviewed in (Ballabh et al., 2004; Engelhardt, 2006; Pardridge, 1999, 
1988; Rebenko-Moll et al., 2006; Sharma, 2005; Vorbrodt and Dobrogowska, 2003). This 
control is possible due to the unique structural elements of the microvasculature – 
endothelial cells of brain capillaries and epithelial cells of the choroids plexus, astrocyte 
end-feet, and pericytes. Brain (spinal cord) capillary endothelial cells are distributed 
along the length of the vessels, completely encircling the lumen and connected via 
adherens and tight junctions. Adherens junctions support intercellular adhesion, as tight 
junctions form a diffusion barrier for most blood-borne substances. The basement 
membrane (i.e. basal lamina), surrounding the endothelial cells and pericytes, supports 
the abluminal surface of the endothelium. The basement membrane, which consists of 
laminin, fibronectin, collagens, and proteoglycans (Dermietzel and Krause, 1991; Rutka 
et al., 1988), separates adjacent tissues, acting as a barrier to the passage of 
macromolecules and cell migration. The astrocyte perivascular end-feet ensheathing 
approximately 95% of the vessel wall appear to have an important role for maintenance 
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of the BBB (Prat et al., 2001). Thus, functional integrity of all BBB/BSCB elements is 
critical for protection of the CNS from various harmful blood substances.  
Impairment of the BBB occurs in various pathological CNS conditions. 
Accumulation of collagen in vascular basement membranes and focal necrotic changes in 
endothelial cells were found in Alzheimer’s patients (Claudio, 1996). Degradation of the 
extracellular matrix may be concomitant with BBB disruption and tissue softening, 
setting the stage for the most pronounced forms of brain swelling and leading to the 
development of severe cerebral edema over subsequent hours and days in stroke patients 
(reviewed in (Avata and Ropper, 2002)). In multiple sclerosis (MS), which is 
characterized by inflammatory lesions within the CNS, BBB disruption enables leakage 
of the serum protein fibrinogen into the brain parenchyma (Kirk et al., 2003; Kwon and 
Prineas, 1994) and may precede myelin damage aggravating the inflammatory process. 
Recently, Vos et al. (Vos et al., 2005) demonstrated that BBB dysfunction in MS patients 
is apparent not only in focal lesions but also in diffuse abnormalities in white matter 
which were detected by postmortem MRI. BSCB breakdown was found in an 
experimental model of traumatic spinal cord injury (Noble and Wrathall, 1989; Olsson et 
al., 1992). It has been shown that spinal nerve lesions also alter BSCB function (Gordh et 
al., 2006). Results of these studies showed increased microvascular permeability leading 
to blood protein extravasation and the formation of vasogenic edema that play important 
roles in the pathophysiology of the diseased or injured spinal cord. 
Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disease 
affecting motor neurons in the spinal cord, motor cortex and brainstem that leads to 
paralysis and death within five years of disease onset (Miller et al., 2000; Rowland and 
Shneider, 2001a). Although numerous hypotheses about the etiology and pathogenesis of 
ALS have been proposed (reviewed in (Bruijn et al., 2004a; Cleveland and Rothstein, 
2001; Strong et al., 2005a)), increasing evidence points to immune system involvement in 
ALS pathogenesis (Alexianu, 1995; Alexianu et al., 2001; Appel et al., 1994; Kawamata 
et al., 1992). In the spinal cord and brain of both ALS patients and animal models, the 
presence of T-cell lymphocytes (Alexianu et al., 2001; Engelhardt et al., 1993b), deposits 
of IgG (Donnenfeld et al., 1984b; Engelhardt and Appel, 1990; Engelhardt et al., 2005a; 
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Mohamed et al., 2002), complement components C3 and C4 (Donnenfeld et al., 1984b), 
and monocyte/macrophage and dendritic cells (Engelhardt et al., 1993b; Henkel et al., 
2004; Troost et al., 1990b) were observed that may have a critical role in motor neuron 
damage. Recently, IgG was detected in the perikarya of motor neurons of the lumbar 
spinal cord in mice after intraperitoneal injection of IgG derived from sera of ALS 
patients (Engelhardt et al., 2005a). Moreover, the uptake of IgG in multivesicular bodies 
in endothelial cells in the affected areas of the spinal cord was found in both ALS patients 
and mice injected with human ALS IgG.   
Additionally, significantly increased levels of albumin, IgG, and C3c have been 
noted in the cerebrospinal fluid of ALS patients (Annunziata and Volpi, 1985b; 
Apostolski et al., 1991; Leonardi et al., 1984b; Meucci et al., 1993). These findings 
suggest that barrier permeability may be affected in ALS. Recently, we showed 
disruption of the BBB and BSCB in areas of motor neuron degeneration in the brain and 
spinal cord in G93A SOD1 mice modeling ALS at both early and late stages of disease 
using electron microscopy (Garbuzova-Davis et al., 2007b). Examination of capillary 
ultrastructure revealed endothelial cell degeneration, which, along with astrocyte 
alteration, compromised the BBB and BSCB. However, the effect of these alterations 
upon barrier function in ALS is still unclear. The aim of this study was to determine the 
functional competence of the BSCB in G93A SOD1 mice modeling ALS at different 
stages of disease. 
 
3.3.  Results 
 
3.3.1.  Disease symptom progression in G93A mice  
  
The G93A mice were monitored weekly for initial disease symptoms and disease 
symptom progression by body weight and extension reflex, beginning at 7 weeks of age. 
Body weights of G93A mice gradually increased until 11 weeks of age and then 
stabilized for 2 weeks (12-13 weeks of age). Tremor, an initial sign of disease, was seen 
in some mice as early as 13 weeks of age. After this time, mice consistently lost body 
 49 
weight due to muscle atrophy. By 18 weeks of age, G93A mice had lost approximately 
14% (p=0.06) of their 13-weeks-of-age body mass, dropping from 25.4±0.38 g to 
21.8±0.55 g (Figure 5, A). Eighteen weeks old G93A mice weighed 28% less than 
C57BL/6J mice of the same age (p=0.007), which continued to maintain their body 
weights until 20 weeks of age.  Deterioration in extension reflex started to appear in 
G93A mice at 13 weeks of age (Figure 5, B). During the next 5 weeks, mice 
demonstrated slowly declining hindlimb extension and by 18 weeks of age, showed no 
extension (p<0.001) and exhibited hindlimb paralysis. Thus, G93A mice at about 13 
weeks of age showed initial signs of disease such as tremor, weight loss, and reduced 
hindlimb extension. Terminal stage of disease in these mice was observed at 17-18 weeks 
of age, as demonstrated by complete hindlimb paralysis, significant reduction of body 
weight and absence of hindlimb extension.  
 
3.3.2.  Motor neurons in the cervical and lumbar spinal cords of G93A mice 
  
Nissl body staining was performed to identify motor neuron condition in the 
spinal cords of G93A mice in early and late stages of disease. In control C57BL/6J mice, 
many healthy motor neurons with large soma and neuritic processes were visible in the 
cervical and lumbar ventral horn of the spinal cords at 12-13 weeks of age (Figure 6A, 
Figure 7A) and 19-20 weeks of age (Figure 6B, Figure 7B). In the cervical spinal cord of 
G93A mice, numerous motor neurons with vacuolization were found at 13 weeks of age, 
concurrent with initial disease symptoms (Figure 2C). When disease symptoms 
progressed and mice were paralyzed, usually at 17-18 weeks of age, the number of motor 
neurons had decreased and motor neurons of various sizes displayed vacuolization 
(Figure 6D). Only a few healthy motor neurons were identified at this time. More 
dramatic changes in motor neuron condition were found in the lumbar spinal cords of 
ALS mice. Most motor neurons in 13 week old mice showed signs of degeneration 
(Figure 7C). In G93A mice at 17-18 weeks of age, the ventral horn was essentially 
devoid of motor neurons (Figure 7D).   
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3.3.3.  Fluorescent detection of Evans Blue in the cervical and lumbar spinal cords of 
G93A mice 
 
Evans Blue, the tracer used to assess disruption of the BSCB, was injected into 
G93A mice at initial (13 weeks of age) and late (17-18 weeks of age) stages of disease 
symptoms prior to euthanasia. C57BL/6J mice were also administered the EB dye. In the 
cervical spinal cord, EB was clearly detected within the blood vessels in the control 
C57BL/6J mice at 12-13 weeks of age (Figure 8A, B, C) or in the cross-sectioned 
capillaries at 19-20 weeks of age (Figure 8D, E). Vascular leakage of EB was 
distinguished in G93A mice with early disease symptoms (Figure 8F, G) and at end-stage 
of disease (Figure 8H, I, J) when more EB extravasation was noted. Interestingly, vessel 
permeability was perceived in both initial (Figure 8F) and late (Figure 8I) symptomatic 
G93A mice. In the lumbar spinal cord, EB dye was observed intravascularly in control 
C57BL/6J mice at 12-13 weeks of age (Figure 9A, B) and 19-20 weeks of age (Figure 
9C, D), similar to results in the cervical spinal cord, while EB extravasation abnormalities 
were found in G93A mice at 13 weeks of age (Figure 9E, F). Significant EB diffusion 
into the parenchyma of the lumbar spinal cord from many blood vessels was detected in 
G93A mice at end-stage of disease, 17-18 weeks of age (Figure 9G, H). Considerable 
vessel permeability was seen in early (Figure 9F) as well as late (Figure 9G) symptomatic 
G93A mice. Thus, vascular leakage of EB was detected in G93A mice not only at end-
stage of disease but also concurrent with early disease symptoms. 
 
3.3.4.  Immunochistochemical characteristics of basement membranes, endothelial cells, 
and astrocytes in the spinal cords of G93A mice 
 
Immunofluorescent staining for laminin-1 (major non-collagenous basement 
membrane glycoprotein) demonstrated well organized microvasculature networks in the 
cervical and lumbar ventral horn of the spinal cords in C57BL/6J mice at 12-13 weeks of 
age (Figure 10A, Figure 11A) and 19-20 weeks of age (Figure 10B, Figure 11B). In these 
control animals, many capillaries of different calibers were visible by laminin detection. 
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Conversely, a marked reduction of labeled vessels was observed in both cervical and 
lumbar spinal cords of G93A mice at early (Figure 10C, Figure 11C) and late (Figure 
10D, Figure 11D) stages of disease, suggesting a loss of vascularization or disruption of 
vascular basement membrane integrity. In some cervical spinal cord sections of G93A 
mice with initial disease symptoms, blurred spots around capillaries were apparent in the 
ventral horn of the spinal cord (Figure 10C), probably due to vascular leakage.   
 Immunofluorescent staining for Glut-1 (glucose transporter 1) showed high 
expression of Glut-1 in microvascular endothelia of the cervical and lumbar ventral horn 
of the spinal cords in C57BL/6J mice at 12-13 weeks of age (Figure 12A, B, H, I) and at 
19-20 weeks of age (Figure 12C, J). The Glut-1 immunoreaction of endothelial cells 
lining the many capillaries of different calibers was low, or none, in both cervical and 
lumbar spinal cords of G93A mice at early (Figure 12D, E, K, L) and late (Figure 12F, G, 
M, N) stages of disease.  
Immunohistochemically, endothelial cells (CD146) and astrocytes (GFAP) were 
of normal appearance in the cervical and lumbar ventral horn of the spinal cords in the 
control C57BL/6J mice at 12-13 weeks of age (data not shown) and 19-20 weeks of age 
(Figure 13A, B; Figure 14A, B, C). Delineated astrocytes and astrocytes with 
perivascular end-feet on the vessel wall were clearly observed. However, endothelia 
surrounding capillaries were partially revealed in the cervical spinal cord of G93A mice 
at initial (Figure 13C, D) or late (Figure 13E, F) stages of disease. Although CD146 
antigen expression was detected in some endothelial cells of early symptomatic G93A 
mice, indistinct immunoreaction for CD146 was observed in G93A mice at end-stage of 
disease. Additionally, swollen endothelial cells (Figure 13F) were found in the cervical 
spinal cord of late symptomatic G93A mice. A small number of delineated astrocytes 
were also noted. In the lumbar spinal cord of G93A mice at initial (Figure 14D, E) and 
late (Figure 14F, G) stages of disease, decreased or unclear CD146 antigen expression 
was noted in endothelial cells. Notably, increased astrocyte activation in both cervical 
(Figure 13F) and lumbar (Figure 14F, G) spinal cords was detected in G93A mice at late 
stage of disease. 
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3.4.  Discussion 
 
In the present study, we investigated the functional competence of the BSCB in 
G93A SOD1 mice modeling ALS at different stages of disease. We observed 
microscopic evidence of  BSCB impairment in cervical and lumbar spinal cords, areas of 
motor neuron degeneration, of ALS mice at initial disease symptoms and, more severely, 
at late stage disease. Our data show EB leakage in cervical/lumbar spinal cord 
microvessels in G93A mice at early (13 weeks of age) and late (17-18 weeks of age) 
stage disease. More leakage was found in lumbar spinal cords of mice at terminal stage 
disease. Additionally, basement membrane disruption was noted at both early and late 
stage disease, as shown by the loss of laminin staining in the G93A mice. 
Downregulation of Glut-1 and CD146 expressions in spinal cord endothelial cells was 
also found in G93A mice at early and late stage disease and may relate to altered 
endothelial lining leading to vascular leakage. Small numbers of delineated astrocytes 
were also established. These results confirm our previous ultrastructural findings 
(Garbuzova-Davis et al., 2007b) on disruption of the BSCB showing functional 
incompetence of BSCB structural elements in ALS mice.  
Significant death of motor neurons in G93A mice occurs at the onset of clinical 
disease (90 days) and by end-stage disease (136 days), mice show up to a 50% loss of 
cervical and lumbar motor neurons (Chiu et al., 1995; Gurney et al., 1994; Weydt et al., 
2003). In G93A mice, motor deficits have been observed in tests of muscle strength and 
coordination as early as 8 weeks of age (Barnéoud et al., 1997). These results extend 
those of our previous studies (Chen, 2003; Garbuzova-Davis et al., 2001; Garbuzova-
Davis et al., 2002), showing initial signs of disease, such as tremor, weight loss, and 
reduced hindlimb extension, in G93A mice at about 13 weeks (90 days) of age. At this 
age, numerous vacuolizated motor neurons were found in the cervical lumbar spinal cord 
and most motor neurons in the lumbar spinal cord showed signs of degeneration.  
The primary BBB/BSCB function is control of the CNS homeostasis by selective 
transport of molecules and cells from the systemic compartment. Substances with a 
molecular weight higher than 400 Da generally cannot cross the barriers by free 
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diffusion. However, certain endogenous large molecules, such as insulin, leptin, 
transferrin, and insulin-like growth factors, enter the brain from blood via specific 
endothelial carrier-mediated or receptor-mediated transporters (reviewed in (Ballabh et 
al., 2004; Pardridge, 2005, 1999, 1988)). Recently, IgG was detected in the perikarya of 
motor neurons of the lumbar spinal cord in mice 24 hours after intraperitoneal injection 
of IgG derived from sera of ALS patients (Engelhardt et al., 2005a). The injected IgG 
was found in the axon terminals of the lumbar ventral horn motor neurons, localizing in 
the microtubules and rough endoplasmic reticulum.  Furthermore, IgG was similarly 
detected in spinal cord motor neurons of ALS patients. There was also evidence of IgG 
intake in endothelial cells in affected areas of the spinal cord in both ALS patients and 
mice injected with human ALS IgG.  Engelhardt et al. (Engelhardt et al., 2005a) suggest 
that “there may be multiple antibodies targeting a variety of epitopes of motor neurons in 
ALS”. The molecular weight of IgG is 150,000 Da and it is unlikely that these molecules 
could cross an intact brain capillary endothelium even by receptor-mediated transcytosis. 
However, Pirttila et al. (Pirttila et al., 2004) showed that insulin-like growth factor (IGF)-
1, IGF binding protein-2, or nitric oxide were not elevated in CSF of ALS patients, 
suggesting that there is not a major disruption in the BCSFB. In another report 
(Kirkinezos et al., 2004), an ALS mouse model with a permissive BBB was created by 
crossing G93A mouse with the mdr1a/b knockout mouse and showed that cyclosporine A 
(CsA), which  cannot cross an intact BBB, BSCB or BCSFB, reached the CNS when 
delivered intraperitoneally into this combined mouse model. Since the authors did not 
investigate BBB or BSCB condition in the original transgenic G93A mice, it is possible 
that disruption or dysfunction of these barriers occur in ALS. The 1200 Da molecular 
weight of CsA is much smaller than that of IgG. Further investigation is needed to 
resolve this apparent discrepancy in ability to cross the BBB/BSCB. 
Our finding of Evans blue extravasion in early symptomatic G93A mice may 
suggest that large molecules such as IgG and other blood proteins appear in the spinal 
cord due to vascular leakage, one possible mechanism accelerating motor neuron 
damage. However, it is unclear if BBB/BSCB disruption appears prior to motor neuron 
degeneration or as result of motor neuron dysfunction. Also, differences between the 
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BBB and BSCB in endothelial protein concentrations may impact observed pathological 
changes in G93A mice. It has been shown that microvascular endothelial cells, isolated 
from murine spinal cord, morphologically similar to BBB endothelial cells, express 
reduced amounts of several prominent BBB proteins such as tight junction-associated 
proteins ZO-1 and occluding, adherens junction-associated proteins beta-catenin and VE-
cadherin, and the efflux transporter P-glycoprotein (Racke et al., 2006).   
Reduction in immunofluorescent labeling of basement membrane of affected 
G93A mice suggests possible membrane disruption. The basement membrane is part of 
the extracellular matrix and is composed of collagens, proteoglycans, elastin and several 
glycoproteins, of which laminin is the most abundant (Dermietzel and Krause, 1991; 
Rutka et al., 1988). Reduced laminin labeling was observed in cervical and lumbar spinal 
cords of both early and late symptomatic G93A mice, possibly indicating vascularization 
changes leading to capillary wall permeability. Interestingly, Ono et al. (Ono et al., 1998) 
showed fragmented and widely separated collagen bundles in capillaries and decreased 
amounts of collagen in postmortem posterior half of the lateral funiculus and in the 
anterior horn of cervical enlargements from patients with sporadic ALS. Although the 
role of these aberrations in the pathogenesis of ALS remains to be determined, the 
authors suggested that abnormalities of collagen in the perivascular spaces of capillaries 
“may be secondary to neuronal degeneration as a underlying mechanism in ALS”.  
It is well known that glucose transport through the BBB (BSCB) is mediated by 
glucose transporter isoform 1 (Glut-1) (Gerhart et al., 1989; Pardridge, 1991). Glut-1 is 
associated mainly with the brain capillary endothelial cells and is asymmetrically 
distributed between the luminal and abluminal membranes (Farrell and Pardridge, 1991). 
This asymmetric intracellular pool of glucose transporter may provide for rapid transport 
of glucose across the abluminal plasmalemma to the brain parenchyma (Stewart et al., 
1994). The alteration of Glut-1 may be related to the pathogenesis of microvascular 
permeability as has been shown, for example, in cerebral edema (reviewed in (Dwyer et 
al., 2002)). In the present study, we found low and mostly absent expression of Glut-1 in 
capillaries of both cervical and lumbar spinal cords of G93A mice at early and late stages 
of disease. This downregulation of Glut-1 expression in the endothelial cells of the BSCB 
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may be related to altered endothelial lining leading to vascular leakage. Alternatively, 
decreased Glut-1 expression may result from aggravated alterations of the BSCB in 
G93A mice. Although additional experiments such as quantitative analysis of Glut-1 
distribution and density in the endothelial plasma membranes are needed to elucidate the 
regulatory mechanisms of Glut-1 expression in the spinal cord, the present study 
indicates that alteration of Glut-1 could be involved in the pathogenesis of ALS.  
Another of our findings was that endothelia surrounding capillaries were partially 
revealed by CD146 antigen expression in the cervical and lumbar spinal cords of G93A 
mice at initial and, more markedly, at late stages of disease. Moreover, small numbers of 
delineated astrocytes were established. These results may indicate that degeneration or, at 
least, partial dysfunction, of non-neuronal cells in ALS occurs. Evidence of widespread 
inflammatory reactions in ALS already exists. The presence of monocyte/macrophage 
cells, activated microglia, and reactive astrocytes was established in the spinal cord tissue 
of most ALS patients (Engelhardt et al., 1993b; Henkel et al., 2004; Ince et al., 1996; 
Sasaki et al., 2000; Troost et al., 1990b). In a mouse model of ALS, 
immune/inflammatory responses (Hall et al., 1998b; Hensley et al., 2006) are present 
even before any evidence of motor dysfunction (Alexianu et al., 2001; Almer et al., 
2001). Strategically, astrocytes are located at the interface between the blood vessels and 
the brain as well as in the spinal cord parenchyma, influencing both the entry of blood 
cells into the CNS and the activity of invading cells once they have entered the brain 
parenchyma (reviewed in (Aschner, 1998; Mucke and Eddleston, 1993)).  It has been 
shown that activated astrocytes and microglia “in response to signals derived from the 
immune system or generated within the CNS” produce various inflammatory molecules 
that may increase the permeability of the endothelial cell barrier (Prat et al., 2001). 
Inhibition of microglia activation, for example, as recently shown in vitro and in vivo 
using minocycline, may protect the brain after ischemic stroke by improving BBB 
viability and integrity (Yenari et al., 2006). It is possible that glial cell activation in ALS 
could lead to vessel leakage. Additionally, decreased numbers of delineated astrocytes 
and their perivascular end-feet at the blood capillaries could affect vessel permeability.  
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Thus, our results confirm our previous ultrastructural findings on disruption of the 
BSCB showing functional incompetence of BSCB structural elements in ALS mice. A 
breakdown in the BSCB is clearly indicated by EB leakage in cervical/lumbar spinal cord 
microvessels in G93A mice at early and late stages of disease. Laminin labeling suggests 
that basement membrane of vessels in the spinal cords of the diseased G93A mice may be 
affected. Additionally, downregulation of Glut-1 and CD146 expressions in the 
endothelial cells of the BSCB may be related to altered endothelial lining leading to 
vascular leakage. Degeneration of astrocytes could influence BSCB integrity. 
Importantly, is BSCB breakdown a primary or secondary mechanism to motor neuron 
degeneration in G93A mice? Demonstrating BSCB disruption prior to the onset of 
disease symptoms and other pathological processes would indicate that BSCB disruption 
plays a primary role in ALS pathogenesis.  
 
3.5.  Materials and Methods 
 
3.5.1.  Animals 
 
All described procedures were approved by the Institutional Animal Care and Use 
Committee at USF and conducted in compliance with the Guide for the Care and Use of 
Laboratory Animals. Transgenic male mice B6SJL-TgN (SOD1-G93A) 1GUR (G93A; 
Jackson Laboratories), over-expressing human SOD1, carrying the Gly93→Ala mutation, 
were used. Fourteen mice at 7 weeks of age were assessed on sensitive indicators of 
degenerative state (body weight and extension reflex). Six C57BL/6J male mice of the 
same age were used as controls. All mice were maintained on a 12:12 h dark:light cycle 
(light on at 06:00 hours). Room temperature was 23° C. Food and water was available ad 
libitum. 
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3.5.2.  Characteristics of disease progression 
 
Body weight was measured weekly throughout the study. Extension reflex was 
also observed weekly, as we previously described (Garbuzova-Davis et al., 2003a; 
Garbuzova-Davis et al., 2003b). Briefly, extension of the hindlimbs was observed while 
the mouse was suspended by its tail. A score (0-2) was given to each mouse indicating: 
normal (2), partial (1) or absent (0) hindlimb extension. Eight G93A mice were 
euthanatized at initial signs of disease (tremor, weight loss, and reduced hindlimb 
extension) at approximately 13 weeks of age, while six were allowed to reach the end-
point of hindlimb paralysis at 17-18 weeks of age, when they were also euthanatized. 
Measures of body weight and extension reflex were recorded for C57BL/6J mice 
according to the same schedule as G93A mice. C57BL/6J mice were euthanatized at 12-
13 weeks (n=3) or 19-20 weeks (n=3) of age.  
 
3.5.3.  Evans Blue dye 
 
Evans Blue dye (EB, Aldrich Chemical), 961 Da, was used as a tracer for 
assessing BBB disruption (Saria and Lundberg, 1983). G93A mice with initial or late 
stage disease and C57BL/6J mice were intravenously injected with 2% EB in saline 
solution via the jugular vein 30-40 min prior to euthanasia. This surgical procedure was 
performed as we previously described (Garbuzova-Davis et al., 2003b). Briefly, mice 
were anesthetized with Isoflurane delivered using a calibrated vaporizer equipped 
induction chamber and nose cone and administered at 2-5% in O2 (2 L/min) to induce 
anesthesia and then decreased to 2% to maintain the anesthesia. The jugular vein was 
exposed and isolated using blunt dissection. The vein was ligated and a 31-gauge needle, 
attached to a 100-µl Hamilton syringe, was placed into the lumen of the vein and sutured 
in place. Evans Blue was delivered (0.2 ml/100g, 40µl/mouse) during 2 min. The needle 
was withdrawn, the suture tightened, and the incision closed with Vetbond. 
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3.5.4.  Euthanatasia and tissue preparation 
 
Euthanatasia of all mice was achieved under deep pentobarbital anesthesia and 
perfusion was not performed to avoid mechanical disruption of blood capillaries. The 
cervical/lumbar spinal cords were removed, fixed in 4% paraformaldehyde (PFA) in 0.1 
M phosphate buffer (PB), pH 7.2, and then cryoprotected in 20% sucrose in 0.1 M PB 
(pH 7.2) overnight. Coronal sections of the cervical (C2-C3) and lumbar (L4-L5) spinal 
cords were cut at 30 μm in a cryostat. 
 
3.5.5.  Immunofluorescence staining 
 
For identification of EB leakage, serial tissue sections of the spinal cords were 
thaw-mounted on slides, washed with deionized water to remove the freezing medium, 
and then rinsed several times in phosphate-buffered saline (PBS). The slides were 
coverslipped with Vectashield (Vector) and examined under an epifluorescence 
microscope. 
Some spinal cord tissues were used for immunofluorescent analysis of the 
basement membrane (laminin), endothelial cells (Glut-1, CD146), and astrocytes 
(GFAP). Briefly, sections of the cervical/lumbar spinal cords were labeled with rat anti-
mouse laminin-1 (α and β chains) monoclonal antibody (1:50, Chemicon), rabbit anti-
mouse Glut-1 polyclonal antibody (1:100, Alpha Diagnostic Int.), or double-stained with 
mouse monoclonal CD146 (1:30, Chemicon) and rabbit polyclonal antibodies against 
glial fibrillary acidic protein (GFAP, 1:500, Dako).  The next day, the slides were 
incubated for 2 hrs with appropriate secondary antibodies conjugated to either rhodamine 
(1:1500, Alexa 594, Molecular Probes) or FITC (1:500-700, Alexa 488, Molecular 
Probes) and, after several rinses in PBS, coverslipped with Vectashield or Vectashield 
with DAPI (Vector) and examined under epifluorescence using an Olympus BX60 
microscope. 
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3.5.6.  Staining of motor neurons in the spinal cord      
             
Coronal sections of the C2-C3 and L4-L5 spinal cords were rinsed in PBS and 
then stained with 0.1% cresyl violet (30 sec) for routine histological analysis of motor 
neurons. Sections were then washed several times in deionized water, air-dried, 
dehydrated, and coverslipped using Permount. 
 
3.5.7.  Statistical analysis  
 
Data are presented as means ± SEM. The nonparametric Mann-Whitney unpaired 
test was used to compare medians. 
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Figure  5.  Characteristics of disease progression in G93A mice. (A) Body weight and 
(B) extension reflex of G93A and control C57BL/6J mice. G93A mice at about 13 weeks 
of age showed initial signs of disease such as weight loss and reduced hindlimb 
extension. Terminal stage of disease was observed at 17-18 weeks of age, as 
demonstrated by complete hindlimb paralysis, significant reduction of body weight and 
absence of hindlimb extension. Arrows indicate the age of mice when euthanatasia was 
performed. The five pointed star in A indicates difference (p=0.06) in body weights 
between G93A mice at 13 weeks of age and 18 weeks of age; the four pointed star 
indicates a significant difference (p=0.007) in body weights between G93A and 
C57BL/6J  mice at 18 weeks of age. The four pointed star in B indicates a significant 
difference in extension reflex (p<0.001) between G93A mice at 13 weeks of age and 18 
weeks of age. 
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Figure  6.  Motor neurons in the cervical spinal cord of G93A mice at early and late stage 
of disease (cresyl violet staining). In the cervical spinal cord, many healthy motor 
neurons with large soma and neuritic processes were identified in the control C57BL/6J 
mice at (A) 12-13 weeks of age and (B) 19-20 weeks of age. In G93A mice, numerous 
motor neurons with vacuolization (asterisks) were found at (C) 13 weeks of age and (D) 
decreased numbers of motor neurons were noted in 17-18 week old mice. Motor neurons 
of various sizes displayed vacuolization (asterisks). Scale bar on left side is 200 μm, right 
side is 50 μm. 
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Figure  7.  Motor neurons in the lumbar spinal cord of G93A mice at early and late stage 
of disease (cresyl violet staining). In the lumbar spinal cord, C57BL/6J mice at (A) 12-13 
weeks of age and (B) 19-20 weeks of age showed numerous motor neurons with strong 
Nissl body staining. Most degenerated or swollen motor neurons (asterisks) were found 
in G93A mice at (C) early (13 weeks of age) and (D) late (17-18 weeks of age) stages of 
disease; most surviving motor neurons were small. Scale bar on left side is 200 μm, right 
side is 50 μm. 
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Figure  8.  Evans Blue fluorescence in the cervical spinal cord of G93A mice at early and 
late stages of disease. In the cervical spinal cord, EB was clearly detected within the 
blood vessels (red, arrowheads) in the control C57BL/6J mice at (A, B, C) 12-13 weeks 
of age or  (D, E) in the lumen of  vessels (brilliant green) at 19-20 weeks of age.  In 
G93A mice, vascular leakage of EB (red, arrows) was detected (F, G) at early (13 weeks 
of age) disease symptoms and (H, I, J) at end-stage of disease (17-18 weeks of age) when 
more EB extravasation was seen. Arrowheads in F and I indicate vessel permeability. 
Scale bar in A-J is 25 μm.  
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Figure  9.  Evans Blue fluorescence in the lumbar spinal cord of G93A mice at early and 
late stages of disease. In the lumbar spinal cord, EB dye (red, arrowheads) was 
determined intravascularly in the control C57BL/6J at (A, B) 12-13 weeks of age and (C, 
D) 19-20 weeks of age similar to the cervical spinal cord. EB extravasation abnormalities 
were found in G93A mice at (E, F) 13 weeks of age (red, arrows). (G, H) Significant EB 
diffusion (red, arrows) into the parenchyma of the lumbar spinal cord from many blood 
vessels was detected in G93A mice at end-stage of disease (17-18 weeks of age). 
Arrowheads in F and G indicate vessel permeability. Scale bar in A-H is 25 μm. 
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Figure  10.  Immunofluorescence staining for laminin in the cervical spinal cord of 
G93A mice at early and late stages of disease. Many blood vessels of different diameter 
were immunoreactive for laminin-1 (red) in the control C57BL/6J mice at (A) 12-13 
weeks of age and (B) 19-20 weeks of age. In G93A mice at (C) initial or (D) late stages 
of disease, capillaries appear to be less numerous. In some early symptomatic G93A 
mice, (C) blurry spots around capillaries were found. The nuclei in A-D are shown with 
DAPI. Scale bar in A, B, C, D is 200 µm; inserts a, b, c, d is 50 µm. 
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Figure  11.  Immunofluorescence staining for laminin in the lumbar spinal cord of G93A 
mice at early and late stages of disease. Various laminin-positive vessels (red) were 
observed in the control C57BL/6J mice at (A) 12-13 weeks of age and (B) 19-20 weeks 
of age similar to cervical spinal cord results. Fewer blood vessels were labeled in G93A 
mice at (C) early or (D) end-stage of disease. The nuclei in A-D are shown with DAPI. 
Scale bar in A, B, C, D is 200 µm; inserts a, b, c, d is 50 µm.  
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e 
0 
 was found in G93A 
ice at (K), (L) early or (M), (N) end-stage of disease. The nuclei in H-N are shown 
ith DAPI. Scale bar in J, M, N is 50 µm; H, I, K, L is 25 µm.  
 
 
Figure  12.  Immunofluorescence staining for Glut-1 in the cervical and lumbar spinal 
cords of G93A mice at early and late stages of disease. Cervical spinal cord. High 
expression of Glut-1 (red) was determined in endothelial lining of many blood vessels of 
various diameters in the cervical spinal cord of the control C57BL/6J mice at (A), (B) 12-
13 weeks of age and (C) 19-20 weeks of age. In G93A mice at (D), (E) initial or (F), (G) 
late stages of disease, immunoreaction for Glut-1 in the endothelial cells appear to b
low, or nonexistent. The nuclei in A-G are shown with DAPI. Scale bar in A and E is 5
µm; B, C, D, F, G is 25 µm. Outline of white dots indicates configuration of blood 
vessels. Lumbar spinal cord. Similar to the cervical spinal cord, most Glut-1-positive 
endothelial cells (red) were observed in the control C57BL/6J mice at (H), (I) 12-13 
weeks of age and (J) 19-20 weeks of age. Less Glut-1 expression
m
w
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cytes 
l or (E, F) late stages of disease. Note: increased astrocyte activation 
 the cervical spinal cord (F, asterisks) was detected in G93A mice at late stage of 
isease. The nuclei in A, C, and E are shown with DAPI. Scale bar in A, C, E is 50 µm; 
, D, F is 25 µm.  
 
Figure 13.  Immunohistochemical staining for endothelial cells (CD146) and astro
(GFAP) in the cervical spinal cord of G93A mice at early and late stages of disease. (A, 
B) Normal appearance of endothelial cells (green, arrowheads) and delineated astrocytes 
(red, asterisk) was observed in the control C57BL/6J mice at 19-20 weeks of age. 
Endothelia (green, arrowheads) surrounding capillaries were partially revealed in G93A 
mice at (C, D) initia
in
d
B
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B, 
 arrowheads) was observed. Note: increased astrocyte activation 
 the lumbar spinal cord (F, G, asterisks) was detected in G93A mice at late stage of 
isease. The nuclei in A, C, D, and F are shown with DAPI. Scale bar in A, C, D, F is 50 
m; B, E, G is 25 µm. 
Figure  14.  Immunohistochemical staining for endothelial cells (CD146) and astrocytes 
(GFAP) in the lumbar spinal cord of G93A mice at early and late stages of disease. (A, 
C) Similar to cervical spinal cord, endothelial cells (green, arrowheads) and astrocytes 
(red, asterisk) in C57BL/6J mice at 19-20 weeks of age appeared normal. In G93A mice 
at (D, E) early or (F, G) end-stage of disease, decreased CD146 antigen expression by 
endothelial cells (green,
in
d
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CHAPTER 4 – THE NEUROPROTECTIVE EFFECTS OF THE SIGMA 
RECEPTOR AGONIST DTG (1,3-DI-O-TOLYLGUANIDINE) ON A MOUSE 
MODEL OF ALS 
 
4.1.  Introduction 
 
 Other aspects of ALS have been of interest to our lab including inflammation and 
excitotoxicity.  Treatments that have been beneficial in rodent models of stroke, for 
example, have potential therapeutic benefits to ALS models.  It has been shown by our 
colleagues (Keith Pennypacker et al.) that in middle cerebral artery occlusion (MCAO) 
sigma receptor agonists are both neuroprotective and anti-inflammatory (Ajmo et al., 
2006). We proposed that sigma receptor activation will protect motor neurons from 
excitotoxicity and microglia mediated inflammation, the key pathological components 
shared by stroke and ALS.  Specifically, we wished to test whether this class of drugs 
was effective at reducing motor neuron degeneration and secondary inflammation in the 
SOD1 G93A mouse model of ALS. 
Inflammatory responses are common to all types of neuronal injury and enhance 
neurodegeneration (DeLegge and Smoke, 2008).  This response is mediated by microglia, 
the endogenous macrophage in the CNS, by astrocytes, and by infiltrating immune cells, 
which include macrophages and lymphocytes.  Resting, nonphogocytic, microglia do not 
contribute to neurodegeneration.  However, upon injury-induced activation, they can 
contribute to the destruction of neurons with the release of TNF-α (Bezzi et al., 2001; 
Hide et al., 2000; Noda et al., 2000), leading to the activation of the transcription of pro-
inflammatory genes, such as inducible nitric oxide synthase and proinflammatory 
cytokines (Gebicke-Haerter, 2001).  Histological analysis of spinal sections obtained 
from SOD1 transgenic mice have shown a three fold increase in activated microglia per 
slice compared to their wild type littermates.  Release of tumor necrosis factor alpha 
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(TNF-α) and nitric oxide (NO) can induce glutamate release from astrocytes (Shibata and 
Kobayashi, 2008). Further neurodegeneration is elicited through macrophages and other 
immune cells infiltrating into the ALS-damaged area of the spinal cord. 
Sigma receptors, first identified by Martin et al., 1976, are found in numerous tissues 
and organs.  These pleiotropic receptors have since been classified into two types on the 
basis of pharmacology, sigma-1 and sigma-2, (Bourrie et al., 2004).  Both subtypes have 
high to moderate affinity for antipsychotics, such as haloperidol, and guanidines, such as 
DTG (1,3-di-o-tolylguanidine). Sigma-1 receptors have two putative transmembrane 
domains and are different than any other known mammalian protein.  While the 
endogenous ligand for sigma receptors has not been clearly identified, various candidates 
have been suggested.  Progesterone, for example, and other neurosteroids, including 
pregnenolone and dehydroepiandrosterone, have high affinity for sigma receptors 
(Maurice et al., 1997).  Given the general neuroprotective properties of neurosteroids and 
their abundance in the cortex, these sigma ligands would be obvious candidates to be 
investigated as possible endogenous ligands to reduce microgliosis and ensuing 
inflammation.  
The current FDA approved therapy for ALS, Riluzole, is thought to modulate 
excitotoxicity by acting as a glutamate receptor antagonist, although use of this drug 
results only in a three month increase in lifespan.  Riluzole treatment, however, does 
nothing for the secondary inflammatory processes, which are critical in the pathology of 
neurodegenerative disorders such as ALS, AD, and stroke.  Taken together, effective 
treatment regimens for ALS (and possibly other neurodegenerative disorders) should 
include strategies to minimize both excitotoxicity and inflammation.  
 Recently, it has been shown that microglia express sigma-1 receptors, making DTG a 
molecule of therapeutic interest in ALS (Hall et al., 2009).  Additionally, sigma receptor 
activation has been proven to modulate cytokine progression and inhibit the secretion of 
TNF-α, NO, and interferon-γ by macrophages induced by lipopolysachharide (LPS) 
injection (Bourrie et al., 1995).  Overall, DTG is an exceptional candidate for ALS 
treatment because it promotes neuronal viability even after neurodegenerative and 
inflammatory processes have already begun.  Furthermore, recent experiments have 
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shown that stimulation of sigma receptors decreases the excitability of neurons. Thus, the 
treatment is two-fold in modulating the excitability of neurons and modulating 
neuroinflammation.  In the following experiments, life expectancy, weight retention and 
motor skills of SOD1 mice were examined following chronic systemic administration of 
DTG. 
 
4.2.  Materials and Methods 
 
4.2.1.  Osmotic Minipumps and subcutaneous implantation 
 
Sterile Alzet osmotic minipumps-model 2004 (Durect Corp. Cupertino, Ca.), with 
a flow rate of 0.25μL/hr were filled with 100mM DTG (1,3-di-o-tolylguanidine- a sigma 
1 receptor agonist) in 3% lactic acid as vehicle and incubated at 37oC in sterile saline for 
48 hours.  All procedures involving experimentation on animals were performed in 
accordance with the guidelines set forth by the University of South Florida Animal Care 
and Use Committee.  Animals (90 days old- 25g) were anesthetized with 1-2% isoflurane 
and shaved and scrubbed with 10% Betadine solution at the site of incision.  A small (3 
cm) incision was made, exposing the neck, and double bladed scissors were used to form 
a subcutaneous pocket along the back of the animal between the scapula and towards the 
tail for placement of the pump. 
 
4.2.2.  Mice 
 
40 SOD1 G93A mice (C57/B6 background) and 10 NTG controls were purchased 
from Jackson Labs (Bar Harbor, ME.).  These mice express 18 copies of mutant SOD1 
and develop ALS pathology at approximately 100 days.  The average lifespan is 
approximately 130 days and the phenotype closely resembles a more aggressive familial 
form of the disease.  The model was chosen because it was so widely accepted in the field 
at the time and the therapeutic/pathological window was short enough to run multiple 
studies in succession.  All surgeries were performed at disease onset (~100 days) and run 
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for 30 days or until the animal reached endpoint stage.  Half of the mice received sham 
infusions (3% lactic acid only). 
 
4.2.3.  Histology and Immunohistochemistry 
 
 Mouse spinal cords were carefully removed and fixed in 10% formaldehyde 
(formalin) for 72 hours and then passed through a series of sucrose solutions (10-30%) 
over another 72 hours.  Tissues were frozen to the peltier stage (Physitemp, Clifton, NJ) 
of a histoslide (Leica, Heerbruug, Switzerland) and sectioned coronally at 25 μm.  After 
incubating the sections with blocking buffer (Tris-buffered saline with 10% normal goat 
serum, 0.1% Triton X-100, and 0.02% sodium azide) for 60 min, primary antibodies 
against SOD1 (1:500) were applied and incubated at 4o C overnight.  After thorough 
washing, the sections were incubated with secondary antibody, Alexa 488 and 594 
fluorophores (1:1000, 1:4000-Invitrogen) in the dark at ambient temperature for 2 hours.  
This incubation was followed by a Hoechst (1:10,000, Sigma, St. Louis, MO) nuclear 
stain, and the sections were washed and sealed with Gel-Mount (Electron Microscopy 
Sciences, Hatfield, PA).  The images were analyzed on a Zeiss Imager Z1 fluorescence 
microscope with a Zeiss Axiocam Mrm camera (Oberkochen, Germany) using 
Axiovision 4.7.  FluoroJade staining was used to identify “dying” motorneurons and 
Cresyl violet staining was used for general morphology of motor neurons and vacuolated 
mitochondria (as previously described). 
 
4.2.4.  Behavior 
 
 Motor deficits and health of the animals were assessed throughout the experiment.  
Body weights were taken biweekly during the 28 day treatment as well as daily 
performance on a rototod test.  The rotorod is designed to assess motor coordination, 
balance and equilibrium.  The mouse is placed on the rod and the rotorod accelerates 
gradually to a pre-set speed.  Latencies for the mice to fall from the rod are recorded.  
The rototod consists of a semi-enclosed chamber, which contains a beam made of ribbed 
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plastic and flanked by round plates on either side to prevent any escape.  The rod is fixed 
at a height of 20 cm above the counter and the mouse is placed on top of the beam facing 
in the orientation opposite to that of its rotation, so that forward locomotion is necessary 
to avoid falling.  The rotorod spins consistently at 1 of 10 pre-set speeds (#5 was chosen) 
for three 2-minute trials.  Latencies in falling from the rod are recorded automatically 
once the fallen animal interrupts a laser thereby stopping the timer.  Each mouse has 3 
trials with a 20 minute interval between trials.  Once it is evident that the mice are unable 
to perform, animals are removed from the study. 
 
4.3.  Results and Conclusions 
 
 Although preliminary data (n=10) with DTG indicated that prophylactic treatment 
of SOD1 G93A mice with DTG increased lifespan and retained body weight compared to 
sham treated littermates, we were unable to confirm either observation in this study 
(n=40).  As table 2 below indicates, the average lifespan for the DTG treated group was 
~134 days as compared to the sham treated group which was ~130 days.  This modest 
increase was not statistically significant (figure 15).  The behavioral data (not shown) and 
weight retention data were similar in that no significant detectable differences could be 
found between the two groups.  Immunohistochemical analysis, though not performed to 
any great extent given the outcome of the study, indicate using Flurojade, that most motor 
neurons were dead or dying by the end of the experiment, proposed earlier as “scortched 
earth” (figure 16).  That is, the damage done to the spinal cord motor neurons was so 
great, that a minor therapeutic benefit could not be observed. If these studies were to be 
repeated, administering DTG prior to disease endpoint or using a different model with a 
larger therapeutic window may be more effective. 
 
 
 
 
 
4.4.  Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2  Lifespan and body mass of mice receiving DTG or sham infusions 
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Figure 15. Graphical representation of lifespan (Y-axis) in table 2 showing modest 
benefit with DTG, but without significance. 
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Figure 16. The “scortched earth” of degenerating neurons (as well as glia) in the spinal 
cord of SOD1 G93A mice were detected by Fluoro-Jade staining. A) Fluoro-Jade detects 
tracts of degenerating neurons. B) At higher magnification, individual neurons are 
visible. (Borrowed from an ALSA grant application- Pennypacker et al. 2006) 
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CHAPTER 5 – THE NEUROPROTECTIVE EFFECTS OF THE CARBOXYL 
TERMINUS OF GAMMA LAMININ, KDI, ON A MOUSE MODEL OF ALS 
 
5.1.  Introduction 
 
 Because the exact cause of Amyotrophic Lateral Sclerosis (ALS) is unknown, 
effective treatments are yet to be developed.  It is for this reason that multiple approaches 
for therapies have been investigated.  Although ALS is a proteinopathy, glutaminergic 
dysregulation and motor neuron death also occur and therefore various neuroprotectants 
have been of interest.  In the following experiments, we investigated the use of laminin, 
namely a fragment of γ-laminin, as a therapy for ALS.  Laminin is a heterotrimeric 
extracellular matrix glycoprotein involved in numerous biological processes.  Recently, it 
has been elucidated that it is, in fact, the soluble tripeptide fragment-lysine, aspartic acid, 
and isoleucine (KDI) on the carboxyl terminus of the γ-laminin chain that promotes 
neurite outgrowth (Liesi et al., 2001).  To date, there are 15 known isoforms of laminin 
that are expressed in mammals in a tissue-specific manner.  Five different α subunits have 
been described, 4 β, and 3 γ which arrange as a cruciform heterotrimer (αβγ) of ~900KD 
in total mass as intact laminin molecules (Miner, 2008).   The molecules are the main 
non-collagenous components of basement membranes and also play diverse roles in the 
extracellular matrix relating to cell structure, adhesion, differentiation, migration, 
signaling, metastasis, and neurite outgrowth.  It has also been shown that laminin is 
upregulated during development and repair of most tissues, and portions of the molecule 
can maintain biological activity following cleavage events.  Some laminin cleavage 
products retain biological activity (Wiksten et al., 2003).  Over the past decade, our 
collaborator, Päivi Liesi, has worked extensively with laminin.  In particular, she has 
elucidated that the carboxyl terminus of γ1-laminin is responsible for neurite outgrowth 
 95 
both in vitro and in vivo (Liebkind et al., 2003; Wiksten et al., 2004b).  Original work 
focused on the decapeptide of the molecule exerting these effects; however, subsequent 
studies of the hexapeptide and finally the tripeptide, KDI, still showed activity as a 
neurite outgrowth factor. KDI has also proven to be a glutamate receptor antagonist via 
patch clamp studies.  In these studies, it was demonstrated that KDI non-competitively 
inhibited ionotropic glutamate receptors (at 1mg/mL) ~100% of AMPA -alpha-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid and 50% of NMDA- N-Methyl-D-
Aspartate  receptors (Moykkynen et al., 2005).  In vitro work on primary human 
embryonic spinal cord cultures and organotypic slices of human embryonic spinal cord 
embedded in Matrigel showed measurable tracts of extending neurites.  The most recent 
experiment performed by Liesi et. al. (2006) showed that rat spinal cords, following 
transsection, could heal with the continued administration of KDI to the site.  In this 
experiment, glial scarring was minimal and the animals were in most cases able to 
completely recover from paralysis (Wiksten et al., 2004b).  The molecule has thus shown 
promise as a therapeutic for neurodegeneration, specifically ALS and AD, and we have 
subsequently investigated its effect in different mouse models of neurodegenerative 
disease.   
         Because it is not yet known whether KDI can cross the blood-brain barrier 
following systemic administration, direct infusion of the molecule into the cerebrospinal 
fluid (CSF) of these mice was required.  Recent work by other groups has proven, 
however, that compounds in the CSF do not diffuse efficiently.  It was therefore 
necessary to continuously infuse the peptide into the intrathecal space (lumbar cistern) of 
the spinal cord of the mice.  This has proven to be an arduous task for many research 
groups and was achieved here with assistance from the ALS Therapy Development 
Foundation.  To the authors’ knowledge, successful long-term intrathecal catheterization 
in mice, particularly in conjunction with Alzet osmotic minipumps, has not been reported 
elsewhere.  
The pathologies of ALS begin in the lower lumbar region of the spinal column 
and progress rostrally causing hindlimb paralysis and eventually death.  A series of 
transgenic animals have been developed over the years to mimic the disease; the most 
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frequently used is the SOD1 G93A model.  This animal has a glycine to alanine 
substitution at the 93rd position of the 153 amino acid SOD1 monomer.  The mice 
become paralyzed at approximately 100 days and live another 20-30 days with ALS-like 
symptoms.  Due to the aggressive disease progression in this model, they were the most 
commonly used model to investigate the disease at the time.  The use of KDI in this 
mouse model of ALS was promising for 2 reasons:  First, because KDI was shown to be a 
neurite outgrowth promoter (Liebkind et al., 2003), enhanced survival, if not MN 
regrowth was anticipated in these mice dying of motor neuron loss.  Second, given KDI’s 
potent ability, similar to riluzole and memantine, to lower synaptic glutamate levels, it 
was reasonable to anticipate KDI might reduce excitotoxic insults in ALS.  
 
5.2.  Materials and Methods 
 
5.2.1.  Intrathecal Catheter Assembly 
 
Intrathecal catheters were fashioned as described previously by first inserting a 
10cm, 0.005” diameter tungsten wire (Small Parts, Inc. Miramar, Fl)  into a 3 cm length 
of polyethylene tubing (PE-10, Becton Dickinson, Sparks, MD.) with an internal 
diameter of 0.011” and stretching the material so it was snug with the wire.  The 
unstretched portion of the PE-10 (outer diameter 0.024”) was next inserted into a 4cm 
long polyvinyl tubing (Durect Corp. Cupertino, Ca.) (internal diameter 0.027’’) with 
approximately 2 cm of overlap.  The difference of 0.003” in the step-up to the larger 
polyvinyl tubing was filled with Locktite 454 adhesive (Plastics One. Roanoke, VA.) and 
secured with a silk suture.  The assemblies were then left to dry overnight and sterile 
water was forced through to assure that the lines were not occluded or damaged. 
 
5.2.2.  Osmotic Minipumps 
 
Sterile Alzet osmotic minipumps-model 2004 (Durect Corp. Cupertino, Ca.), with 
a flow rate of 0.25μL/hr were filled with 200ug (1mg/mL) of KDI (NeoMPS, San Diego, 
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CA) diluted in artificial CSF (Harvard Apparatus, Holliston, MA) and incubated at 37oC 
in sterile saline for 48 hours.  Typically, catheters were attached and primed at this time, 
but the tungsten wire needed to remain in place for stability during insertion into the 
spine. 
 
5.2.3.  Mice 
 
20 SOD1 G93A mice (C57/B6 background) were purchased from Jackson Labs 
(Bar Harbor, ME.).  These mice express 18 copies of mutant SOD1 and develop ALS 
pathology at approximately 100 days.  The average lifespan is about 130 days, and the 
phenotype closely resembles a more aggressive familial form of the disease.  This ALS 
mouse model was chosen because at the time it was widely accepted in the field and the 
therapeutic/pathological window was short enough to run high throughput studies in 
succession very timely.  All surgeries were performed at disease onset (~100 days) and 
run for 28 days or until the animal reached endpoint stage.  
 
5.2.4.  Intrathecal Infusions 
 
All procedures involving experimentation on animals were performed in 
accordance with the guidelines set forth by the University of South Florida Animal Care 
and Use Committee.  Animals (90 days old- 25g) were anesthetized with 1-2% isoflurane 
and shaved and scrubbed with 10% Betadine solution at the site of incision.  A small (3 
cm) incision was made, exposing the lumbar region of the vertebral column, and double 
bladed scissors were used to form a subcutaneous pocket along the back of the animal 
between the scapula and towards the head.  A puncture was then made between the L2 
and L3 vertebrae with a 23 gauge needle that allows the small, stretched portion of PE-10 
(stabilized with the tungsten wire) to be inserted 0.9 cm into the intrathecal space and 
stopped by the silk suture used to adjoin the two different sized tubings.  Accurate 
placement of the catheter was visualized in every instance by a brief tail flick or muscle 
twitch, at which point the tungsten wire was removed and Alzet pump attached.  Another 
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silk suture was used to “anchor” the catheter into the superficial erector musculature 
dorsal the vertebral column.  The placement of the second suture into the musculature 
immediately caudal to the first “assembly” stitch on the catheter prevented them from 
being pulled out during the course of the experiment.  The pumps infused for 28 days, 
around which time the animals were at the terminal stages of paralysis. 
 
5.2.5.  Histology and Immunohistochemistry 
 
 Mouse spinal cords were carefully removed and fixed in 10% formaldehyde 
(formalin) for 72 hours and then passed through a series of sucrose solutions (10-30%) 
over another 72 hours.  Tissues were frozen to the peltier stage (Physitemp, Clifton, NJ) 
of a histoslide (Leica, Heerbruug, Switzerland) and sectioned coronally at 25 μm.  After 
incubating the sections with blocking buffer (Tris-buffered saline with 10% normal goat 
serum, 0.1% Triton X-100, and 0.02% sodium azide) for 60 min, primary antibodies 
against SOD1 (1:500) were applied and incubated at 4 o C overnight.  After thorough 
washing, the sections were incubated with secondary antibody, Alexa 488 and 594 
fluorophores (1:1000, 1:4000-Invitrogen) in the dark at ambient temperature for 2 hours.  
This incubation was followed by a Hoechst (1:10,000, Sigma, St. Louis, MO) nuclear 
stain, and the sections were washed and sealed with Gel-Mount (Electron Microscopy 
Sciences, Hatfield, PA). FluoroJade staining was used to identify “dying” motorneurons.  
The images were analyzed on a Zeiss Imager Z1 fluorescence microscope with a Zeiss 
Axiocam Mrm camera (Oberkochen, Germany) using Axiovision 4.7.   
 
5.2.6.  Behavior 
 
 Motor deficits and the animals’ health were assessed throughout the experiment.  
Body weights were taken daily during the 28 day treatment as well as biweekly 
performance on a rototod test.  The rotorod is designed to assess motor coordination, 
balance and equilibrium.  The mouse is placed on the rod and the rotorod accelerates 
gradually to a pre-set speed.  Latencies for the mice to fall from the rod are recorded.  
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The rotorod consists of a semi-enclosed chamber which contains a beam made of ribbed 
plastic and flanked by round plates on either side to prevent any escape.  The rod is fixed 
at a height of 20 cm above the counter, and the mouse is placed on top of the beam facing 
in the orientation opposite to that of its rotation, so that forward locomotion is necessary 
to avoid falling.  The rotorod spins consistently at 1 of 10 pre-set speeds (#5 was chosen) 
during three 2-minute trials.  Latencies for the mice to fall from the rod are recorded 
automatically once the fallen animal interrupts a laser, thereby stopping the timer.  Each 
mouse was given 3 trials with a 20 minute interval between trials.  Once it was evident 
that the mice were no longer able to perform the task, they were removed from the study. 
 
5.3.  Results and Conclusion 
 
 KDI was of particular interest to us as a therapeutic for ALS for several reasons.  
First and foremost, it was demonstrated both in vitro and in vivo that KDI was a potent 
neurite outgrowth factor.  Previous work by Liesi et all demonstrated that neurons would 
extend long processes when embedded in matrigel containing KDI as compared to 
standard media (figure 17).  More work from her laboratory revealed that KDI, following 
a full transection of rat spinal cords at L5-L6, could restore the animal’s ability to walk 
within a couple of weeks with drastic changes in gross morphology of the SC (figure 18).  
Hematoxylin eosin staining reveled that glial scarring was also minimized and that 
neurons were actually able to grow through the wound (figure 19).  Further investigation 
from her lab revealed, using patch clamp studies on human neocortical neurons, that KDI 
was a potent inhibitor of glutamate receptors (both AMPA and NMDA).  The only FDA 
approved drug for ALS, riluzole, functions by lowering synaptic levels of glutamate.  
Memantine is another glutamate reducing agent that has shown benefit to transgenic ALS 
mice.  Glutamate excitotoxicity unequivocally plays a role in the pathogenesis of ALS 
and the therapeutic effects of these compounds supports that.  We were confident that we 
had a small molecule of similar biological capability that would benefit the animals in 
two ways: reduced glutamate concentrations at synapses and promotion of axonal growth. 
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 As indicated in the table below (table 3), KDI had no significant effect (p=0.62) 
on lifespan in the treated cohort. The animals were monitored daily and given a score 1-
10 based on their condition.  Their ability to walk, to groom, and to control bodily 
functions were taken into account and a clinical endpoint was established when the 
animal was paralyzed completely, unable to attain food and water.  There were no 
differences between the groups in this analysis regarding the progression of the disease in 
theses animals (data not shown).  Rotarod performance in these studies were 
inconclusive.  Extensive histological and biochemical analysis of tissues were not 
warranted, at this time, based on survival and progression data and studies with KDI and 
ALS were halted.  Fluorojade analysis revealed a “scortched earth” effect in the tissues of 
mice at the end stage in previous studies.  That is, the number of dying or dead motor 
neurons was so high that any changes induced by KDI would have been imperceivable.  
 Transgenic mouse models, we have found, are limited in most cases to answering 
the questions that they were designed for. The SOD1 G93A mouse model, for example, 
has about 18-22 copies of the mutant gene being expressed, which does not correlate in 
any way with fALS cases, let alone sporadic cases in which the inclusions have little or 
no WT SOD1 bound (Bruijn et al., 2004b).  Moreover, using a model of protein 
aggregation to study glutamate reducing compounds can be misleading in assessing the 
effects.  There is some justification that glutamate is dysregulated in these mice based 
upon levels of mutant SOD1, though results have varied in that determination (Tortarolo 
et al., 2006) (Tovar-y-Romo and Tapia, 2006).  In retrospect, the phenotype in this model 
was so aggressive that it was difficult to test therapeutic compounds with it.  The mice 
would begin to be paralyzed at 90 days of age, which was quite young for the surgeries 
involved.   Then they would quickly decline and need to be euthanized as quickly as 15-
20 days later (statistically no different than untreated animals).  The value of the SOD1 
G93A mouse to the ALS research community has since been questioned.  Personal 
communication with the inventor of the SOD1 G93A transgenic mouse in July 2006 
revealed that his lab no longer uses this particular mouse for ALS studies supporting our 
decision to discontinue working with them. 
5.4.  Figures 
 
             
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.  Lifespan of KDI-treated (blue) and sham treated (black) SOD1 G93A mice 
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Figure 17. Liesi et al. 2003 (previous work and rationale for experiment) TUJ1-
immunoreactive (tubulin/axon labeling) neurons from the human embryonic spinal cord 
on top of the injured monolayers of the human spinal cord glial cells after 48 hr in vitro. 
In a, a neuron in the lower right corner of the photograph extends a long neurite in the 
presence of 0.1 μg/ml of the KDI peptide in the culture medium. Note that the moderate 
TUJ1 immunoreactivity of the majority of the underlying glial cells cannot be seen 
because of dark exposure of the photograph. Only the intense neuronal and some more 
intense glial immunoreactivity can be seen. In b, a spinal cord neuron fails to extend long 
neurites when no KDI peptide is present in the culture medium. Scale bar = 17 μm. 
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Figure 18.  Liesi et al. 2004 (previous work and rationale for experiment) Stereo 
microscopic images of paraformaldehyde-fixed KDI-treated (a, b) and placebo-treated (c, 
d) spinal cords 14 weeks after operation. Dorsal images (a, c) show a connective tissue 
scar that forms at the site of laminectomy (arrow). It is obvious from these stereo images 
that dorsal (a) and ventral (b) poles of the spinal cord of the KDI-treated animal (motor 
score 3/4) are both better preserved than are dorsal (c) and ventral (d) poles of the spinal 
cord of the placebotreated animal (motor score 1/1). Placebo-treated spinal cord consists 
of semitranslucent bloody opaque tissue at the transection site whereas KDI-treated 
spinal cord looks more intact. 
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Figure 19. Liesi et al. 2004 (previous work and rationale for experiment) Examples of 
longitudinally cut hematoxylin-eosin-stained paraffin sections (4 μm) through the ventral 
spinal cord show extent of damage in KDI-treated (a–c) and placebo-treated (d–f) 
animals. The motor score of each animal after 14 weeks is indicated in the left upper 
corner of each figure. Results indicate that spinal cords were transected completely and 
confirm that all KDI treated spinal cords (even the one in c) show less damage and 
smaller scar areas than do any placebo-treated spinal cords. KDI treatment thus reduces 
tissue damage and cavity formation and improves the chances for the tissue to heal. Scale 
bar 500 μm. 
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CHAPTER 6 – A NOVEL TECHNIQUE FOR SIMULTANEOUS BILATERAL 
BRAIN INFUSIONS IN A MOUSE MODEL OF NEURODEGENERATIVE 
DISEASE 
 
Steven P. Bennett1,2, Tim Boyd1,2 , Michelle Norden1,2,3, Jaya Padmanabhan1,2, Peter 
Neame2, Inge Wefes2,3, Huntington Potter1,2,3 1-Johnnie B. Byrd Sr. Alzheimer’s Center 
and Research Institute, Tampa , Florida 33613  2-University of South Florida, 
Department of Molecular Medicine, Tampa 33612  3-Eric Pfeiffer Suncoast Alzheimer’s 
and Gerontology Center 
 
6.1.  Abstract 
 
  A common problem faced by researchers using transgenic models to study 
disease is the phenotypic variability that exists within a group or colony of animals.  
Significant pathological analyses thus often require large numbers of mice to perform.  
Many lines of transgenic mice harboring the gene for human amyloid precursor protein 
(APP) with different mutations causing familial Alzheimer’s disease have been 
developed over the past decade to study plaque deposition and other aspects of AD.   
However, variations in size, density, plaque number, and total amyloid load between 
animals of the same age and genotype have been identified by our lab and others. 
Therefore, to study the effects of compounds on amyloid pathology, it was imperative to 
develop a technique that would allow each brain hemisphere to receive different 
infusions.  We have developed catheters that facilitate simultaneous bilateral infusion in 
mouse brains, thereby using the contralateral hemisphere of the same animal as an 
internal control while studying, for example, the effect of compounds on amyloid 
plaques, a pathological hallmark of the progression of Alzheimer’s disease (AD).  Several 
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molecules have been identified within the plaques including the major component, the Aβ 
peptide, and two inflammation-related proteins, apolipoprotein E (apoE) and the serine 
protease inhibitor α-1 antichymotrypsin (ACT).   In these experiments, ACT was infused 
unilaterally over a period of 28 days into the parenchyma and lateral ventricles of 
PS/APP mice and observed to associate with amyloid plaques, with minimal mortality.  
Utilizing the ACT/Aβ interaction, an outline of this procedure is discussed here in detail.  
 
6.2.  Introduction 
 
 Alzheimer’s disease is the most common form of neurodegeneration, affecting 
over 5 million people nationwide.  Approximately 1 person in 8 will be diagnosed with 
AD by the age of 65, and 1 in 2 by the age of 85 (National Institutes of Health U.S. 
Department of Health and Human Services).  The disease is characterized by severe 
cognitive decline, leading to dementia and death within an average of 8 years from 
diagnosis.  Pathologically, the disease outcome is massive neuronal loss, extracellular 
deposits of amyloid, and intracellular accumulation of neurofibrillary tangles (Selkoe, 
1986).  Several proteins have been identified within the plaques including Aβ, 
apolipoprotein E (apoE) (Wisniewski and Frangione, 1992) and Alpha 1-
antichymotrypsin (ACT) (Abraham et al., 1988).  Aβ is the primary component of the 
plaques and is a 40-43 amino acid peptide proteolytically derived from the amyloid 
precursor protein (APP) (Hardy and Selkoe, 2002).  Mutations in the APP gene that cause 
AD result in an increased production of pathogenic forms of Aβ (Tanzi et al., 1991).  
ApoE and ACT are part of a local inflammatory process in the brain.  Aβ binds to ACT 
and ApoE, and these proteins serve to catalyze the conversion of Aβ into filaments in 
vitro (Ma et al., 1996; Wisniewski et al., 1994), and in vivo to form beta-pleated 
structured amyloid deposits (Bales et al., 1999; Nilsson et al., 2001). 
 ACT is a 68 kDa acute phase serum glycoprotein from the family of serine 
protease inhibitors (serpins).  Systemically, it is released by hepatocyes and monocytes in 
response to inflammation and functions as a suicide inhibitor of cathepsin G released by 
neutrophils (Kalsheker, 1996).  In the brain, ACT is known to be produced by and 
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released from astrocytes in response to IL-1β stimulation by microglia following trauma, 
infection, or amyloidoses (Abraham, 2001; Das and Potter, 1995).  ACT is highly 
upregulated in AD brain and is involved both in the formation of amyloid plaques 
(Abraham et al., 1988) and in the phosphorylation of tau (Padmanabhan et al., 2006).  
Using a transgenic mouse carrying a mutated human presenilin gene (PS) and a mutated 
human APP gene (PS/APP), we observed the co-localization of ACT on existing amyloid 
plaques in adult PS/APP mice, utilizing a novel brain infusion technique. 
 Amyloid plaque load can vary significantly from animal to animal of the same 
APP transgenic genotype as well as from hemisphere to hemisphere of the same animal 
(Figure 20).  We analyzed the brains of 6 PS/APP mice at 10 months of age at 5 sections 
per brain front to back for variations in plaque load.  Although variability does exist from 
hemisphere to hemisphere in this model per a given section (11%), we have demonstrated 
that the variability from animal to animal is almost 3 times that from that of total 
hemisphere to hemisphere comparison (78% from mean compared to 28%, respectively) 
(Figure 20B).   For this reason, we designed a bilateral delivery technique that would 
allow one of the two hemispheres to serve as an internal control.  This technique allows 
researchers to use fewer mice than an experiment of this nature would typically require 
and with more accurate results.  Thus ACT, for the purposes of our work, could be 
delivered to one hemisphere and the vehicle, artificial cerebrospinal fluid (aCSF), to the 
other.  Current systems for drug/compound delivery to the mouse brain use pedestal 
cannulae which are commercially available, but tend to be bulky and irritating to the 
animal, restrictive to the researcher, and lead to high mortality rates.  Furthermore, use of 
two independent pedestal-based cannulae infusions in the same mouse is not possible due 
to their large size.  Therefore, we designed and constructed novel catheters that are 
implanted subcutaneously and contoured to the skull.  They are minimally invasive and 
virtually eliminate iatrogenic mortality.  Our data show that this method is reliable for 
studying the chronic delivery of ACT into PS/APP mice to study its effects on amyloid 
pathology.  Moreover, because the catheters are custom made, they can easily be adapted 
to study the impact of virtually any compound in other mouse models of 
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neurodegeneration or brain disease as well as on non-transgenic mice in order to study 
the effects of these compounds on normal physiology. 
 
6.3.  Materials and Methods 
 
6.3.1.  Catheter Construction 
 
The catheters (patent pending- PCT/US08/73974) used for this experiment were 
made by first taking a 1.25 cm length of 30 gauge stainless steel tubing (Small Parts, Inc. 
Miramar, Fl) and carefully inserting it into a 20g needle (tip removed) to the appropriate 
depth under a dissecting microscope (Leica, Heerbruug, Switzerland), and bending it at 
2.5 mm to approximately 90 degrees being very careful not to crimp the tube.  The 
remaining length of the tube was bent again at 5 mm to an angle of 120-160 degrees, 
approximating the contour of each animal’s skull.  These metal cannulae were inserted 
into a 3 cm length of polyethylene (PE-10) tubing with an internal diameter of 0.28 mm 
and an outer diameter of 0.61 mm.  One centimeter of the PE-10 was then itself inserted 
into a 4.5 cm length of sterile polyvinyl tubing (PV-50-I.D. 0.69 mm/ O.D. 1.14 mm, 
Durect Corp., Cupertino, Ca), held in place using a bead of Locktite 454 adhesive 
(Plastics One. Roanoke, VA.), and cured overnight.  The following day, sterile water was 
forced through each catheter assembly to ensure that the lines were not obstructed.  The 
osmotic pumps were then filled with solution, attached to the catheters and primed and 
implanted as described below.  The proven catheters were later custom manufactured by 
Braintree Scientific (Braintree, MA) with some minor changes: The adhesive was 
supplanted by heat sealing PE-10 to PE-50 tubing and, because the diameters of the PV-
50 and new PE-50 were not exactly the same, a sheath of silicone (SIL 047) was placed 
over the PE-50 with an extra 2 mm overhang to attach it to the flow modulator of the 
pump, forming a tight, leak-proof seal (Figure 21).  
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6.3.2.  Transgenic Mice 
 
PS/APP (presenilin 1/amyloid precursor protein) mice and PS/APP/ACT mice 
were generated by crossing heterozygous PDGF-hAPP (V717F) mice with PDGF-hPS1 
(M146L) on both Swiss Webster and C57BL/6 backgrounds.  In some cases, PS/APP 
mice were bred with mice harboring a gene for human ACT (hACT) under a GFAP 
promoter (Nilsson et al., 2001) were used to be compared to ACT-infused animals.  
Genotyping was performed using comparative real-time PCR (Bio-Rad iCycler- 
Hercules, CA).  Pathogenically, these Alzheimer's mouse models are characterized by 
robust accumulation of amyloid plaques and the development of microgliosis between 6-
10 months.  The mice used in these studies ranged from 9-10 months of age. 
 
6.3.3.  Materials 
 
Purified human α-1 antichymotrypsin (ACT) was purchased lyophilized from 
Fitzgerald (Concord, MA) and was reconstituted in artificial CSF (Harvard Apparatus, 
Holliston, MA) to a concentration of 1mg/mL.  ACT was infused directly into the 
hippocampal parenchyma or lateral ventricles for 28 days using the novel catheters 
attached to Alzet osmotic minipumps (Alzet model 1004, Durect Corp. Cupertino, CA) 
with an average flow rate of 0.12μL/hour.  The pumps and catheters were submerged in 
0.9% sterile saline at 37oC and primed for 48 hours prior to implantation.   
 
6.3.4.  Intracranial Infusions 
 
All procedures involving experimentation on animals were performed in 
accordance with the guidelines set forth by the University of South Florida Animal Care 
and Use Committee.  Animals (9 month-old PS/APP- 25-35g) were anesthetized with 1-
2% isoflurane, shaved and scrubbed with 10% Betadine solution at the site of incision, 
and placed into a dual arm stereotaxic frame (Kopf Instruments. Tujunga, Ca.).  A small 
(5 cm) incision was made, exposing the skull and neck, and double bladed scissors (10 
 111 
cm curved Strabismus, Fine Science Tools, Foster City, CA.) were used to form a 
subcutaneous pocket along the back of the animal into which 2 osmotic minipumps were 
inserted with catheters attached.  One of the stereotaxic arms held an Ideal Micro-drill 
(Roboz Surgical Instrument Co., Gaithersburg, MD) holding a 0.32 mm diameter carbide 
drill bit.  Using the drill bit on the stereotaxic arm to find the proper coordinates (from 
Bregma -2.2-2.5 mm anterior-posterior, +/- 2.2-2.5 mm medial-lateral),  two holes were 
carefully drilled into the skull and a 30 gauge needle from a Hamilton syringe (Hamilton 
Co., Reno, Nevada) was attached to the second arm of the stereotaxic frame.  The needle 
was inserted to the appropriate depth (2.2-2.5 mm corresponding to the posterior portion 
of the CA1/CA2 hippocampus) and allowed to sit for 5 minutes for the surrounding tissue 
to adjust.   Alternatively, holes were drilled corresponding to the lateral ventricles at the 
following coordinates: from Bregma -0.2 mm anterior-posterior, +/- 1.0 mm medial-
lateral, and to a depth of 2.2-2.5 mm.  After removing the needle, the tips of the cannulae 
were held directly over the holes with forceps and then gently inserted straight into the 
preformed holes.  Pulling back slightly on the catheters by the base of the osmotic pumps 
while inserting the cannulae provided stability which prevented them from moving and 
potentially damaging tissue while they were affixed.  The cannulae were firmly affixed to 
the skull with Locktite 454 adhesive (Plastics One. Roanoke, VA.) and secured down 
with a piece of nitrile, approximately 1 cm in diameter.  After the adhesive cured, the 
scalp was closed with 6-7 silk sutures.  For analgesia, the animal received an immediate 
subcutaneous dose of ketoprofen (10mg/kg) and up to every 6 hours, as needed, for a 
maximum of 48 hours post-operatively.  After the 28 day period, the animals were given 
an overdose (~150mg/kg) of sodium pentobarbital (i.p.) and were transcardially perfused 
with 0.9% saline.  The brains were carefully removed and analyzed as outlined below.  At 
this time, the integrity of the catheters was confirmed again by forcing water through 
them, and the pumps were also determined to be empty.   
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6.3.5.  Preparation of Brain Extracts and Western Blot Analysis 
 
The neocortex and hippocampus were each microdissected on ice, immediately 
snap frozen in powdered dry ice, and stored at -80o C until use.  The tissue samples were 
then dounce homogenized in cold RIPA buffer (50 mM TrisHCl pH7.4, 150 mM NaCl, 2 
mM EDTA, 1% NP-40, 0.1% SDS) in the presence of a protease inhibitor cocktail 
(Complete mini protease inhibitor tablet -Roche Diagnostics, Indianapolis, IN).  Samples 
were subsequently spun at 20,000 g for 30 min (Eppendorf 5417R, Westbury, NY) and 
the supernatants removed, aliquoted, and frozen at -80oC.  Equal amounts of protein from 
each sample were mixed with 2x sample buffer (Invitrogen, Carlsbad, CA), boiled for 5 
min, and subjected to 10-20% Tris Tricine SDS gel electrophoresis (Invitrogen).  Purified 
hACT and nontransgenic brain homogenates were used as controls.  The electrophoresed 
proteins were wet transferred onto 0.2 µm nitrocellulose (Whatman, Dassel, Germany) 
and probed with a rabbit anti-mouse polyclonal antibody to ACT (1:1000- Dako, 
Glostrop, Denmark).  The secondary antibody was horseradish peroxidase-conjugated 
donkey anti-rabbit IgG (Pierce, Rockford, IL).  The immuno-labelled proteins were 
visualized with an enhanced chemiluminesence detection kit (SuperSignal pico, Pierce, 
Rockford, IL).  After different exposures, autoradiographs were developed with a 
Konica/Minolta SRX101A (Tokyo, Japan), scanned using a Ricoh Aficio MP3010 
(Tokyo, Japan) and quantified using Image J. 
 
6.3.6.  Histology and Immunohistochemistry 
 
Mouse brain tissues were fixed in 10% formaldehyde (formalin) for 72 hours and 
then passed through a series of sucrose solutions (10-30%) over another 72 hours.  Brains 
were frozen to the peltier stage (Physitemp, Clifton, NJ) of a histoslide (Leica, 
Heerbruug, Switzerland) and sectioned coronally at 25 μm. After incubating the sections 
with blocking buffer (Tris-buffered saline with 10% normal goat serum, 0.1% Triton X-
100, and 0.02% sodium azide) for 60 min, primary antibodies against ACT (1:500- Dako, 
Glostrop, Denmark) and Aβ (6E10,1:1000- Covance, Princeton, NJ) were applied and 
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incubated at 4 o C overnight.  After thorough washing, the sections were incubated with 
secondary antibodies, Alexa 488 and 594 fluorophores (1:1000, 1:4000-Invitrogen) in the 
dark at ambient temperature for 2 hours.  This incubation was followed by a Hoechst 
(1:10,000, Sigma, St. Louis, MO) nuclear stain, and the sections were washed and sealed 
with Gel-Mount (Electron Microscopy Sciences, Hatfield, PA).  The images were 
analyzed on a Zeiss Imager Z1 fluorescence microscope with a Zeiss Axiocam Mrm 
camera (Oberkochen, Germany) using Axiovision 4.7 software and quantified using 
Image J.   Based on previous plaque analyses performed in our lab and others, for animal 
to animal, hemisphere to hemisphere plaque comparison, 5 sections from 6 mice (30 
total) were stained using Thioflavin S to label the beta-pleated amyloid deposits from 
anterior to posterior hippocampus in each hemisphere of each mouse.  Since the analysis 
is pairwise, i.e. every data point is compared to every data point, this number was 
sufficient to show relative variance.  Coronal sections of brain (25µm) were mounted to 
slides and let to adhere overnight.   The sections were then rinsed with deionized water 
and submerged in a 1% Thioflavin S aqueous solution (Sigma-Aldrich, St. Louis, MO) 
for 5 minutes.  The sections were differentiated in 70% ethanol for 5 minutes, rehydrated 
in 30% ethanol for 5 minutes, washed with deionized water coverslipped, imaged, and 
quantified as described previously. 
 
6.4. Results 
 
6.4.1.  Animal Recovery 
 
Intracranial delivery of molecules, though invasive, is a common procedure to 
confirm results from in vitro experiments in an in vivo system and to test various 
compounds in transgenic animals via targeted delivery.  As an additional advantage, the 
novel method described here bypasses concerns related to the blood-brain barrier 
permeability of the administered compound.  ACT, a serine protease inhibitor that is 
known to contribute to the formation of amyloid pathology in Alzheimer's disease, was 
infused into the hippocampi or lateral ventricles of 9-month-old PS/APP mice for a 
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period of 28 days.  ACT was infused into one hemisphere and aCSF (vehicle) into the 
other hemisphere, thus allowing a comparative analysis to be made within the same 
animal.  In all cases, the animals recovered very quickly from the procedure and resumed 
eating and grooming within minutes of awakening.  All animals were monitored closely 
during the 4 week infusion.  In only a few instances did animals scratch at the incisions, 
but in no case were they able to open the wound and remove or damage any of the 
implanted pumps and catheters.  In most cases, the hair grew back within 2 weeks, and 
the animals became virtually indistinguishable from non-treated animals, with the 
exception of bulges on the haunches from the implanted osmotic pumps (Figure 22A).  
The implants caused minimal discomfort to the animals, and procedural mortality was 
practically eliminated from these studies. When harvesting tissues following the 28 day 
infusion, the catheters were checked to ensure they were still connected to the pumps 
(Figure 22B) and to the cannulae (Figure 22C).  The nitrile cap is indicated by the arrow 
in figure 22D. The entire assembly is shown attached to an Alzet osmotic minipump 
model 1004 (Durect Corp., Cupertino, CA.) in Figure 22E.  Finally, when removing the 
brains only 2 small holes are visible (Figure 22F) showing that there is no lateral 
movement of the cannulae during infusion.  No serious damage or impairment was 
caused by the cannula, although tissue is displaced where inserted.  Figure 23 shows, on 
the left hemisphere, exactly where the cannula was placed and that surrounding tissue 
was intact following infusion.  Figure 24 A and B show a region of the hippocampus 
anterior to the infusion site which also does not show signs of damage.  To be noted, the 
gauge of the cannulae used in this experiment (30g or 0.30 mm O.D.) is the same of those 
used in commercially available cannulae (Alzet, PlasticsOne), but without the irritation to 
the animal, inflammation, occasional motor impairment, and high mortality rates 
associated with them.   
 
6.4.2.  Bilateral Brain Infusion 
 
Due to the increased variability in plaque load between animals, even within a 
largely inbred transgenic mouse line, it is often difficult to compare treated and untreated 
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mice with a reasonably small number of animals.   This phenomenon can be caused by 
phenotypic variability and/or differential expression of transgenes.  Upon analysis of 6 
untreated PS/APP mice at 10 months of age, we found that plaque load can vary 
significantly from animal to animal (78% mean standard deviation in pixel count).  This 
fact makes it difficult to draw conclusions on the effects that different molecules might 
have on amyloid deposition or other features of the transgenic brain when comparing 
animals where hemispheres vary much less (28%) when compared.  Figure 20A and B 
demonstrates the variation in plaque load between hemispheres and within animals of this 
genotype.   Therefore, in order to study promoters and inhibitors of AD pathology 
directly in the brain, it would be preferable (almost twice the efficiency) to compare the 
individually-treated hemispheres of each animal rather than to compare the brains of 
littermates or matched cohorts from other litters. Western blots and immunocytochemical 
techniques demonstrated that our catheters functioned properly and that ACT was 
delivered successfully to the ventricles and parenchyma, respectively (Figures 23, 24, and 
25).  If ACT is infused into a PS/APP mouse that has plaques for it to interact with, it 
binds to the plaques and diffuses very little (Figure 24C & D).  However, if ACT is 
delivered into the hemispheres of nontransgenic mice it diffuses, but still remains in the 
intended hemisphere (Figure 24A and B).  
 
6.4.3.  Interaction of ACT and amyloid 
 
It is well established that ACT is localized, together with the Aβ peptide, in the 
amyloid plaques of Alzheimer’s disease (Abraham et al, 1988).  However, the 
mechanism and effect of this interaction are still under investigation.  Previous in vitro 
experiments indicated that ACT can bind to Aβ and become integrated into amyloid 
filaments as they are formed, and the same mechanism was presumed to occur in vivo 
(Mucke et al., 2000).   Using the application method described here, we successfully 
delivered ACT into individual brain hemispheres of adult PS/APP mice and found that 
ACT binds to the perimeter of existing plaques in a similar manner as found for ACT 
association with amyloid plaques in PS/APP/ACT transgenic mice (Nilsson et al., 2001) 
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(Figure 26).  While the application of exogeneous ACT did not lead to increased amyloid 
load during the time frame of these experiments, it should be noted that ACT was infused 
for only 28 days.  A longer exposure could result in an increased plaque load and is 
currently being investigated.  At the same time, while ACT is known to enhance plaque 
formation, the perimetrical binding of ACT to pre-exisiting Aβ plaques, as shown here, 
might indicate that ACT involvement in AD pathogenesis not only occurs concurrent 
with plaque formation but also afterwards.  This conclusion is consistent with the fact 
that ACT is highly upregulated in adult AD brains (Abraham et al, 1988) and also 
induces the phosphorylation of tau (Padmanabhan et al, 2006).   
            Although there is evidence that ACT's involvement in AD is not restricted to its 
participation in plaque formation, the purpose of using ACT in this model was to 
demonstrate the utility of our infusion system.  The catheters and cannulae described here 
served as an outstanding tool for targeted delivery of ACT into individual brain 
hemispheres and will facilitate further examination of the mechanistic involvement of 
ACT and other molecules in the pathology of Alzheimer's disease.   
 
6.5.  Discussion 
 
  The variability of plaque load (i.e. size, density, and number) between brain 
hemispheres in PS/APP mice, though a factor to consider in these types of experiments, is 
substantially less than plaque variability from mouse to mouse (Figure 20A and B.). 
Based on our analysis of 6 untreated, unrelated animals in our colony, we determined the 
plaque load data from 5 brain sections through 6 ten-month-old PS/APP mice and 
compared the standard deviation (plaque variance) between sides of the same slice 
(11%), between total hemispheres of the same animal (28%), and between individual 
animals (78%). All of the data from the left hemisphere were compared with the right for 
each mouse (Hemi-Hemi, 1 data point for each mouse); the left half of a single slice is 
compared with the right side (Left-Right, 1 data point for each slice); and a permuted 
comparison of each mouse with every other mouse (Mouse-Mouse, 1 data point for each 
pair of mice). Where data were aggregated, (Hemi-Hemi and Mouse-Mouse), the mean of 
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the aggregated counts was used to make the standard deviation comparable to the single 
slice data (standard deviation of two numbers). The data indicate that evaluation of whole 
hemispheres in the same mouse is about 4 times less varied than comparing different 
animals to each other.  Because of this variability, it was advantageous to develop a 
technique for the delivery of drugs and small molecules that would allow the treatment of 
individual brain hemispheres.  By exposing one hemisphere to an experimental 
compound and the contralateral hemisphere to the vehicle only, our novel technique 
described here easily allows each animal to serve as its own histological and biochemical 
control.   
   Previously, bilateral treatment, either into lateral ventricles or brain 
parenchyma was difficult to accomplish with mice.  Because transgenic mice provide an 
important experimental system for disease studies, such as Alzheimer’s disease, it was 
imperative to develop a durable and reliable technique for simultaneous bilateral delivery 
into the brain that is well-tolerated by mice.  Commercially available bilateral delivery 
devices for mice are pedestal cannulae, which have proven problematic for a variety of 
reasons:  1) The pedestals are bulky and require large amounts of adhesive to fix into 
place because the cannula surface that comes into contact with the skull is flat while the 
skull is curved.  This design requires that enough adhesive be applied to fill the gaps and 
to secure the applicator in place.  Frequently, the adhesive does not have a chance to cure 
completely and reacts with surrounding tissue, causing irritation and the need for animals 
to be removed from the experiment. 2) The pedestals and tubing remain partially 
exposed, allowing the animals access to the catheters potentially compromising 
experiments and also causing concern for their health (inflammation, cachexia, death).  3) 
The bilateral pedestals have limited flexibility for the spacing of the catheters.  If they are 
designed with fixed distances and fixed depths, their placement in a 25 gram mouse is 
very different compared to a 35 gram mouse, leading to improper placement of the 
cannula.  4) Other systems require specialized arms to lower the catheter into place, 
whereas these are best manipulated individually by hand to be reliably and reproducibly 
positioned.  5) Moreover, the entire catheters and pumps we used can be completely 
removed without terminating the life of the animal.   This is generally not true of 
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commercially available catheters, which, when removed cause damage to the skull and do 
not leave the scalp in healthy enough condition to be sutured.  6) Lastly, since these 
catheters remain completely subcutaneous, behavioral testing can be safely performed 
while an animal is being treated, which is not a possibility with pedestals.  Overall, the 
stereotaxic placement of pedestal cannulae, particularly bilateral pedestal cannulae, into a 
mouse brain is very restrictive and problematic.  
 Our catheter system described here facilitates targeted compound delivery to 
individual mouse hemispheres and is remarkably adaptable to reaching any region of the 
mouse brain and overcomes the challenges listed above.  Because the stainless steel 
catheters can be fashioned to any depth and are implanted individually, variability in the 
size of the mouse brains can be easily accounted for and accurate catheter placement and 
proper contouring is ensured. Most importantly, the entire system is implanted 
subcutaneously with little if any protrusion.  The use of the non-reactive nitrile cap to 
secure the catheters in place requires only a fraction of the adhesive compared to the 
pedestal method, thereby giving ample time for it to cure properly before the scalp is 
sutured.  Our observations demonstrate that, in most cases, the animals re-grow hair over 
the scalp in a very short time and never scratch or over-groom the site or damage the 
catheters.  The mortality in experiments using this method is closer to 2-3% as opposed to 
30-40% using conventional techniques over the 28-day infusion period.   
 Here we demonstrated that ACT binds to pre-existing amyloid plaques in APP 
transgenic mice only in the infused hemisphere.  We also showed that ACT could be 
delivered both to the parenchyma of the mouse hippocampus and into lateral ventricles 
using our new catheters.   Changes in total plaque load, however, in the presence of ACT 
were not observed over the 28 day infusions.  Although ACT is known to be involved in 
the process of fibrillization of Aβ both in vitro and in vivo, we did show that mature 
plaques retain binding capacity for ACT.  The morphology of the amyloid plaques after 
ACT infusion strongly resembles the plaque morphology in PS/APP/ACT transgenic 
mice (Figure 26).  Our observation suggests that our delivery system is an effective 
method to test various compounds in mouse models of neurodegenerative and other 
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diseases. Ongoing investigations with inhibitors of the Aβ/ACT interaction will help to 
determine ACT's role in AD both during and beyond plaque promotion. 
 In sum, using our novel catheter system, we have studied the infusion of a protein 
known to be a component of AD pathology into a mouse model of AD.  The potential 
application of this system, however, is quite broad.  While we have focused on 
intrahippocampal and intracerebroventricular (ICV) delivery, our catheters can 
conceivably be inserted in any depth and be bent to any angle to deliver compounds to 
any region of the brain in other mouse models of neurodegenerative disease.  Bilateral 
pedestal cannulas do not provide users with such adaptability, since accounting for 
variability in animal size poses a problem.  Likewise, using 2 independent pedestal 
catheters to achieve bilateral delivery in mice is prohibited due to the large size of the 
pedestals.  The technique described here even allows for the implantation of 2 cannulae 
per hemisphere (4 per brain), which would allow delivery of multiple agents to either 
hemisphere in the same mouse with minimum mortality. 
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Figure 20. A) Thioflavin S staining on 25μm coronal sections (montages) of 3 different 
PS/APP mice at 10 months of age showing plaque variability in the hippocampus and 
neighboring cortex. B) Scatter-plot of plaque load data from 5 brain sections through 6 
ten-month-old PS/APP mice comparing standard deviation (plaque variance) between 
total hemispheres of the same animal (28%), between sides of the same section (11%) 
and between animals (78%). All of the data from the left hemisphere are compared with 
the right for each mouse (Hemi-Hemi, 1 data point for each mouse); the left half of a 
single slice is compared with the right side (Left-Right, 1 data point for each slice); and a 
permuted comparison of each mouse with every other mouse (Mouse-Mouse, 1 data point 
for each pair of mice). Where data were aggregated, (Hemi-Hemi and Mouse-Mouse), the 
mean of the aggregated counts was used to make the standard deviation comparable to 
the single slice data (standard deviation of two numbers).  
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Figure 21. Catheter assembly. A- First bend of 30g stainless steel tubing. B- Second 
“contour” bend. C- polyethylene PE-10 tubing. D- Heat seal. E- PE-50. F- Silicone sleeve 
(SIL047).  
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Figure 22. A 10 month-old PS/APP mouse with 2 osmotic pumps following 28 days of 
infusion while still active (A) and after transcardial perfusion showing the Alzet pumps 
(B) and cannulae (C) still securely attached. The arrow in figure D shows the nitrile cap 
used to affix the catheters to the skull and Figure E shows the entire assembly attached to 
an Alzet 1004 osmotic minipump. When the brain is removed, only small holes are 
visible where the cannulae were inserted (F). 
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Figure 23.  A) A montage of images taken at 10x from 25μm sections of an animal 
treated with ACT on the left and aCSF control on the right. The top section is immuno-
labelled with the Aβ antibody 6E10 and the bottom with ACT antibodies.  Inlays (40x) 
show Aβ in green, ACT in red, and Hoechst nuclear stain in blue. B) Semi-quantitative 
analyses of ACT and Aβ immunostaining in the hippocampus and cortex of PS/APP mice 
(n= 4) infused with ACT into the parenchyma of one hemisphere and aCSF in the 
contralateral hemisphere. 
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Figure 24.  Montage images of 25μm coronal sections of 10 month old nontransgenic (A 
& B) and PS/APP mice (C & D) immuno-labeled with and antibody against α- 1 
antichymotrypsin following 28 day infusion demonstrating that ACT stays on the infused 
hemisphere with or without the presence of plaques. 
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Figure 25.  A) Western Blot of PS/APP of RIPA homogenized mouse hemispheres 
receiving ACT (red arrows) or aCSF (white arrows) into lateral ventricles (ICV).  The 
green arrow denotes ACT taken from an osmotic pump implanted for 28 days to show 
minimal degradation of the protein during the experiment.  
B) Quantification of ACT in hemispheres infused with ACT or aCSF.  
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Figure 26. Comparison of ACT associated with amyloid plaques (40x) from a 
PS/APP/ACT transgenic mouse (A) and a PS/APP ACT-infused mouse (B) both at 9 
months of age. Immuno-labeling of Aβ is shown in green (6E10 antibody), ACT in red, 
and Hoechst nuclear stain in blue. 
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CHAPTER 7 – THE NEUROPROTECTIVE EFFECTS OF THE 
CARBOXYL TERMINUS OF GAMMA LAMININ, KDI, ON A MOUSE MODEL 
OF ALZHEIMER’S DISEASE 
7.1.  Introduction 
 Although AD is classified as a proteinopathy, the two currently FDA approved 
medications used to treat the disease, Aricept and Namenda, act on distinctly different 
aspects of the disease.  Aricept (donezepil HCL) is an acetylcholinesterase inhibitor and 
is believed to improve cognition in patients by increasing synaptic concentrations of the 
neurotransmitter acetylcholine.  The exact mechanism of this effect is not known, but it 
has been suggested that Aricept increases the expression of IGF-1 in hippocampal 
neurons, increases neurogenesis in the dentate gyrus, and increases cerebral blood flow in 
parenchymal arterioles (Narimatsu et al., 2009).  Namenda (memantine) functions 
differently as its primary function is believed to be inhibition of NMDA receptors in 
glutamate neurotransmission.  Blocking these receptors in a noncompetitive, voltage 
mediated (ionotropic) manner thereby inhibiting the prolonged influx of Ca2+ ions that 
induce excitotoxic damage to the neuron.   
 Over the past decade, our collaborator, Päivi Liesi, has worked extensively with 
laminins.  In particular, she has elucidated that the carboxyl terminus of γ1-laminin is 
responsible for neurite outgrowth both in vitro and in vivo.  To date, there are 15 known 
isoforms of the laminin expressed in mammals in a tissue-specific manner.  Five different 
α subunits have been described, 4 β, and 3 γ which arrange as a cruciform heterotrimer 
(αβγ) of ~900KD in total mass as intact laminin molecules.   The molecules are the main 
non-collagenous components of basement membranes and also play diverse roles in the 
extracellular matrix relating to cell structure, adhesion, differentiation, migration, 
signaling, metastasis, and neurite outgrowth.  It has also been shown that laminin is 
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upregulated during development and repair of most tissues and portions of the molecule 
can maintain biological activity following cleavage events.   
 Original work focused on the gamma laminin decapeptide exerting these 
neuroregenerative and neuroprotective effects; however, subsequent studies of the 
hexapeptide and finally the tripeptide, KDI, still showed activity as a neurite outgrowth 
factor and functioned as a non-competitive ionotropic glutamate receptor antagonist.  In 
vitro work, using patch clamp analysis, revealed that KDI could inhibit ~50% of NMDA 
receptors and 100% of AMPA receptors (Moykkynen et al., 2005).  Further work showed 
in vivo that pretreatment of the rat hippocampus with bolus injections of KDI protected 
the brain region from subsequent injections of kainic acid, a glutamate analog (Wiksten et 
al., 2004a).  If indeed dysregulation of glutamate is an etiology found in AD and 
Namenda has proven to have some efficacy, we proposed that KDI would work in a 
similar manner to ameliorate the symptoms of AD and improve cognition.  
 In these experiments, KDI was used to treat PS/APP mice.  Since it is not yet 
known whether this molecule can cross the blood-brain barrier following systemic 
administration, direct infusion of the molecule into the hippocampal parenchyma of these 
models was required.  In order to determine if KDI could improve working memory, 
similar to memantine, the animals were tested in a RAWM following 28 days of chronic 
infusion.  Preliminary data suggested improvement with treatment of KDI, but without 
change in plaque load.  Therefore, since KDI was reported to bind glutamate receptors, 
another avenue was investigated- Long term potentiation.  Long-term potentiation (LTP) 
is a molecular mechanism involving synapse strengthening upon recent patterns of 
activity.  It serves as a model for memory and learning in several brain areas, described 
first in the hippocampus (McKay, 1997).  Briefly, it involves the binding of glutamate to 
ionotropic glutamate receptors, post-synaptic depolarization, influx of calcium, 
phosphorylation of Thr286 and constitutive activation of CaM Kinase II, resulting in the 
upregulation of more AMPA receptors and activation of relevant genes (Schlett, 2006). 
 During the time that the KDI infusions were being performed, EIIKDI was cloned 
into an expression vector.  This was done in anticipation of achieving longer term 
expression of the molecule in the brain.  In vivo electroporation has been used in 
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numerous tissues for gene expression (Heller and Heller, 2006).  Briefly, the technique 
works by injecting plasmid into tissue and surrounding the site with an electric field to 
perforate the cells and allow the plasmid to enter cells and be expressed.  This method 
has many advantages over traditional means of transfection that involve developing viral 
vectors and contending with an immune response.  Electroporation is effective as a 
“proof-of principle” that introduced genes will be a) expressed and b) exert a 
physiological response within the cell before developing more complicated transfection 
strategies.  Previous work in ours and other labs has demonstrated that this technique is 
safe in the CNS of mice and was optimized first using an EGFP expression vector (figure 
27).  
 
7.2.  Materials and Methods 
 
7.2.1.  Catheter Construction 
 
The catheters (patent pending- PCT/US08/73974) used for this experiment were 
made by first taking a 1.25 cm length of 30 gauge stainless steel tubing (Small Parts, Inc. 
Miramar, Fl) and carefully bending it at 2.5 mm under a dissecting microscope (Leica, 
Heerbruug, Switzerland), to approximately 90 degrees, being careful not to crimp the 
tube.  The remaining length of the tube was bent again at 5 mm to an angle of 120-160 
degrees, approximating the contour of each animal’s skull.  These metal cannulae were 
inserted into a 3 cm length of polyethylene (PE-10) tubing with an internal diameter of 
0.28 mm and an outer diameter of 0.61 mm.  One centimeter of the PE-10 was then itself 
inserted into a 4.5 cm length of sterile polyvinyl tubing (PV-50-I.D. 0.69 mm/ O.D. 1.14 
mm, Durect Corp., Cupertino, Ca), held in place using a bead of Locktite 454 adhesive 
(Plastics One. Roanoke, VA.), and cured overnight.  The following day, sterile water was 
forced through each catheter assembly to ensure that the lines were not obstructed.  The 
osmotic pumps were then filled with solution, attached to the catheters and primed and 
implanted as described below.  The proven catheters were later custom manufactured by 
Braintree Scientific (Braintree, MA) with some minor changes: The adhesive was 
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supplanted by heat sealing PE-10 to PE-50 tubing and, because the diameters of the PV-
50 and new PE-50 were not exactly the same, a sheath of silicone (SIL 047) was placed 
over the PE-50 with an extra 2 mm overhang to attach it to the flow modulator of the 
pump, forming a tight, leak-proof seal.   
 
7.2.2.  Osmotic Minipumps 
 
Sterile Alzet osmotic minipumps-model 2004 (Durect Corp. Cupertino, Ca.), with a flow 
rate of 0.25uL/hr were filled with 200ug (1mg/mL) of KDI (NeoMPS, San Diego, CA) 
diluted in artificial CSF (Harvard Apparatus, Holliston, MA) and incubated at 37oC in 
sterile saline for 48 hours.  Typically, catheters are attached and primed at this time, but 
the tungsten wire needed to remain in place for stability during insertion into the spine. 
 
7.2.3.  Transgenic Mice 
 
PS/APP (presenilin 1/amyloid precursor protein) mice were generated by crossing 
heterozygous PDGF-hAPP (V717F) mice with PDGF-hPS1 (M146L) on both Swiss 
Webster and C57BL/6 backgrounds.  Genotyping was performed using comparative real-
time PCR (Bio-Rad iCycler- Hercules, CA).  Pathogenically, these Alzheimer's mouse 
models are characterized by robust accumulation of amyloid plaques and the 
development of microgliosis between 6-8 months of age. 
 
7.2.4.  Intracranial Infusions 
 
All procedures involving experimentation on animals were performed in accordance with 
the guidelines set forth by the University of South Florida Animal Care and Use 
Committee.  Animals (8 month-old PS/APP- 25-35g) were anesthetized with 1-2% 
isoflurane, shaved and scrubbed with 10% Betadine solution at the site of incision, and 
placed into a stereotaxic frame (Kopf Instruments. Tujunga, Ca.).  A small (3 cm) 
incision was made, exposing the skull and neck, and double bladed scissors were used to 
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form a subcutaneous pocket along the back of the animal into which 2 osmotic 
minipumps were inserted with catheters attached.  Two holes were drilled into the skull 
(from Bregma -2.2-2.5 mm anterior-posterior, +/- 2.2-2.5 mm medial-lateral, and the 30 
gauge catheters were inserted to a depth of 2.2-2.5 mm) corresponding to the posterior 
portion of the CA3 hippocampus.  Alternatively, holes were drilled corresponding to the 
lateral ventricles (from Bregma -0.2 mm anterior-posterior, +/- 1.0 mm medial-lateral, 
and to a depth of 2.2-2.5 mm).  Once they were inserted, the cannulae were affixed to the 
skull with Locktite 454 adhesive (Plastics One. Roanoke, VA.) and secured down with a 
piece of nitrile, approximately 1 cm in diameter (Fig 3D).  After the adhesive cured, the 
scalp was closed with 6-7 silk sutures.  For analgesia, the animal received an immediate 
dose of ketoprofen (10mg/kg) and up to every 6 hours, as needed, for a maximum of 48 
hours post-operatively.  After the 28 day period, the animals were given an overdose 
(~150mg/kg) of sodium pentobarbital (i.p.) and were transcardially perfused with 0.9% 
saline.  The brains were carefully removed and analyzed as outlined below.  At this time, 
the integrity of the catheters was confirmed again by forcing water through them, and the 
pumps were also determined to be empty. 
 
7.2.5.  Electroporation 
 
 The mouse codons for the longer peptide, EIIKDI, were determined and 
oligomers were synthesized with a small portion of a leader sequence to a length of 98 
nucleotides (IDT, San Jose, CA).  The sense and antisense strands were annealed and 
blunt-end cloned into a PCDNA3.1+ expression vector between the XbaI and ecoRV 
sites and confirmation of insertion, copy, and orientation was confirmed by DNA 
sequencing.  An EGFP clone was used to optimize the electroporation procedure as it was 
roughly the same size (5 kB) and provided easy visibility of transfection efficiency 
(figure 26)  The procedure is similar to what was mentioned above. Animals (8 month-
old PS/APP- 25-35g) were anesthetized with 1-2% isoflurane, shaved and scrubbed with 
10% Betadine solution at the site of incision, and placed into a stereotaxic frame (Kopf 
Instruments. Tujunga, Ca.).  A small (3 cm) incision was made, exposing the skull and 
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landmarks.  3 holes were made, the first at from Bregma -2.2-2.5 mm anterior-posterior, 
+ 2.2-2.5 mm medial-lateral, corresponding to the CA3 region of the hippocampus.  The 
other 2 holes were drilled at 1mm caudal and 1mm rostral to the first hole and were for 
placement of the electrodes (at a depth of 2.5mm). 5 μg of EGFP DNA (1 μg/μL) was 
injected into the center hole to a depth of 2.5 mm and the plasmid is pulsed into the 
surrounding cells.  The square pulse generator (BTX, Hollister, Maine) is then set to 
225V with 10 pulses, 2Ms each and 250Ms intervals between pulses.  The animal was 
given an overdose (~150mg/kg) of sodium pentobarbital (i.p.) 24 hours later and the 
brain carefully removed under a fluorescence dissecting scope (Leica, Heerbruug, 
Switzerland) and photographed with a Leica stereoscopic camera (Leica, Heerbruug, 
Switzerland).  EGFP was electroporated both in the hippocampus and subventricular zone 
(figure 27). 
 
7.2.6.  Behavior  
 
For the RAWM task of spatial working memory (Arendash et al., 2007; Arendash et al., 
2001; Ethell et al., 2006), an aluminum insert was placed into a 100cm circular pool to 
create 6 radially-distributed swim arms emanating from a central circular swim area 
(Figure 28).  An assortment of 2-D and 3-D visual cues surrounded the pool.  The number 
of errors prior to locating which one of the 6 swim arms contained a submerged escape 
platform (9cm diameter) was determined for 5 trials/day.  There was a 30-min time delay 
between the 4th trial (T4; final acquisition trial) and 5th trial (T5; memory retention trial).  
The platform location was changed daily to a different arm, with different start arms for 
each of the 5 trials semi-randomly selected from the remaining 5 swim arms.  During 
each trial (60 s maximum), the mouse was returned to that trial’s start arm upon 
swimming into an incorrect arm and the number time required to locate the submerged 
platform was recorded. If the mouse did not find the platform within a 60-s trial, it was 
guided to the platform for a 30-s stay.  The numbers of errors and escape latency during 
trials 4 and 5 are both considered indices of working memory and are temporally similar 
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to standard registration/recall testing of specific items used clinically in evaluating AD 
patients. 
 
7.2.7.  Preparation of Brain Extracts and Western Blot Analysis 
 
The neocortex and hippocampus were each microdissected on ice, immediately 
snap frozen in powdered dry ice, and stored at -80o C until use.  The tissue samples were 
then dounce homogenized in cold RIPA buffer (50 mM TrisHCl pH7.4, 150 mM NaCl, 2 
mM EDTA, 1% NP-40, 0.1% SDS) in the presence of a protease inhibitor cocktail 
(Complete mini protease inhibitor tablet -Roche Diagnostics, Indianapolis, IN).  Samples 
were subsequently spun at 20,000 g for 30 min (Eppendorf 5417R, Westbury, NY) and 
the supernatants removed, aliquoted, and frozen at -80oC.  Equal amounts of protein from 
each sample were mixed with 2x sample buffer (Invitrogen, Carlsbad, CA), boiled for 5 
min, and subjected to 10-20% Tris Tricine SDS gel electrophoresis (Invitrogen).  Aβ and 
plaques were immunolabeled using 6E10 and 4G8 antibodies (1:1000) (Covance, 
Princeton. NJ)  The secondary antibody was horseradish peroxidase-conjugated donkey 
anti-rabbit IgG (Pierce, Rockford, IL).  The immuno-labelled proteins were visualized 
with an enhanced chemiluminesence detection kit (SuperSignal pico, Pierce, Rockford, 
IL).  After different exposures, autoradiographs were developed with a Konica/Minolta 
SRX101A (Tokyo, Japan), scanned using a Ricoh Aficio MP3010 (Tokyo, Japan).  
Quantification was not performed due to a lack of correlation between plaques of treated 
and untreated animals. 
 
7.2.8.  Histology and Immunohistochemistry 
 
Mouse brain tissues were fixed in 10% formaldehyde (formalin) for 72 hours and 
then passed through a series of sucrose solutions (10-30%) over another 72 hours.  Brains 
were frozen to the peltier stage (Physitemp, Clifton, NJ) of a histoslide (Leica, 
Heerbruug, Switzerland) and sectioned coronally at 25 μm. After incubating the sections 
with blocking buffer (Tris-buffered saline with 10% normal goat serum, 0.1% Triton X-
 138 
100, and 0.02% sodium azide) for 60 min, primary antibodies against ACT (1:500- Dako, 
Glostrop, Denmark) CAMKII (1:500), pCAMKII (1:1000), GlutR1 (1:1000), pGlutR1 
(1:1000), synaptophysin (1:250), synaptopodin (undiluted), synaptobrevin, PSD-95 
(1:500), β-tubulin (1:1000) and GAP-43 (1:500) and Aβ (6E10,1:1000- Covance, 
Princeton, NJ) were applied and incubated at 4 o C overnight.  After thorough washing, 
the sections were incubated with secondary antibodies, Alexa 488 and 594 fluorophores 
(1:1000, 1:4000-Invitrogen) in the dark at ambient temperature for 2 hours.  This 
incubation was followed by a Hoechst (1:10,000, Sigma, St. Louis, MO) nuclear stain, 
and the sections were washed and sealed with Gel-Mount (Electron Microscopy Sciences, 
Hatfield, PA).  The images were analyzed on a Zeiss Imager Z1 fluorescence microscope 
with a Zeiss Axiocam Mrm camera (Oberkochen, Germany) using Axiovision 4.7 
software and quantified using Image J. 
 
7.3.  Results and Conclusions 
 
Memantine (Namenda) functions through inhibition of NMDA receptors in order 
to reduce the effects of glutamate on post synaptic neurons.  Glutamate excitotoxicity is a 
common pathology for most neurodegenerative diseases and is generally accepted as part 
of the AD pathogenesis (Schaeffer and Gattaz, 2008).  This issue, however, is debated 
since earlier experiments with transgenic mice were somewhat conflicting and the effects 
of memantine on AD patients are modest at best (Farlow et al., 2008).  In these 
experiments, we used the tripeptide carboxyl terminus of gamma laminin, KDI, to 
determine if a) glutamate excitotoxicity is a factor in a mouse models of Alzheimer’s and 
b) if KDI would reduce the excitotoxic damage and reverse cognitive decline in these 
mice.  Previous work with the peptide fragment revealed that it is a potent non 
competitive ionotropic glutamate receptor antagonist that inactivates most AMPA 
receptors and ~50% of NMDA receptors (Moykkynen et al., 2005).  In another set of 
experiments, this same group showed that pretreatment of the rat hippocampus with KDI 
followed by an injection of kainate, a glutamate analog, prevented excitoxicity and 
neuron loss in a dose-dependent manner.  This evidence, taken together with the fact that 
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KDI is a potent neurite outgrowth factor, indicated it had excellent therapeutic potential 
in AD. 
Initially, the transgenic KDI-treated group was showing improvement in cognition 
from RAWM trials (figures 29 and 30).  This was true when comparing individual 
animals before and after treatment as well as between sham and treated groups of 
animals.  This prompted some excitement and although no change in plaque load was 
detected, the idea that cognition was improved through the glutamate pathway led us 
towards thinking about LTP as a possible mechanism for cognitive enhancement.  LTP 
has been identified as a possible molecular mechanism for learning in the DG.  Briefly, 
glutamate binds to AMPA and NMDA receptors and triggers the influx of sodium and 
calcium, respectively into the postsynaptic cell, which causes a short-lived depolarization 
called the excitatory postsynaptic potential (EPSP).  With repeated stimulation, the next 
EPSP will occur prior to the decay of the previous.  The sum of this is that postsynaptic 
neurons can be more readily depolarized following a succession of EPSPs and the influx 
of ions causes a temporary upregulation of the cellular kinases CamKII, PKC, and PKA 
which function to phosphorylate dormant AMPA receptors, bringing them activated to 
the synapse and essentially amplifying the signal in the post-synaptic neuron (Kerchner 
and Nicoll, 2008).  To this end, changes in expression of CamKII, pCamKII, GluR1, and 
pGluR1 were looked into, but not observed.  Similarly, there were no detectable changes 
in synaptophysin, synaptotagmin, synaptobrevin or GAP-43, suggesting that there was 
not increased synaptogenesis occuring in the treated mice.  Furthermore, subsequent 
behavioral trials failed to repeat what was seen in the first cohort and it was decideded, 
conclusively, that KDI was of no therapeutic benefit to AD mice. 
 
7.4.  Figures 
 
 
 
 
40x 
 
Figure 27. Demonstration of successful EGFP vector electroporation in the hippocampus  
and subventricular zone of mouse brain. 
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Figure 28. Schematic of radial arm water maze for rodents in testing working (short- 
term) memory. 
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Figure 29.  Preliminary latency plots in  the RAWM of KDI treated and 
untreated Tg2576 AD mouse models.  Results were not repeatable in 2 
subsequent cohorts- no change was seen between groups (data not shown). 
 
 
 
 142 
 
Figure 30.  Preliminary error plots in the RAWM of KDI treated and 
untreated Tg2576 AD mouse models.  Results were not repeatable in 2 
subsequent cohorts- nochange was seen between groups (data not shown). 
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CHAPTER 8 – ACT INDUCES THE PHOSPHORYLATION OF TAU 
IN MOUSE MODELS OF AD 
 
8.1.  Introduction 
 
  Alpha 1-antichymotrypsin (ACT) is an acute phase serum glycoprotein and serine 
protease inhibitor that has been shown conclusively to accelerate amyloid fibril and 
plaque formation in vitro and in vivo (Ma et al., 1994; Nilsson et al., 2004).  ACT is 
upregulated in the injured and AD brain and released by astrocytes surrounding the 
neurotoxic insult. Whereas ACT has a direct role in the in the formation of amyloid 
plaques, recent work from our lab has shown that it can also induce the phosphorylation 
of tau, which is an important step in the formation of neurofibrillary tangles (NFTs), the 
other classical protein misfolding hallmark of AD.  NFTs are comprised mainly of the 
microtubule binding protein tau.  Tau activity is regulated by phosphorylation and 
hyperphosphorylation of tau promotes its misfolding and dissociation from microtubules. 
ptau assembles into paired helical filaments (PHF) that eventually aggregate into 
insoluble NFTs causing disruption of the cytoskeleton, abnormal axonal transport, and 
neurotoxicity.  The upregulation of soluble ACT in the AD brain, the resulting 
hyperphoshorylation of tau and the inclusion of ACT in the formation of amyloid 
plaques, make ACT a link between the amyloidogenic and and tauopathic pathways in 
Alzheimer’s disease. 
 Further evidence for ACT’s involvement in the phosphorylation of tau comes 
from examination of post mortem brain tissue from individuals of other tauopathies.  
Known to be closely involved with AD pathology, ACT was found to be upregulated and 
colocalized to tau deposits in frontotemporal dementia (FTD), corticobasal degeneration 
(CBD), and progressive supernuclear palsy (PSP) patients in neurons and astrocytes.  
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Moreover, these inclusions are all PHF-1 immunopositive, suggesting that an interaction 
between ACT and tau might be partly responsible for the pathogenic events in these 
diseases.  ACT is a suicide protease inhibitor, which binds to its target, changes its 
conformation, and is then, together with the bound protease, endocytosed.  Although 
ACT has been found in astrocytes (Abraham, 2001), it was initially not found in neurons.  
While early northern blot analyses failed to detect ACT mRNA in neurons, subsequent 
immunocytochemical analyses demonstrated its presence both in neurons and astrocytes.  
This observation strongly suggests that ACT, after inhibition of its target protease, enters 
neurons and then interacts with tau.  Alternatively, tau phosphorylation could occur 
through signal transduction cascades once ACT binds to a receptor, though no evidence 
for these hypotheses has been yet obtained.  Nonetheless, human cortical neurons and 
mouse embryonic neurons treated with ACT demonstrate increased phosphorylation of 
tau at pSer202, Pthr 231, and pser 396/404 (PHF-1) as well as intraneuronal ACT 
staining (Padmanabhan et al., 2006). 
 In the following experiments, we wished to intracranially infuse ACT into the 
hippocampal parenchyma of transgenic mice that expresse human tau, but no mouse tau, 
to determine if tau phosphorylation and NFT formation would ensue.  ACT is well 
established in the AD field as an amyloid promoter.  If it could also be proven to be a part 
of the ensuing Alzheimer’s tauopathy it would link these two pathologies.  
Demonstrating that ACT serves as such a link might make it a viable therapeutic target 
for multiple forms of tauopathies and neurodegeneration. 
 
8.2.  Materials and Methods 
 
8.2.1.  Catheter Construction 
 
The catheters (patent pending- PCT/US08/73974) used for this experiment were 
made by first taking a 1.25 cm length of 30 gauge stainless steel tubing (Small Parts, Inc. 
Miramar, Fl) and carefully bending it at 2.5 mm under a dissecting microscope (Leica, 
Heerbruug, Switzerland), to approximately 90 degrees, being careful not to crimp the 
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tube.  The remaining length of the tube was bent again at 5 mm to an angle of 120-160 
degrees, approximating the contour of each animal’s skull.  The metal cannulae were 
inserted into a 3 cm length of polyethylene (PE-10) tubing with an internal diameter of 
0.28 mm and an outer diameter of 0.61 mm.  One centimeter of the PE-10 was then itself 
inserted into a 4.5 cm length of sterile polyvinyl tubing (PV-50-I.D. 0.69 mm/ O.D. 1.14 
mm, Durect Corp., Cupertino, Ca), held in place using a bead of Locktite 454 adhesive 
(Plastics One. Roanoke, VA.), and cured overnight.  The following day, sterile water was 
forced through each catheter assembly to ensure that the lines were not obstructed.  The 
osmotic pumps were then filled with solution, attached to the catheters and primed and 
implanted as described below.  The proven catheters were later custom manufactured by 
Braintree Scientific (Braintree, MA) with some minor changes: The adhesive was 
supplanted by heat sealing PE-10 to PE-50 tubing and, because the diameters of the PV-
50 and new PE-50 were not exactly the same, a sheath of silicone (SIL 047) was placed 
over the PE-50 with an extra 2 mm overhang to attach it to the flow modulator of the 
pump, forming a tight, leak-proof seal.   
 
8.2.2.  Transgenic Mice 
 
10 htau mice (B6.Cg-Mapttm1(GFP)Klt Tg(MAPT)8cPdav/J) were purchased from 
Jackson Labs.  These mice are homozygous for knock out of the the targeted endogenous 
mtau alleles and hemizygous for the transgene.  Although no endogenous mtau is 
detected, all six isoforms (including both 3R and 4R forms) of human MAPT are 
expressed.  Hyperphosphorylated tau is detected in cell bodies and dendrites by three 
months.  Paired helical filaments of aggregated insoluble MAPT can be isolated from 
brain tissue as early as two months of age.  Overall, these mice develop tau pathology 
very quickly and are fertile and viable for studies where they are bred with other AD 
transgenics. 
 
 
 
 147 
8.2.3.  Materials 
 
Purified human α-1 antichymotrypsin (ACT) was purchased lyophilized from 
Fitzgerald (Concord, MA) and was reconstituted in artificial CSF (Harvard Apparatus, 
Holliston, MA) to a concentration of 1mg/mL.  ACT was infused directly into the 
hippocampal parenchyma for 28 days using the novel catheters attached to Alzet osmotic 
minipumps (Alzet model 1004, Durect Corp. Cupertino, CA) with an average flow rate of 
0.12μL/hour.  The pumps and catheters were submerged in 0.9% sterile saline at 37oC 
and primed for 48 hours prior to implantation.  
 
8.2.4.  Intracranial Infusions 
 
All procedures involving experimentation on animals were performed in 
accordance with the guidelines set forth by the University of South Florida Animal Care 
and Use Committee.  Animals (3 month-old htau- 20-25g) were anesthetized with 1-2% 
isoflurane, shaved and scrubbed with 10% Betadine solution at the site of incision, and 
placed into a stereotaxic frame (Kopf Instruments. Tujunga, Ca.).  A small (3 cm) 
incision was made, exposing the skull and neck, and double bladed scissors were used to 
form a subcutaneous pocket along the back of the animal into which 2 osmotic 
minipumps were inserted with catheters attached.  Two holes were drilled into the skull 
(from Bregma -2.2-2.5 mm anterior-posterior, +/- 2.2-2.5 mm medial-lateral, and the 30 
gauge catheters were inserted to a depth of 2.2-2.5 mm) corresponding to the posterior 
portion of the CA3 hippocampus.  Once they were inserted, the cannulae were affixed to 
the skull with Locktite 454 adhesive (Plastics One. Roanoke, VA.) and secured down 
with a piece of nitrile, approximately 1 cm in diameter (Fig 3D).  After the adhesive 
cured, the scalp was closed with 4-6 silk sutures.  For analgesia, the animal received an 
immediate dose of ketoprofen (10mg/kg) and up to every 6 hours, as needed, for a 
maximum of 48 hours post-operatively.  After the 28 day period, the animals were given 
an overdose (~150mg/kg) of sodium pentobarbital (i.p.) and were transcardially perfused 
with 0.9% saline.  The brains were carefully removed and analyzed as outlined below.  At 
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this time, the integrity of the catheters was confirmed again by forcing water through, and 
the pumps were also determined to be empty. 
 
8.2.5.  Preparation of Brain Extracts and Western Blot Analysis 
 
The neocortex and hippocampus were each microdissected on ice, immediately 
snap frozen in powdered dry ice, and stored at -80o C until use.  The tissue samples were 
then dounce homogenized in cold RIPA buffer (50 mM TrisHCl pH7.4, 150 mM NaCl, 2 
mM EDTA, 1% NP-40, 0.1% SDS) in the presence of a protease inhibitor cocktail 
(Complete mini protease inhibitor tablet -Roche Diagnostics, Indianapolis, IN).  Samples 
were subsequently spun at 20,000 g for 30 min (Eppendorf 5417R, Westbury, NY) and 
the supernatants removed, aliquoted, and frozen at -80oC.  Equal amounts of protein from 
each sample were mixed with 2x sample buffer (Invitrogen, Carlsbad, CA), boiled for 5 
min, and subjected to 10-20% Tris Tricine SDS gel electrophoresis (Invitrogen).  Purified 
hACT and nontransgenic brain homogenates were used as controls.  The electrophoresed 
proteins were wet transferred onto 0.2 µm nitrocellulose (Whatman, Dassel, Germany) 
and probed with a rabbit anti-mouse polyclonal antibody to monoclonal/polyclonal 
antibodies to PHF-1 (1:1000- Peter Davies, Albert Einstein Inst. NY), pSer202/CP-13 
(1:1000-Peter Davies), MC-1 (1:500- Peter Davies),  Tg5 total tau (1:1000- Peter 
Davies), pGSK3α/β (1:1000- Cell Signaling, Beverly, MA), pAKT (1:1000- Cell 
Signaling), pERK (1:1000- Cell Signaling), pThr231 (1:1000-Invitrogen), pSer422 
(1:1000- Invitrogen), pSer262 (1:1000- Invitrogen), AT-100 (1:1000- ThermoScientific, 
Waltham, MA),  ACT (1:1000- Dako, Glostrop, Denmark).  The secondary antibodies are 
horseradish peroxidase-conjugated goat anti-mouse IgG and donkey anti-rabbit IgG 
(Pierce, Rockford, Il) and the bands were visualized with an enhance SuperSignal pico 
(Pierce, Rockford, Il).  The immuno-labelled proteins were visualized with an enhanced 
chemiluminesence detection kit (SuperSignal pico, Pierce, Rockford, IL).  After different 
exposures, autoradiographs were developed with a Konica/Minolta SRX101A (Tokyo, 
Japan), scanned using a Ricoh Aficio MP3010 (Tokyo, Japan) and quantified using 
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Image J.  Alternatively, the secondary antibodies used were infrared (Licor, Lincoln, NE) 
and visualized at both 680 and 800 nm using the Odyssey (Licor). 
 
8.2.6.  Histology and Immunohistochemistry 
 
Mouse brain tissues were fixed in 10% formaldehyde (formalin) for 72 hours and 
then passed through a series of sucrose solutions (10-30%) over another 72 hours.  Brains 
were frozen to the peltier stage (Physitemp, Clifton, NJ) of a histoslide (Leica, 
Heerbruug, Switzerland) and sectioned coronally at 25 μm.  After incubating the sections 
with blocking buffer (Tris-buffered saline with 10% normal goat serum, 0.1% Triton X-
100, and 0.02% sodium azide) for 60 min, a set of primary monoclonal/polyclonal 
antibodies was applied.  Primary antibodies (mono and polyclonal) included antibodies to 
PHF-1 (1:250- Peter Davies, Albert Einstein Inst. NY), pSer202/CP-13 (1:250-Peter 
Davies), MC-1 (1:100- Peter Davies), Tg5 total tau (1:250- Peter Davies), pGSK3α/β 
(1:250- Cell Signaling, Beverly, MA), pAKT (1:250- Cell Signaling), pERK (1:250- Cell 
Signaling), pThr231 (1:250-Invitrogen), pSer422 (1:250- Invitrogen), pSer262 (1:250- 
Invitrogen), AT-100 (1:250- ThermoScientific, Waltham, MA), ACT (1:500- Dako, 
Glostrop, Denmark). All were applied and incubated at 4 o C overnight.  After thorough 
washing, the sections were exposed to secondary antibodies, Alexa 488 and 594 
fluorophores (1:1000, 1:4000-Invitrogen) in the dark at ambient temperature for 2 hours.  
This incubation was followed by a Hoechst (1:10,000, Sigma, St. Louis, MO) nuclear 
stain, and the sections were washed and sealed with Gel-Mount (Electron Microscopy 
Sciences, Hatfield, PA).  The images were analyzed on a Zeiss Imager Z1 fluorescence 
microscope with a Zeiss Axiocam Mrm camera (Oberkochen, Germany) using 
Axiovision 4.7 software. 
 
8.3.  Results and Conclusions 
 
It was also discovered recently that ACT is not only upregulated in AD, but other 
tauopathies including FTDP, CBD, and PSP (Padmanabhan et al., 2006).  When 
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considering that ACT is highly overexpressed in the AD brain and is part of amyloid 
plaques, taken together with ACT’s role in tauopathies, we hypothesized that ACT could 
be a trigger for tau phosphorylation in AD.  A primary focus in AD research has been 
finding relationships between the two primary hallmarks of the disease, amyloid and tau.  
Whereas it was believed for some time that these pathologies existed independently of 
each other, new evidence suggests that both amyloid aggregates and intracellular AB can 
stimulate the phosphorylation of tau.  In these experiments, we demonstrate that ACT, an 
acute phase serum glycoprotein, contributes to phosphorylation of tau in vivo.   
Previously, it was demonstrated in human and PDAPP mouse cortical neurons that 
adding ACT to the culture media resulted in AD-specific phosphorylations of tau known 
to contribute to AD pathogenesis.  When ACT is chronically infused into the 
hippocampus of an htau mouse, these same phosphorylation events occur, although not 
due to the activity of the same intracellular kinases. 
Immunohistochemical analyses revealed that increased levels of phosphor-tau 
were found in the hippocampus of the ACT infused hemisphere of 5 month old htau mice 
and in 12 month old PDAPP mice.  Specifically, strong staining for pSer202 (CP-13 
antibody) was detected in htau mice (figure 32) and pThr231 in PDAPP Mice (figure 36).  
Western blot analysis confirmed the results in the htau mice.  Brain homogenates from 
ACT-treated and untreated htau brain hemispheres were run side by side.  Pser202 was 
increased in each case where ACT was infused (figure 33).  Moreover, it was also 
determined that there was an increase in pSer396/Thr404 (PHF-1) in the presence of 
ACT (figure 31), a phosphorylation event closely associated with pre-tangle formation.   
This site has been shown to be phosphorylated by GSK-3β and activation of GSK-3β 
(indicated by dephosphorylation at 51KDa) is evident in this study (figure 34).  All of 
these data are consistent with previous in vitro data.  One difference between the studies 
was that ERK was activated (indicated by increased phosphorylation at 42/44KDa) in the 
presence of ACT in vitro and appears inactivated in vivo following ACT infusions (figure 
35).  The exact mechanism by which tau becomes hyperphosphorylated in Alzheimer’s 
disease is not known. In vitro analysis of tau phosphorylation have shown that several 
kinases can induce phosphorylation of tau at numerous sites, roughly half of which are 
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observed to be hyperphosphorylated in Alzheimer’s disease brains.  Inhibition of GSK-
3β, for example, was shown to reduce the phosphorylation of tau and increase cell 
viability.  GSK-3β, amongst other kinases, is elevated in the brains of Alzheimer patients, 
which suggests that molecules, in this case inflammation-related, can trigger their 
activation, contributing to tau hyperphosphorylation and tangle formation. 
 In these experiments, we build upon our previous work in which we propose that 
the increased Aβ level in Alzheimer’s disease brain activates microglia to express 
inflammatory proteins like IL-1B.  IL-1B, in turn, activates astrocytes to release large 
amounts of ACT into the surrounding parenchyma (Abraham, 2001).  ACT then triggers 
increased expression or activation of certain kinases, such as GSK-3, which results in tau 
hyperphosphorylation, tangle formation and neuronal degeneration (Hooper et al., 2008). 
Therefore, our data support the theory of an inflammatory cascade in AD, brought on by 
Aβ.  More experiments are currently underway to determine which other kinases are 
activated in response to ACT that result in tau phosphorylation.  Inhibition of kinase 
activity is currently being pursued as a potential therapy for AD (Perez-Martinez, 2009).  
These results suggest that ACT could be a candidate as an upstream target in both the 
formation of amyloid plaques and phosphorylation of tau. 
Taking together the in vitro and in vivo tau data, these results suggest that 
inhibiting ACT upstream from tangle formation (and amyloid plaque formation- chapter 
9) could be a potential therapy for AD. 
 
 
 
 
 
 
 
 
 
 
8.4.  Figures 
 
 
 
R L L R L L R L R R 
htau htau htau 
NTG NTG 
 
Figure 31. ACT infusion induces increases in phospho tau (PHF-1) in htau mice.  Whole 
brain homogenates from ACT treated (right) and untreated (left) hemispheres of htau 
mice are run alongside each other in a western blot and visualized using infrared 
secondary antibodies (Lycor). The white arrows indicate where ACT (in red) was 
infused.  PHF-1 is shown in green and the signal intensity increases in the presence of 
ACT.  Data is not quantified due to the small number of animals used. 
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Figure 32. Immunohistochmical analysis of an htau mouse following ACT infusion (left 
side).  The montage was taken at 5x and the inlays taken at 40x.  ACT is shown in red, 
pSer202 is shown in green and is upregulated in the presence of ACT.  Data is not 
quantified due to the small number of animals used.  
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Figure 33. Whole brain homogenates from ACT treated) and untreated hemispheres of 
htau mice are run alongside eachother in a western blot and visualized using an infrared 
secondary antibody (Lycor).  PSer202 signal intensity (green) increases in the presence of 
ACT. 
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Figure 34. ACT infusion leads to a dephosphorylation, thus activation, of GSK3 as  
 
indicated by the arrows on a westen blot of whole brain homogenates from htau mice. 
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Figure 35. ACT infusion leads to decreased phosphorylation, thus inactivation, of ERK  
 
as indicated by the arrows on a westen blot of whole brain homogenates from htau mice. 
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Figure 36. Infusion of ACT into the hippocampus of a PDAPP mouse induces 
phosphorylation of endogenous mouse tau at Thr231 (left) as compared to aCSF into the 
contralateral hemisphere (right). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 157 
 158 
 
 
 
 
 
 
CHAPTER 9 – THE EFFECTS OF CHRONIC INTRACEREBRAL INFUSION 
OF ACT ON AMYLOID PLAQUES:   INHIBITION WITH A-ΒETA RELATED 
PEPTIDES 
 
9.1.  Introduction 
 
 Previous work in our laboratory and others have demonstrated that inflammation 
and an acute phase response are initiated in the extracellular periphery of amyloid 
plaques (Abraham et al., 1988; Potter et al., 2001).  This inflammation appears to be 
initated when increased levels of oligomeric/fibrillar Aβ activate microglia, inducing 
them to release cytokines such as IL-1β, IL6 and TNFα. IL1 and IL6, in turn trigger the 
production and release of ACT and apoE from astrocytes (Das and Potter, 1995). These 
two products of inflammation have been termed pathological chaperones because they 
accelerate the fibrillization of the Alzheimer Aβ peptide and subsequent amyloid plaque 
formation. ACT, a serine protease inhibitor (serpin) is serum glycoprotein that is 
normally made in the liver in response to inflammation and inhibits proteases in order to 
maintain homeostasis and prevent undue tissue destruction during the acute phase 
response. ACT is upregulated significantly in the brain of AD patients (Porcellini et al., 
2008).  ApoE is also upregulated and released from astrocytes and microglia during brain 
damage and inflammation.  The ApoE4 isoform has been shown to be the strongest 
heritable  risk factor for the disease and is also released by astrocytes and microglia 
during the acute phase response (Abraham, 2001).  Evidence that polymorphisms in the 
ACT gene are also risk factors for developing is accumulating but does not come near the 
strength of the apoE4 effect (Nilsson et al., 2004). 
 It has been demonstrated that synthetic Aβ peptides self-polymerize in vitro under 
various physiological conditions to form filaments that resemble the beta-pleated amyloid 
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structures found in AD by transmission electron microscopy (TEM) (Castelletto et al., 
2008) and attenuated total reflection-FTIR spectroscopy (Cerf et al., 2009).  These 
preparations of filaments have also proven to be neurotoxic to primary neuronal cell 
cultures.  The polymerization of Aβ, it was found, could be accelerated by ACT, and to a 
greater extent by ApoE4.  Moreover, it has been established that ACT and ApoE each 
bind to different regions on the AB peptide (Ma et al., 1994).  ACT binds to the 
hydrophilic N-terminus (amino acids 2-9) and ApoE to the 12-28 region of the Aβ 
peptide.  These small fragments, when incubated with full length Aβ and their respective 
pathological chaperones (ACT and ApoE) inhibit the catalyzed polymerization of fibrils 
in a dose-responsive manner. When these reactions were added to cultures of human 
cortical neurons, it was found that the two inhibitory peptides prevented apoE and ACT 
respectively from promoting Aβ polymerization and neurotoxicity, thus enhancing cell 
survival, as visualized by MTT assays (Ma et al., 1996). 
 Work with transgenic mice has extended and supported the cell culture findings 
described above.  Breeding PDAPP mice with and without endogenous mouse ApoE and 
and with and without a hACT transgene demonstrated that both ACT and ApoE act 
independently, but synergistically to facilitate the formation of amyloid plaques.  
Moreover, it was determined that the regions of the brain containing plaques were 
somewhat different. In the absence of ApoE, ACT-positive plaques were localized to the 
hippocampus and in the presence of ApoE,  ACT-positive plaques were found in the 
hippocampus and cortex (Nilsson et al., 2001).  These experiments also showed that 
cognitive deficits in the PDAPP mice, as assayed by the Morris Radial Arm Water Maze 
and the Radial Arm Water Maze, depended on the presence of ACT and/or apoE-
promoted amyloid deposits (Bales et al., 1999; Nilsson et al., 2001) 
 In December 2006, Wiesniewski et al. created a compound named Aβ12-28P 
representing a modified 12-28 peptide that reduced amyloid burden when injected 
systemically into APP-expressing mice.  The modifications to the peptide included 
exchanging the valine in position 18 for proline, thus rendering the peptide 
nonfibrillogenic and preventing the molecule from binding to plaques.  Additionally, 
AB12-28P was synthesized in a slightly modified version by using D-amino acids and 
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end-protected by acetylation and amidation of the N and C termini, respectively.  These 
modifications decreased the potential for immunogenicity and extended the serum half-
life of the peptide. AB12-28P was, however, still able to cross the BBB and to inhibit 
apoE/Aβ binding with these modifications.  Specifically, the compound was able to 
decrease amyloid burden by 51.6% and 45.6% in the cortex and hippocampus, 
respectively, of 7 month old Tg2576 mice and 50.7% and 40.0% in PS/APP (PS-Tg2576) 
mice (Sadowski et al., 2006). Evidentally, the ability of Aβ 12-28 to serve as a decoy 
peptide and prevent apoE from binding to Aβ in vitro was duplicated in vivo, and 
suggests that the modified peptide designed by Wisniewski and colleagues is a potential 
therapy for Alzheimer’s disease. 
 Because the effect of the interaction of Aβ peptides with ACT on the formation of 
amyloid was well established, we desired to determine whether this interaction could be 
exploited to develop a novel Alzheimer therapy.  We first studied the effects of ACT on 
existing plaques by infusing purified human ACT intracranially into PDAPP mice at ~ 8 
months of age and assessing the morphology of the plaques. In the next phase of the 
research, we wished to determine whether the N-terminus of Ab could inhibit the 
ACT/Aβ interaction in a manner similar to the inhibition of the ApoE/Aβ interaction in 
vivo by the modified 12-28 peptide.  To this end, experiments were designed in which 
ACT was co-infused with Aβ 1-11 into the hemispheres of PS/APP mice as was the Aβ 
1-11 fragment alone. 
 
9.2.  Materials and Methods 
 
9.2.1.  Catheter Construction 
 
The catheters (patent pending- PCT/US08/73974) used for this experiment were 
made by first taking a 1.25 cm length of 30 gauge stainless steel tubing (Small Parts, Inc. 
Miramar, Fl) and carefully bending it at 2.5 mm under a dissecting microscope (Leica, 
Heerbruug, Switzerland), to approximately 90 degrees, being careful not to crimp the 
tube.  The remaining length of the tube was bent again at 5 mm to an angle of 120-160 
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degrees, approximating the contour of each animal’s skull.  These metal cannulae were 
inserted into a 3 cm length of polyethylene (PE-10) tubing with an internal diameter of 
0.28 mm and an outer diameter of 0.61 mm.  One centimeter of the PE-10 was then itself 
inserted into a 4.5 cm length of sterile polyvinyl tubing (PV-50-I.D. 0.69 mm/ O.D. 1.14 
mm, Durect Corp., Cupertino, Ca), held in place using a bead of Locktite 454 adhesive 
(Plastics One. Roanoke, VA.), and cured overnight.  The following day, sterile water was 
forced through each catheter assembly to ensure that the lines were not obstructed.  The 
osmotic pumps were then filled with solution, attached to the catheters and primed and 
implanted as described below.  The proven catheters were later custom manufactured by 
Braintree Scientific (Braintree, MA) with some minor changes: The adhesive was 
supplanted by heat sealing PE-10 to PE-50 tubing and, because the diameters of the PV-
50 and new PE-50 were not exactly the same, a sheath of silicone (SIL 047) was placed 
over the PE-50 with an extra 2 mm overhang to attach it to the flow modulator of the 
pump, forming a tight, leak-proof seal.   
 
9.2.2.  Transgenic Mice 
 
PS/APP (presenilin 1/amyloid precursor protein) mice and PS/APP/ACT mice 
were generated by crossing heterozygous PDGF-hAPP (V717F) mice with PDGF-hPS1 
(M146L) on both Swiss Webster and C57BL/6 backgrounds.  Genotyping was performed 
using comparative real-time PCR (Bio-Rad iCycler- Hercules, CA).  Pathologically, these 
Alzheimer's mouse models are characterized by robust accumulation of amyloid plaques 
and the development of microgliosis between 6-8 months of age. 
 
9.2.3.  Materials 
 
Purified human α-1 antichymotrypsin (ACT) was purchased lyophilized from 
Fitzgerald (Concord, MA) and was reconstituted in artificial CSF (Harvard Apparatus, 
Holliston, MA) to a concentration of 1mg/mL. The Aβ 1-11 was suspended at 5 mg/mL 
(Rpeptide, Bogart, GA)   ACT was infused directly into the hippocampal parenchyma for 
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28 days using the novel catheters attached to Alzet osmotic minipumps (Alzet model 
1004, Durect Corp. Cupertino, CA) with an average flow rate of 0.12μL/hour.  The 
pumps and catheters were submerged in 0.9% sterile saline at 37oC and primed for 48 
hours prior to implantation.   
 
9.2.4.  Intracranial Infusions 
 
All procedures involving experimentation on animals were performed in 
accordance with the guidelines set forth by the University of South Florida Animal Care 
and Use Committee.  Animals (8 month-old PS/APP- 25-35g) were anesthetized with 1-
2% isoflurane, shaved and scrubbed with 10% Betadine solution at the site of incision, 
and placed into a stereotaxic frame (Kopf Instruments. Tujunga, Ca.).  A small (5 cm) 
incision was made, exposing the skull and neck, and double bladed scissors were used to 
form a subcutaneous pocket along the back of the animal into which 2 osmotic 
minipumps were inserted with catheters attached.  Two holes were drilled into the skull 
(from Bregma -2.2-2.5 mm anterior-posterior, +/- 2.2-2.5 mm medial-lateral, and the 30 
gauge catheters were inserted to a depth of 2.2-2.5 mm) corresponding to the posterior 
portion of the CA3 hippocampus.  Alternatively, holes were drilled corresponding to the 
lateral ventricles (from Bregma -0.2 mm anterior-posterior, +/- 1.0 mm medial-lateral, 
and to a depth of 2.2-2.5 mm).  Once they were inserted, the cannulae were affixed to the 
skull with Locktite 454 adhesive (Plastics One. Roanoke, VA.) and secured down with a 
piece of nitrile, approximately 1 cm in diameter (Fig 3D).  After the adhesive cured, the 
scalp was closed with 6-7 silk sutures.  For analgesia, the animal received an immediate 
dose of ketoprofen (10mg/kg) and additional doses once every 6 hours, as needed, for a 
maximum of 48 hours post-operatively.  After the 28 day period, the animals were given 
an overdose (~150mg/kg) of sodium pentobarbital (i.p.) and were transcardially perfused 
with 0.9% saline.  The brains were carefully removed and analyzed as outlined below.  At 
this time, the integrity of the catheters was confirmed again by forcing water through, and 
the pumps were also determined to be empty. 
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9.2.5.  Histology and Immunohistochemistry 
 
Mouse brain tissues were fixed in 10% formaldehyde (formalin) for 72 hours and 
then passed through a series of sucrose solutions (10-30%) over another 72 hours.  Brains 
were frozen to the peltier stage (Physitemp, Clifton, NJ) of a histoslide (Leica, 
Heerbruug, Switzerland) and sectioned coronally at 25 μm.  After incubating the sections 
with blocking buffer (Tris-buffered saline with 10% normal goat serum, 0.1% Triton X-
100, and 0.02% sodium azide) for 60 min, primary antibodies against Aβ (6E10 and 
4G8,1:1000- Covance, Princeton, NJ) as well as Iba1(1:1000) (Wako Chemicals, USA. 
Inc., Richmond, VA.) were applied and incubated at 4 o C overnight.  After thorough 
washing, the sections were incubated with secondary antibodies, Alexa 488 and 594 
fluorophores (1:1000, 1:4000-Invitrogen) in the dark at ambient temperature for 2 hours.  
This incubation was followed by a Hoechst (1:10,000, Sigma, St. Louis, MO) nuclear 
stain, and the sections were washed and sealed with Gel-Mount (Electron Microscopy 
Sciences, Hatfield, PA).  The images were analyzed on a Zeiss Imager Z1 fluorescence 
microscope with a Zeiss Axiocam Mrm camera (Oberkochen, Germany) using 
Axiovision 4.7 software and quantified using Image J. 
 
9.3.  Results and Conclusions 
 
Previous work from our and other laboratories has shown that Aβ is the primary 
component of amyloid plaques found in the AD brain.  It has been shown in vitro that Aβ 
can self polymerize into fibrils and that this process is accelerated by extracellular 
pathological chaperones (Wisniewski and Frangione, 1992).  The term “pathological 
chaperone” which was coined by Thomas Wiesnieski in 1992 is used to describe 
molecules that promote a pathological change in a protein of interest, in our case Aβ.  
Molecular chaperones, on the other hand, are responsible for promoting the folding of 
proteins into their physiological, rather than a pathological conformation.  Previous work 
has demonstrated that both ACT and ApoE have roles as pathological chaperones in AD.  
Not only can they accelerate the formation of Aβ fibrils in vitro (Ma et al., 1994), but 
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transgenic animal studies have also revealed that these molecules bind directly to Aβ 
fibrils and become part of the ensuing amyloid plaques (Nilsson et al., 2004). 
ApoE and ACT are both upregulated in the AD brain and released by residing glia 
as part of the chronic inflammation induced by Aβ (or Aβ oligomers).  The normal 
psysiological roles of these molecules are also known.  ApoE is released by hepatocytes 
and is the major binding protein of LDL during cholesterol transport to tissues.  ACT, on 
the other hand, is released by hepatocytes and neutrophils to inhibit cathepsin G during 
inflammation to remodel damaged tissues and possibly engulf pathogens (Kalsheker, 
1996).  ACT is a serine protease inhibitor that is produced in concert with several serine 
proteases that would otherwise go out of homeostatic balance during growth and repair 
and cause damage to cells and tissues.  The normal roles of ApoE and ACT in the brain, 
however, are not as clear.  One possibility for the presence of ACT was proposed by our 
lab some time ago:  Because the structural homology between cathepsin G, chymotrypsin 
and Aβ is striking, Aβ might be recognized by ACT as a protease and bound to inhibit its 
action (Ma et al., 1994). 
 To interfere with the interaction of ACT and Aβ, thereby the formation of 
amyloid, novel strategies have been developed to inhibit the binding of these molecules.  
Previous therapeutic approaches have been focused on inhibiting the secretase enzymes 
that overproduce Aβ, on immunizing patients against the Aβ peptide, or on manipulating 
cholinergic and glutaminergic neurotransmission.  Inhibiting the interaction of Aβ with 
ApoE and ACT respectively, was a new approach that has also proven effective in mouse 
models.  Early experiments showed ACT and ApoE could accelerate the formation of Aβ 
fibrils in vitro, but also that this promotion could be inhibited with small fragments of the 
Aβ peptide itself.  The amino acids that correspond to aminoacids 12-28 in the Aβ 1-42 
peptide, attenuated the formation of fibrils significantly when incubated with ApoE (Ma 
et al., 1996).  Similarly, when Aβ 1-42 was incubated with ACT and the amino acids that 
correspond to positions 2-9 of the Aβ 1-42 fragment, attenuated fibril formation was 
observed as well.  Additionally, when these reactions were cultured with human cortical 
neurons, MTT cell survival assays determined that the cells were more viable with 
increasing concentrations of the inhibiting peptides.  In sum, these experiments 
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demonstrated that “decoy” fragments of Aβ could bind ApoE and ACT, thereby 
preventing these proteins from binding to full length Aβ and accelerating the formation 
of amyloid. 
The next phase of this research, in vivo, was carried out by Wiesnieski et al. in 
2006.  In this set of experiments, the modified 12-28 peptide, previously described, was 
delivered systemically in mice harboring the Swedish APP mutation and was found to 
drastically reduce amyloid load and improve cognition.  In my experiments described 
here, the rationale was very similar in that the an Aβ fragment of 11 amino acids, 
covering the 2-9 region of Aβ was used to interrupt the Aβ/ACT interaction.  However, 
in these experiments, the peptide was delivered without modification and via direct 
infusion into the hippocampus of PS1/PDAPP mice.  Though preliminary, the delivery of 
the 1-11 peptide in a small group of animals (n=4) virtually eliminated plaques in the 
vicinity of the infusions (figures 37 and 38- quantitation figure 39) as well as the 
presence of microglia (Iba1 staining- figure 40).  The use of both 6E10 (figure 37) and 
4G8 (figure 38) antibodies to show plaque clearance is notable because they bind the 1-
16 and 17-24 residues on Aβ, respectively, which correspond to the binding sites of ACT 
and ApoE.  One might expect that the epitope for ACT be bound to the decoy peptide and 
not available for the antibody, but staining was strong using both antibodies.  Because 
these mice did not carry the human ACT gene, the interpretation of this finding is not 
perfectly clear, but it is known that mice have a serpin homologue (Serpin A3N) that is 
found in plaques that cross-reacts with the ACT antibody.  Perhaps the Aβ 1-11 peptide 
binds to this endogenous protein, and prevents it from promoting amyloid filament 
formation.  Moreover, it appears that the application of the Aβ 1-11 peptide  not only 
interferes with the formation of plaques, but also contributes to the clearance of already 
existing plaques.. The lack of microglial staining on the treated hemisphere would 
suggest that microglia engulfed amyloid deposits and then departed.  Further clarification 
is currently being pursued with additional experiments.  However, it is already evident 
from this study and the work performed by Wiesniewski et al. that Aβ fragments make 
effective decoys to bind to the pathological chaperones ApoE and ACT and provide 
another potential therapy for AD. 
9.4.  Figures 
 
 
Aβ 1-11 infusion site 
#981 
 
 
Figure 37. Infusion site of Aβ 1-11 into 8 month old PS/APP mice (n=4) immunolabeled 
with 6E10 showing marked plaque reduction. 
 
 
 
 
 
 
 
 
 
 
 
 
 166 
  
Aβ 1-11 infusion site 
#981 
 
 
Figure 38. Infusion site of Aβ 1-11 into 8 month old PS/APP mice (n=4) immunolabeled 
with 4G8 showing marked plaque reduction. 
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Figure 39. Semi-quantification of 4 mice treated with Aβ 1-11 stained with  
both 6E10 and 4G8 antibodies, with significance of p= 0.024 and p= 0.058 respectively. 
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Figure 40. A) Immunostaining of Aβ 1-11 treated mice with the microglial marker Iba1       
showing an absence of microglia on the treated side 
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Figure 40. B) Quantification (semi) of above immunohistochemical analysis of Iba1 
(n=2) 
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10.1.  Abstract 
 
Objectives: Rheumatoid arthritis (RA) is a negative risk factor for the development of 
Alzheimer’s disease (AD). While commonly assumed that RA patients’ usage of non-
steroidal anti-inflammatory drugs (NSAIDs) helped prevent onset and progression of AD, 
NSAID clinical trials have proven unsuccessful in AD patients. To determine whether 
intrinsic factors within RA pathogenesis itself may underlie RA’s protective effect, we 
investigated the activity of colony-stimulating factors, up-regulated in RA, on the 
pathology and behavior of transgenic AD mice. 
Methods: 5μg bolus injections of macrophage, granulocyte, and granulocyte-macrophage 
colony- stimulating factors (M-CSF, G-CSF, or GM-CSF) were administered unilaterally 
into the hippocampus of aged cognitively-impaired AD mice and the resulting amyloid 
load reductions determined one week later, using the artificial cerebrospinal fluid (aCSF)-
injected contralateral sides as controls. 20 daily subcutaneous injections of 5µg of GM-
CSF (the most amyloid-reducing CSF in the bolus experiment) were administered to 
balanced cohorts of AD mice after assessment in a battery of cognitive tests. Reductions 
in amyloid load and improvements in cognitive function were assessed. 
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Results: G-CSF and more significantly, GM-CSF reduced amyloidosis throughout the 
treated brain hemisphere one week following bolus administration to AD mice.  
Moreover, subcutaneous GM-CSF administration significantly reduced brain amyloidosis 
and completely reversed the cognitive impairment, while increasing hippocampal 
synaptic area and microglial density. 
Interpretation: These findings, along with two decades of accrued safety data using 
Leukine, recombinant human GM-CSF, in elderly leukopenic patients, suggest that 
Leukine should be tested as a treatment to reverse cerebral amyloid pathology and 
cognitive impairment in AD. 
  
10.2.  Introduction 
 
Although numerous studies have reported Rheumatoid arthritis (RA) to reduce the 
risk of Alzheimer’s disease (AD), the mechanisms for RA’s protective effect are still 
unknown (McGeer et al., 2006).  These reports have commonly assumed that RA 
patients’ usage of non-steroidal anti-inflammatory drugs (NSAIDs) may help prevent the 
onset and progression of AD (McGeer et al., 2006), but the largest NSAID clinical trials 
have not demonstrated efficacy in reducing the incidence of dementia, and recently 
Naproxen was reported to be detrimental, with increased risk of cardiovascular and 
cerebrovascular events (Martin et al., 2008).  These results suggested to us that intrinsic, 
probably immunological factors within RA pathogenesis itself, may underlie RA’s 
protective effect against AD. We surmised that up-regulated local cellular populations in 
RA would have the highest potential to enter into the brain and inhibit the development 
of AD pathology and/or neuronal dysfunction. 
Alzheimer’s disease is an age-related, progressive neurodegenerative disorder that 
presents as increasing decline in cognitive and executive function. Alzheimer dementia is 
associated with cerebrovascular dysfunction (Humpel and Marksteiner, 2005), 
extracellular accumulation of amyloid β (Aβ) peptides in the brain parenchyma and 
vasculature walls (Rhodin et al., 2000; Scheuner et al., 1996) (predominantly Aβ1-42 and 
Aβ1-40), and intraneuronal accumulation of neurofibrillary tangles consisting of 
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hyperphosphorylated Tau proteins (Padmanabhan et al., 2006).  Associated 
neuroinflammation may contribute to AD pathogenesis (Griffin et al., 1989), as the 
inflammatory proteins apolipoprotein E (apoE) and α1-Antichymotrypsin (ACT) catalyze 
the polymerization of Aβ peptides into amyloid filaments in vivo and in vitro (Ma et al., 
1996; Nilsson et al., 2004; Padmanabhan et al., 2006; Potter et al., 2001; Wisniewski et 
al., 1994). Conversely, it has also been shown that amyloid plaques form rapidly and then 
become decorated by microglia (Koenigsknecht-Talboo et al., 2008; Meyer-Luehmann et 
al., 2008), both resident and bone marrow-derived, suggesting an ability and intention to 
remove amyloid (Malm et al., 2005; Simard and Rivest, 2004; Simard et al., 2006). Thus 
it is unclear whether neuroinflammation is deleterious or beneficial in the AD brain, and 
indeed the role of microglia in AD is complex and may involve different states of 
activation with different activities. 
  Rheumatoid arthritis is an autoimmune disease in which inflamed synovial tissue 
and highly vascularized pannus form, irreparably damaging the cartilage and bone. In this 
inflammatory pannus, leukocyte populations are greatly expanded, and many 
proinflammatory factors are produced that work together in feed-forward mechanisms, 
further increasing leukocytosis, cytokine/chemokine release, osteoclastogenesis, 
angiogenesis, and autoantibody production (rheumatoid factors and anti-citrullinated 
protein antibodies) (Schellekens et al., 2000; Szekanecz and Koch, 2007).  Additionally, 
the adaptive immune system presents a Th17 phenotype within CD4+ lymphocytes, with 
ultimate production of interleukin 17 (IL-17) which is then responsible for inducing much 
of the pro-inflammatory effects (Cox et al., 2008; Parsonage et al., 2008). Further 
enhancements of leukocyte populations come from increased expression of structurally-
unrelated colony-stimulating factors: M-CSF (macrophage), G-CSF (granulocyte), and 
GM-CSF (granulocyte-macrophage) (Kawaji et al., 1995; Nakamura et al., 2000; 
Olszewski et al., 2001; Xu et al., 1989). 
Although up-regulated leukocytes in RA could potentially enter into the brain and 
inhibit development of AD pathology and/or neuronal dysfunction, lymphocytic 
infiltrates into AD patient brains have not been reported. The lack of infiltration suggests 
that proliferation and activation of the innate immune system might be responsible for 
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preventing AD pathology in RA patients. Evidence supporting the innate immune 
system’s role in AD pathogenesis show that complement proteins are up-regulated in AD 
brain, and that inhibition of C3 convertase significantly increases amyloid pathology in 
AD mice (Wyss-Coray et al., 2002). Bone marrow-derived microglia also play a critical 
role in restricting amyloid deposition, but this association and many associated receptors 
and enzymes, such as CD36, scavenger receptor A, and receptor for advanced glycation 
end products, or neprilysin, insulysin, and matrix metalloproteinases, decline with age, 
while AD pathology increases (El Khoury et al., 2007; Hickman et al., 2008; Simard et 
al., 2006).  
To investigate the interplay of the innate immune system and AD, we studied the 
effects on AD pathology of the three colony-stimulating factors (M-CSF, G-CSF, and 
GM-CSF), which are up-regulated during RA pathogenesis (Kawaji et al., 1995; 
Nakamura et al., 2000; Olszewski et al., 2001; Xu et al., 1989).  These CSFs enhance the 
survival and function of their respective leukocytes and drive their proliferation and 
differentiation from myeloid lineage precursors. GM-CSF induces dendritic cells, 
macrophages, and granulocytes (neutrophils, basophils, and eosinophils), while M-CSF 
and G-CSF respectively induce the macrophage and granulocyte subsets of the innate 
immune system. These innate cells have the ability to diapedese from the circulatory 
system and to differentiate further into various specialized immune cells within organs 
(microglia, Langerhan’s cells, etc.). GM-CSF and G-CSF are also known to be involved 
in erythropoiesis, and GM-CSF and erythropoietin act synergistically in the maturation 
and proliferation of the burst-forming and colony-forming erythroid units to the 
normoblast stage of erythropoiesis (Fisher, 2003).  Circulating Aβ binds to complement 
opsonin C3b in an antibody-independent fashion, and C3-opsonized particles bind to the 
complement receptor CR1on erythrocytes and to CR1g on liver-resident kupffer 
macrophages (Helmy et al., 2006; Rogers et al., 2006).  Thus GM-CSF could function in 
both the peripheral clearance of Aβ and in bone marrow-derived microglial activity, since 
it is involved in the proliferation, differentiation, and maintenance of most innate 
leukocytes. 
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Here, we report on experiments that investigated the effect of CSF administration 
on amyloid plaque deposition, microglial activation, synaptic function, and associated 
cognitive decline in a mouse model of AD. Our results, particularly with GM-CSF, 
provide a compelling explanation for RA’s inverse relationship with AD.  Moreover, the 
reduction of amyloidosis and enhancement of cognition by GM-CSF warrant clinical 
investigation of Leukine for the treatment of Mild Cognitive Impaired (MCI) and AD 
patients, especially with Leukine’s long-standing safety history in leukopenic patients.  
 
10.3.  Materials and Methods 
 
All procedures involving experimentation on animals were performed in 
accordance with the guidelines set forth by the University of South Florida Animal Care 
and Use Committee. Transgene detections were performed using QPCR (Bio-Rad 
iCycler, Hercules, CA). 
 
10.3.1.  Transgenic  Mouse Studies Involving Intracerebral Administration of CSFs 
 
PS/APP mice in this study, which begin accumulating robust amyloid plaques at 
6-8 months, were generated by crossing heterozygous PDGF-hAPP (V717F) mice with 
PDGF-hPS1 (M146L) on both Swiss Webster and C57BL/6 backgrounds.  
M-CSF was bilaterally infused directly into the lateral ventricles (5 µg/day) for 14 days 
using a novel intracranial catheter infusion system (Bennett, 2009). This completely 
subcutaneously-contained system allows bilateral intracerebral infusion of test substances 
ipsilaterally and vehicle contralaterally, and overcomes the problem of amyloidosis 
variance between animals, effectively making each animal its own control 
(Supplementary Figure 1). All three CSFs were stereotaxically-injected (5 µg/injection) 
into the (ipsilateral) hippocampus, with aCSF vehicle injected contralaterally into four 
PS/APP mice each (all 10-12 months old, 25-35 g, both genders). Two holes were drilled 
into the skull (from bregma -2.5 mm anterior-posterior, +/- 2.5 mm medial-lateral, and 
the 30 gauge needle inserted to a depth of 2.5 mm). Mice were perfused with 0.9% cold 
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saline 7 days later and their brains placed in 10% neutral buffered formalin. Recombinant 
mouse GM-CSF (rmGM-CSF), recombinant murine G-CSF (rmG-CSF), and 
recombinant mouse M-CSF (rmM-CSF) (R&D Systems, Minneapolis, MN) will be 
referred to as GM-CSF, G-CSF, and M-CSF throughout this publication.  
 
10.3.2.  Immunohistochemistry and Image Analysis of Intrahippocampal-injected Mice  
 
Formalin-fixed brains were either coronally cryosectioned at 14-µm, or paraffin-
embedded and sectioned at 5-µm, with standard deparaffination and antigen retrieval 
steps (boiled in 10mM Sodium Citrate buffer for 20 minutes) performed before 
immunohistochemical staining of 5 sections at 150 µm intervals. To significantly reduce 
cost of reagents and antibodies with paraffin-embedded slides, a novel magnetic 
immunohistochemical staining device was developed (patent pending, Tech ID# 
09A015). Standard fluorescent immunohistochemical techniques used primary anti-Aβ 
antibodies 6E10 (Covance, Emeryville, CA, 1:1000), and MabTech’s 3740-5 (MabTech, 
Cincinnati, OH, 1:5000) to immunolabel amyloid deposition coupled with Alexa 
fluorophore-labelled secondary antibodies (Molecular Probes, Eugene, OR, 1:1000, 
1:4000), and Hoechst (Sigma) nuclear staining. Immunofluorescence was detected on a 
Zeiss Imager.Z1 microscope (Oberkochen, Germany) using Axiovision 4.7 software and 
digital images quantified using ImageJ (Supplementary Figure 5-6 Appendix B).  
 
10.3.3.  Behavioral Transgenic Mouse Study Involving GM-CSF Treatment  
 
Mice in this study were derived from the Florida Alzheimer’s Disease Research 
Center mouse colony, wherein heterozygous mice carrying the mutant APPK670N, 
M671L gene (APPsw) are routinely crossed with heterozygous PS1 (Tg line 6.2) mice to 
obtain APPsw/PS1, APPsw, PS1, and non-transgenic (NT) genotype offspring with a 
mixed C57/B6/SW/SJL background. Eleven APPsw, 4 APPsw/PS1, and 17 NT mice, all 
12-months old, were selected and evaluated for 8 days in the RAWM task of working 
memory as previously described (Arendash et al., 2001) and Supplementary Figure 7). 
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Numerous experiments have revealed that various genotypes of AD mice perform equally 
once they reach cognitive impairment. Thus, the 15 Tg mice were divided into two 
groups, balanced in RAWM performance, with 2 APPsw/PS1 mice included in each 
group. The 17 NT mice were also divided into two groups, balanced in RAWM 
performance. Two weeks following pre-treatment testing, one group of Tg mice (n = 7) 
and one group of NT mice (n = 9) were started on a 10-day treatment protocol with 
GM-CSF (5 µg/day given subcutaneously), while animals in the control Tg and NT 
groups (n = 8 per group) concurrently received daily vehicle (saline) treatment 
subcutaneously.  On the 11th day of injections, all mice began four days of RAWM 
evaluation, were given 2 days of rest, then evaluated in 4 days of Cognitive Interference 
task testing as previously described (Echeverria et al., 2009; Loewenstein et al., 2004). 
Daily GM-CSF and saline injections were continued throughout the behavioral testing 
period. After completion of behavioral testing at 20 days into treatment, all mice were 
euthanatized, brains fixed as described above, and paraffin-embedded. Careful visual 
examination of all tissues upon necropsy revealed no morphological abnormalities, and 
the mice tolerated daily subcutaneous injections well. Each analysis was done by a single 
examiner blinded to sample identities, and statistical analyses were performed by a single 
examiner blinded to treatment group identities. The code was not broken until analyses 
were completed. 
 
10.3.4.  Immunohistochemistry and Image Analysis of Subcutaneous GM-CSF-treated   
Mice 
 
Five 5-μm sections (150-μm apart) were made of formalin-fixed, paraffin-
embedded sections throughout the hippocampus of each mouse and immunoreactivity 
was developed using the Vectastain ABC Elite kit (Vector Laboratories, Burlingame, 
CA) coupled with the diaminobenzidine reaction, according to the manufacturer’s 
protocol. Immunostaining used biotinylated anti-Aβ clone 4G8 (Covance, Emeryville, 
CA, 1:200), synaptophysin (DAKO, Carpinteria, CA, undiluted), and Iba1 (Wako, 
Richmond, VA, 1:1000) as primary antibodies. Images were acquired using an Olympus 
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BX60 microscope and digital images were quantified using SimplePCI software (Compix 
Inc., Imaging Systems, Cranberry Township, PA), according to previous methods 
(Sanchez-Ramos et al., 2009).  Each analysis was done by a single investigator blinded to 
sample identities and genotype. 
 
10.4.  Results 
 
10.4.1.  Intracerebral administration of CSFs  
 
Following bilateral intracerebroventricular infusion of M-CSF for two weeks into 
PS/APP mice, immunohistochemical analysis of both experimental and control mice 
showed considerable variances of amyloid deposition between mice of similar age 
(Supplementary Figure 1-Appendix B), significantly compromising our ability to 
determine M-CSF’s effect in a limited mouse cohort. While improving our drug delivery 
system by developing novel bilateral brain infusion catheters (Bennett, 2009), we found 
that parenchymally-infused recombinant peptides remained localized to the infused 
hemisphere. These findings led us to administer the CSFs as a unilateral 
intrahippocampal bolus with a contralateral injection of vehicle as control, thus obviating 
the need for large numbers of transgenic mice and age-matched littermate controls to 
obtain statistical significance. Each CSF was stereotaxically injected into the 
hippocampus of 4 mice, with artificial cerebrospinal fluid vehicle (aCSF) injected 
contralaterally. The mice were sacrificed 7 days post-injection. 
M-CSF injections into mice resulted in swelling of the entire hemisphere as 
compared to the control side, and in one mouse, an apparent hyperplasia had formed at 
the injection site (Supplementary Figure 2-Appendix B). Quantification of amyloid 
plaque loads from anterior to posterior of each mouse showed similar deposition in the 
M-CSF-injected hemispheres as compared to the control sides (data not shown). In 
contrast to M-CSF, G-CSF injections did not induce swelling and showed some modest 
reductions of amyloid deposition (Supplementary Figure 3- Appendix B), which was 
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subsequently corroborated by independent observations from fellow investigators 
(Sanchez-Ramos et al., 2009). 
GM-CSF-injections, however, demonstrated pronounced decreases in amyloid 
deposition, as compared to control hemispheres, in visual observations of coronal tissue 
sections (Figure 41a; Supplementary Figure 4- Appendix B). Quantification of amyloid 
plaques anterior to posterior revealed significant reductions within individual mice and 
overall significant reductions for all plaque parameters measured (Figure 41b and 
Supplementary Figure 5- Appendix B).  
 
10.4.2.  Daily subcutaneous injection of GM-CSF 
 
Based upon the positive results from intrahippocampal injections, we investigated 
the effect of subcutaneous GM-CSF injection on AD pathology and cognitive function. 
Prior to GM-CSF treatment, APPsw+PS1(Tg) mice were first confirmed by RAWM 
testing to be cognitively-impaired for working memory. Both the non-transgenic control 
mice (NT) and the Tg mice were then sub-divided into two cognitively-balanced groups, 
for either GM-CSF or saline treatment. RAWM testing post-injection re-confirmed that 
Tg control mice were substantially impaired compared to NT control mice. This 
impairment was evident in individual blocks of testing, but also over all 4 days of testing 
(Figure 42a). In sharp contrast, GM-CSF-treated Tg mice performed equally well or 
better than NT control mice during individual blocks and overall. GM-CSF-treated NT 
mice performed as well as or slightly better than NT controls (Figure 42a).  
  Before evaluation in the Cognitive Interference Task, the mice rested two days. 
This task mimics human interference testing, which discriminates between normal aged, 
MCI, and AD patients (Loewenstein et al., 2004).  In all four cognitive interference 
measures assessed over 4 days of testing (Figure 42b), Tg control mice were clearly 
impaired compared to NT mice, and Tg mice treated with GM-CSF exhibited 
significantly better three-trial recall and delayed recall compared to Tg controls. Indeed, 
for all four cognitive measures, GM-CSF-treated transgenic AD mice performed 
similarly to NT mice. A particularly strong effect of GM-CSF treatment in Tg mice was 
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evident for the proactive interference measure during the first half of testing (Figure 42c), 
wherein GM-CSF-treated Tg mice performed substantially better than Tg controls and 
identically to both groups of NT mice. Proactive interference susceptibility has been 
reported to be a more sensitive marker for differentiating MCI and AD patients from aged 
normals than traditional measures of delayed recall and rate of forgetting (Loewenstein et 
al., 2004).  Parenthetically, even the GM-CSF-treated NT mice showed a trend towards 
improved cognition in behavioral studies, albeit not statistically significant. Subsequent 
analysis of brains from Tg mice of this study revealed that GM-CSF treatment induced 
large reductions in amyloid burdens within entorhinal cortex (↓55%) and hippocampal 
(↓57%) compared to control Tg mice (Figure 43).   
The improved cognitive function and reduced cortical amyloidosis of GM-CSF-
treated Tg mice were paralleled by increased microglial density as compared to saline-
treated Tg mice (Figure 44), implying an augmented ability to bind and remove amyloid 
deposition (El Khoury et al., 2007; Hickman et al., 2008).  The GM-CSF-treated Tg mice 
similarly demonstrated increased synaptophysin immunoreactivity in both CA1 and CA3 
regions (Figure 45), indicating increased synaptic area in these hippocampal areas. Prior 
work has shown that adult neural stem cells in hippocampal dentate gyrus (DG) express 
GM-CSF receptors, and GM-CSF increases neuronal differentiation of these cells in a 
dose-dependent fashion (Kruger et al., 2007). Thus, one mechanism for the observed 
GM-CSF-induced cognitive improvement is enhanced removal of deposited Aβ in 
hippocampus, with ensuing neuronal growth/synaptic differentiation of DG mossy fiber 
innervation to CA3, resulting in increased innervation/synaptogenesis of Schaffer 
collaterals into CA1. Removal of deposited Aβ from entorhinal cortex may also increase 
perforant pathway viability to hippocampal projection fields in DG and CA1.  
Thus GM-CSF-induced reduction of amyloidosis and enhancement of 
hippocampal/entorhinal cortex circuitry, critical for working (short-term) memory, may 
underlie GM-CSF’s reversal of working memory impairment in Alzheimer’s Tg mice. 
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10.5.  Discussion 
 
Since peripheral leukocyte populations are increased in RA and possess the ability 
to infiltrate into the brain, we initially investigated M-CSF, G-CSF, and GM-CSF to 
determine which CSF might affect amyloidosis. In the vasculature, all three CSFs work 
to drive the proliferation, differentiation, and survival of their respective innate 
leukocytes from monocytic precursors.  
In our study, we found different functional effects for each intrahippocampal-
injected CSF. In the M-CSF injected mice, there was no effect on amyloidosis but 
pathological changes were noticed, such as swelling and hyperplasia (Supplementary 
Figure 2- Appendix B). Parenchymal overexpression of M-CSF in any organ is probably 
not advisable as overexpression of M-CSF and/or its receptor within mammary glands 
has similarly resulted in tumor formation and hyperplasia (Kirma et al., 2004).  In a study 
by Boissonneault et al. (2009), the authors published that chronic intraperitoneal  
injection of M-CSF prevents and reverses amyloid deposition and cognitive impairment 
and induces brain accumulation of bone marrow-derived microglia (Boissonneault et al., 
2009). Although the authors did not relate their findings to RA’s inverse relationship with 
AD, their data provides evidence that up-regulated M-CSF in RA pathogenesis and 
systemic administration of M-CSF in AD patients may impart protection against AD 
onset or progression. Peripheral administration of G-CSF has also been recently found to 
ameliorate amyloid pathology and reduce cognitive defects in AD models (Sanchez-
Ramos et al., 2009), which corroborates our observations of modest amyloid reduction by 
intrahippocampal injection.  
Although the M-CSF and G-CSF findings are encouraging, our GM-CSF 
intrahippocampal injections into an AD mouse model demonstrated a much more 
pronounced reduction of amloidosis. Furthermore, subcutaneous administration of GM-
CSF resulted in reversal of cognitive impairment resulting in function similar to that of 
wild-type mice, and an average of about 50% reduction of amyloidosis. Explanations for 
these very robust effects are multiple, including the aforementioned augmentation of 
peripheral erythropoietic amyloid-clearance mechanisms (Fisher, 2003; Helmy et al., 
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2006; Rogers et al., 2006), as well as increased neurogenesis (Kruger et al., 2007), 
increased cerebral angiogenesis (Schneider et al., 2007), neuroprotection from apoptosis 
(Schabitz et al., 2008), reduction in amyloidosis (Figures 41, 43, and Supplementary 
Figure 5- Appendix B) and , increased neuronal plasticity (Figure 45). These effects 
mirror those reported for G-CSF (Sanchez-Ramos et al., 2009), and supports the current 
practice of interchangeable prescription of either recombinant human GM-CSF (Leukine) 
or G-CSF (Granocyte, Neupogen, and Neulasta) into patients with depressed bone 
marrow function. G-CSF primarily treats neutropenia while GM-CSF treats all 
leukopenia, and both have long records of safety data from two decades of FDA-
approved usage. Rare adverse events are usually mild febrile incidents that quickly 
subside upon cessation of administration. G-CSF is currently in clinical trial for stroke 
and was recently approved for an AD Phase II clinical trial. However, GM-CSF/Leukine 
is more effective in the AD mouse model and while neutrophils are short-lived 
leukocytes, and the fact that GM-CSF induces up-regulation of all innate cells means that 
it could potentially impart prolonged protective effects against AD.  
The beneficial effects of CSFs, especially GM-CSF in mouse models of AD, point 
to a potential new approach to AD therapy and support our hypothesis that up-regulated 
leukocytosis, induced in RA, may impart the protective effect of RA against AD. Indeed, 
they also indicate, with the failure of NSAID clinical trials in AD which encouraged us to 
develop and test our hypothesis that intrinsic pathogenic properties of RA are protective 
against AD, that age-linked depressed hematopoiesis may be etiological for AD 
pathogenesis.  
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Figure 41. Intrahippocampal injection of GM-CSF (left) and aCSF (right).  (a) 
Representative coronal tissue cryo-sectioned at 14 µm and stained with MabTech α-
Aβ/Alexa 546. Image is a montage of about 145 pictures taken at 10X. White spots 
indicate amyloid plaque immunolabelling (see Supplementary Figure 4 Appendix B for 
representative montaged sections of all 4 mice). (b) Overall plaque reductions seen in all 
4 plaque parameters measured from 5 quantified sections per mouse (n = 4 mice). Each 
analyzed picture per coronal section was thresholded equally to the same standard 
deviation from the histogram mean, and analyzed for area, perimeter, feret diameter, and 
integrated density parameters of each plaque. Area and Perimeter data were calculated 
from the total number of plaque values in each hemisphere per section, and Feret 
Diameter and Integrated Density were calculated from the average values of the plaques 
measured in each hemisphere per section. Each section quantified contained analysis of 
15-25 individual 10X pictures per hemisphere, with less pictures quantified in the 
anterior brain and more in posterior brain (see Supplementary Figure 6 Appendix B). 
Error bars are ± Standard Error of the Mean. Statistical significance from ipsilateral GM-
CSF administration versus contralateral aCSF-injection hemispheres was obtained by 
paired Students t-test with p values (Area: p < 1.11E-07; Perimeter: p < 1.41E-06; Feret 
Diameter: p < 2.36E-09; Integrated Density: p < 1.11E-07). 
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Figure 42. Behavioral analysis following daily subcutaneous GM-CSF injections. (a) 
Standard Radial Arm Water Maze errors. Tg control mice (n = 8) show substantial 
impairment on working memory trials T4 and T5 compared to NT control mice (n = 8) in 
individual blocks of testing (upper), and over all 4 days of testing (lower). GM-CSF-
treated Tg mice (n = 7) performed as well as or better than NT control mice on working 
memory trials T4 and T5 during individual blocks and over all. GM-CSF-treated NT 
mice (n = 9) performed similarly to or slightly better than NT controls (Note significantly 
better performance of NT+GMCSF group versus NT group for T4 of Block 1), although 
this effect was not significant overall. Statistical significance determined by one-way 
ANOVA for the 8-days of pre-treatment testing (four 2-day blocks) and the 4-days of 
post-treatment testing (two 2-day blocks), with evaluation for individual blocks, as well 
as over all blocks. Thereafter, post hoc pair-by-pair differences between groups were 
resolved with the Fisher LSD (least significant difference) test.  (**p < 0.05 or higher 
significance versus all other groups; † p < 0.05 or higher significance versus Tg+GM-
CSF and NT+GM-CSF). (b) Cognitive Interference Task. Overall (4 Days) Tg control 
mice are impaired compared to NT mice on all four cognitive measures assessed.  GM-
CSF-treated Tg mice exhibited significantly better 3-trial recall (A1-A3) and delayed 
recall (A5) compared to Tg controls and performed similarly to NT mice in all four 
cognitive measures.  GM-CSF treatment of NT mice did not result in significantly better 
performance compared to NT controls, although trends for a beneficial GM-CSF effect in 
NT mice were evident overall. For statistical analysis, both 2-day blocks were analyzed 
separately, as were all four days collectively. One way ANOVA’s were employed for 
each of the four behavioral measures analyzed, followed by post hoc Fisher’s LSD test to 
determine significant group differences at p < 0.05. (*Tg significantly different from 
NT+GM-CSF, **Tg significantly different from all other groups). (c) Cognitive 
Interference Task. Proactive Interference testing (First 2 days). GM-CSF-treated Tg mice 
performed significantly better than Tg controls and equally to NT and GM-CSF-treated 
NT mice. Statistical significance determined by one-way ANOVA (**p < 0.05 or higher 
significance versus all other groups).  
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Figure 43. Amyloid deposition in subcutaneous GM-CSF-injected mice. (a-d) 
Photomicrographs of coronal 5-µm paraffin-embedded sections immunolabelled with 
anti-Aβ antibody (clone 4G8 in Entorrhinal cortex (E) and hippocampus (H)). Since the 
4G8 antibody was obtained with biotin label, the secondary step of the ABC protocol was 
omitted. However, treatment with 70% formic acid prior to the pre-blocking step was 
necessary. Phosphate-buffered saline (0.1 mM, pH 7.4) was used instead of primary 
antibody or ABC reagent as a negative control.  Pictures are representative of amyloid 
load closest to the mean of the GM-CSF- or saline-treated Tg groups. Scale bar = 50 µm. 
(e) Percent of amyloid burden from the average of five 5-μm sections (150-μm apart) 
through both anatomic regions of interest (hippocampus and entorhinal cortex) per mouse 
of GM-CSF-treated (n = 5) versus saline- treated (n = 6). A threshold optical density was 
obtained that discriminated staining from background, and each region of interest was 
manually edited to eliminate artifacts.  Data are reported as percentage of immunolabeled 
area captured (positive pixels) relative to the full area captured (total pixels). Statistical 
significance was determined by two-tailed homoscedastic Student’s t-test with a p value 
of < 0.05 considered significant: Entorhinal cortex (*p  < 0.026), and Hippocampus (p = 
0.12).  
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Figure 44. Microglial immunostaining in subcutaneous GM-CSF-injected mice.  
(a-d) Photomicrographs of coronal 5µm paraffin-embedded sections immunolabelled 
with Iba-1 antibody in Entorrhinal cortex (E) and hippocampus (H). Normal rabbit serum 
was used instead of primary antibody or ABC reagent as a negative control. Pictures are 
representative of Iba-1 immunolabelling closest to the mean of the GM-CSF- or saline 
control- treated groups. Scale bar = 50µm. (e) Percent of Iba1 burden from the average of 
five 5-µm sections (150 µm apart) through both anatomic regions of interest (H and EC) 
per  mouse of GM-CSF-treated (n = 5) versus saline-treated (n = 6). A threshold optical 
density was obtained that discriminated staining from background, and each region of 
interest was manually edited to eliminate artifacts. Data are reported as percentage of 
immunolabeled area captured (positive pixels) relative to the full area captured (total 
pixels). Differences between the two groups were statistically significant by two-tailed 
homoscedastic Student’s t-test with a p value of <0.05 considered significant: H(p  < 
0.02), EC(p  < 0.05). 
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Figure  45. Synaptophysin immunostaining in subcutaneous GM-CSF-injected mice.  
(a-d) Photomicrographs of coronal 5-µm paraffin-embedded sections immunolabelled 
with anti-synaptophysin antibody. Normal rabbit serum was used instead of primary 
antibody or ABC reagent as a negative control.  Pictures are representative of 
synaptophysin immunolabelling closest to the mean of the GM-CSF- or saline control- 
treated groups. Scale bar = 50 µm. (e) Percent of synaptophysin immunoreactivity from 
the average of 5 sections per mouse of GM-CSF-treated (n = 5) versus saline control-
treated (n = 6). To evaluate synaptophysin immunoreactivity, after the mode of all images 
was converted to gray scale, the average intensity of positive signals from each image 
was quantified in the CA1 and CA3 regions of hippocampus as a relative number from 
zero (white) to 255 (black). Albeit numerically small, differences between the two groups 
were statistically significant by two-tailed homoscedastic Student’s t-test with a p value 
of < 0.05 considered significant: CA1(p  < 0.0013), CA3(p  < 0.0023). 
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CHAPTER 11 – DISCUSSION 
 
Neurodegeneration describes the selective and progressive loss of structure and 
function in neurons.  Although the initiating factors, symtoms, and pathologies of 
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s, Huntington’s, and 
Amyotrophic Lateral Sclerosis may be different, they share common pathophysiologies.  
Primary hallmarks of these pathologies are atypical accumulations of protein deposits, 
often due to misfolding.  Often associated with these deposits are dysfunctional 
mitochondria, oxidative stress, disrupted axonal transport, inflammation, and apoptotic 
cell death (DeLegge and Smoke, 2008; Gebicke-Haerter, 2001; Gendron and Petrucelli, 
2009; Swerdlow, 2009).  If these disruptions occur in motor neurons, as in ALS, motor 
function is impaired and if the deposits are found in cortical neurons, as in Alzheimer’s 
disease, the outcome is dementia (Soto, 2003; Weisman et al., 2006).  Why these neurons 
are selectively vulnerable in each disease is unknown and, unfortunately for many people, 
preventions and therapies remain elusive.  In the work described here, mouse models of 
neurodegenerative disease were used to investigate promoters and inhibitor of 
neurodegeneration in the proteinopathies ALS and AD.  
Mouse models are a common and useful research tool for investigating disease 
pathology and developing potential therapies prior to clinical trials in humans.  In 
comparison to other animals, their short lifespan averaging 2.5 years, high reproductive 
rate, and relative ease of modification for the incorporation and expression of transgenes 
make mice ideal for studying human diseases.  Additionally, controlled and standardized 
environments keep behavioral testing rather objective and every mouse is completely 
naïve to each experiment.  Therefore, responses to novel environments are controlled and 
readily quantifiable.  Another benefit of mice, though a potentially confounding variable, 
is their hardy immune system.  They are very capable of resisting iatrogenic infection 
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during intracranial and intrathecal penetration as well as during subcutaneous 
implantation of osmotic pumps in conditions where complete sterility is simply not 
possible. 
 There are also some clear disadvantages and challenges to using transgenic mouse 
models.  In both AD and ALS, only 5-10% of the disease is caused directly by gene 
mutations (Gros-Louis et al., 2006; Hardy, 2006).  The efficacy of genetic approaches to 
the study of neurodegenerative diseases is also limited by the fact that many such 
disorders have a wide display of phenotypes and varied etiology.  In addition, the 
interpretation of results obtained in animal models has to integrate the fact that often non-
physiological levels of selected proteins such as Aβ or SOD1 are used to recapitulate a 
disease in a mouse within a reasonable experimental time frame.  Moreover, because it is 
not yet known if the proteinaceous aggregates in these diseases are causes, byproducts, or 
neuroprotective factors, one must be mindful of the exact query to the system and of the 
interpretation of the results.   In addition, while it is reasonable to try possible 
interventions on already established mouse models instead of engaging in the time 
consuming and tedious process of producing alternative mouse models, approaches with 
suboptimal mouse models can sometimes fail to produce conclusive answers.   It may be 
in this context that several of the experiments conducted here did not result in favorable 
outcomes.  For example, many animals in my experiments were designed to make 
amyloid plaques, tau tangles, and SOD1 inclusions.  Naturally studies that focused on 
exacerbating or ameliorating these phenotypes were more successful than testing 
compounds involved in a different, though important, facet of the disease. 
 The focus of my work presented here has been on mouse models of 
neurodegenerative diseases, taking the good with the bad.  I successfully studied the 
permeability of the blood brain barrier and the spontaneous formation of autorosettes in 
the SOD1 G93A mouse.  Other positive results were obtained from practical, engineering 
approaches to working with the mice.  Intrathecal delivery of compounds in mice is 
arduous, and historically experiments that required delivery of compounds into the CSF 
would enter through the lateral ventricles.  Over some time, I have developed a tool and 
technique to effectively and reproducibly deliver compounds directly to the site of early 
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ALS pathology in the lumbar region of the spinal cord.  After years of struggling with 
commercially available intracranial catheters and experiencing high mortality rates, 
infections, physical damage to hardware or the animal, and pain/discomfort, enough 
incentive to devise a better means presented itself.  Not only can the patented intracranial 
catheter assembly obviate concern for these pitfalls, but it solved another major issue 
with the AD mice: plaque variability within the colony.  If one hemisphere could serve as 
the other’s control, differences in amyloid load between genetically identical animals 
could be compensated. In another novel application, though not a novel concept, I used in 
vivo electroporation, into the CNS, a procedure that had not been published for such use 
at the time I started out.  Although it may appear rather crude, electroporation is an 
excellent tool for “proof of principle” gene delivery prior to designing attenuated viral 
vectors (Heller and Heller, 2006).   
Ultimately, scientific success was generally achieved by directly focusing queries 
on what the mouse models were designed for (inclusions, plaques, tangles) or 
characterization of these pathologies in mice.  Human tau mice were used to investigate 
phosphorylation and tangle formation, and PS/APP mice were used to study the effects of 
ACT and plaque build up.  Most noteworthy are the experiments that reduce plaque load 
in the animals, which was achieved with 2 completely different approaches (Aβ 1-11 and 
GM-CSF).  It is still unknown whether plaques and tangles are the cause of AD or a 
bystander effect, but they are nonrtheless the focal point of most AD research. 
 The first set of experiments focused on a well-studied and relatively common 
aspect of neurodegenerative disease: transmissibility.  In 1994, Stanley Pruisner received 
the Nobel Prize for ground breaking work with prion protein.  Bovine spongiform 
encephalopathy (BSE), scrapie of sheep, and Creutzfeldt-Jakob disease (CJD) of humans 
are the most commonly known prion diseases (Prusiner, 1998).  Prions are proteins that 
can acquire a misfolded conformation that nucleates the misfolding of other normally 
folded prion proteins and form beta sheet amyloid structures (Wickner et al., 2008).  It 
has since been discovered that amyloid plaques from post-mortem human or mouse brain, 
once suspended and injected into the brain of a young PDAPP transgenic mouse, can 
trigger the early seeding of plaques (Walker et al., 2002).  More recently, it has been 
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shown that a misfolded tau mutant could seed tangle formation when injected into an htau 
mouse (Clavaguera et al., 2009).  We hypothesized that such an outcome could also be 
triggered by SOD1 aggregates to initiate ALS.  After homogenizing spinal cords from 
end-stage SOD1 G93A animals, the homogenates were infused into the lumbar cistern of 
younger transgenics to see if ALS pathology could be seeded or accelerated.  Prior to our 
experiments, there were conflicting reports from breeding experiments with mutant and 
wild type SOD1 mice stating that the mutant SOD1 may exert a conformational change in 
the WT and accelerate the disease (Wang et al., 2009), whereas other groups found no 
difference (Bruijn et al., 2004b).  When SOD1 aggregates were infused in our 
experiments, we could not detect any changes in the behavior or lifespan in the animals.  
Our negative result could be explained as follows: 1) Aggregates were infused into the 
CSF and not directly into the tissue out of concern about causing damage to the animal.  
2) There was already a ceiling effect with ~18 copies of mutant SOD1 being expressed, 
and the infusions could not enhance this effect any further.  Moreover, the human SOD1 
gene is flanked by Alu repeats (retrotransposons) (Maguire et al., 2006) and colonies 
would eventually begin to lose copy number as a result.  As mentioned in Chapter 2, 
Mark Gurney, the investigator who discovered the G93A mutation, disclosed in a 
personal communication that his own lab has not use this SOD1 transgenic mouse model 
for quite some time. The SOD1 G93A mouse was designed to form inclusions and 
develop an aggressive paralytic phenotype after only 100 days of age and persists for 30 
days until the animals had to be euthanized.  Although this therapeutic window seems 
appealing to researchers for successive high throughput drug studies, the most effective 
therapies have been siRNA (Rizvanov et al., 2009) and antisense oligonucleotides (Smith 
et al., 2006).  In addition, these approaches would only be useful in reducing the amount 
of mutant protein that is being heavily overproduced.  Accordingly, these therapies might 
only translate to individuals with that particular SOD1 mutation, while there are in fact 
over 150 ALS-causing SOD1 mutations known (Turner and Talbot, 2008).  While 
inflammation and excitotoxicity are very clearly implicated in ALS pathogenesis, we 
came to conclude that SOD1 aggregation has the most dominant effect.  Therefore DTG 
and KDI, though potentially useful compounds, had only marginal if any effect on this 
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mouse model.  However, given the potential of both of these compounds, further research 
in other models (G85R, G37R), even prophylactically, may be warranted but was not 
pursued by our lab. 
 As previously stated, some of our observations in the SOD1 G93A mouse were 
noteworthy.  Inflammation is a hallmark of all neurodegenerative disorders and is evident 
in this model from activation of microglia and astrocytes (DeLegge and Smoke, 2008; 
Gebicke-Haerter, 2001).  Recently it was also suggested that the adaptive immune system 
plays a role in ALS (Banerjee et al., 2008).  In chapter 3, we show that the blood brain 
barrier is compromised in the G93A mouse.  Previous work showed that T cells 
(Donnenfeld et al., 1984b; Engelhardt and Appel, 1990; Engelhardt et al., 2005a; 
Mohamed et al., 2002) and IgG (Alexianu et al., 2001; Engelhardt et al., 1993b) were 
actually present in high amounts in the CSF of ALS patients and also in these mice 
(Garbuzova-Davis et al., 2007a).  The increased permeability of the BBB in later stages 
of the disease would provide a logical explanation for this phenomenon.  Furthermore, 
we have identified the formation of autorosettes in this model (appendix A), which has 
been shown to be a T cell marker.  Taken together, our observations show that ALS may 
involve activation of both the innate and adaptive immune systems.  Unfortunately, the 
model was of little use for the study of potential therapeutics.   
It was at this time that I shifted my efforts from studies on ALS to investigations 
related to Alzheimer’s disease.  Initially I transferred the idea of testing KDI, the 
tripepetide of γ-laminin, as a potential therapeutic for neuodegenerative diseases to the 
treatment of cognitive impairment.  We investigated the effects of KDI on plaque load in 
treated PS/APP and Tg2576 mice, no changes were observed.  Nonetheless, the reported 
potent in vitro effects of KDI as a neurite outgrowth factor and NMDA/AMPA receptor 
antagonist (Moykkynen et al., 2005) (similar to Namenda) left us optimistic that it could 
provide some benefit to the mice.  Because the first cohort of KDI treated animals, as 
shown in chapter 7, showed marked restoration in cognitive abilities as tested with the 
RAWM, the effects of KDI on LTP and synaptogenesis were investigated.  While the 
brains from the first cohort were analyzed, the second cohort of animals was starting on 
their 28 day infusions.  Using immunohistochemical analyses, synaptic markers including 
 202 
synaptophysin, synaptotagmin, synaptopodin, synaptobrevin, GAP-43, and PSD-95 
antibodies revealed no changes between treated and untreated mice; the possibility of 
delivering bilaterally was not yet available at this time.  In another hypothesis we 
speculated that we were interfering with the glutamate neurotransmission in such a 
manner as to stimulate the phosphorylation, thus activation, of dormant AMPA receptors 
leading to the possibility that KDI was inducing LTP.  GluRI, pGluRI, CamKII, and 
pCamKII levels were compared between KDI treated and untreated mice, but no 
differences were observed.  Moreover, additional behavior tests that were performed 
twice with new animal cohorts, but did not show significant differences between KDI-
treated and untreated animals either.  We interpreted this outcome as follows: 1) If the 
data published on KDI and its ability to function as a potent non-competitive ionotropic 
glutamate receptor antagonist is accurate, then our results just show little relevance of 
glutamate dysregulation in AD, i.e KDI does not yield a therapeutic effect in AD, which, 
at the same time, helps to explain Namenda’s modest benefit. 2) The chosen mouse 
model was possibly not the best system to investigate the relevance of excitotoxicity in 
AD. 3) KDI’s effects had, for the most part, been limited to in vitro studies and cannot be 
translated to the mice. 
 When studying the htau mice, we focused directly on phosphorylation events that 
lead to tangle formation.  Tau has ~45 AD-related phosphorylation sites, and numerous 
kinases and phosphotases are responsible for regulating the phosphorylation status and 
thus the conformation of tau.  Previous in vitro work from our laboratory showed that in 
most tauopathies, including CBD, PSP, FTDP-17, and AD, antichymotrypsin is 
upregulated and subsequently found in aggregates in post mortem brain tissues 
(Padmanabhan et al., 2006).  This observation was of particular interest to us, because 
ACT is well-established to have a role in Aβ fibrillization in vitro (Ma et al., 1996) and 
amyloid plaque formation in transgenic mice (Nilsson et al., 2001).  ACT, like ApoE, has 
been termed a “pathological chaperone” (Wisniewski and Frangione, 1992) in the 
development of plaques in AD.  In chapter 8, I demonstrated how chronic intracranial 
infusion of ACT into an htau mouse increased levels of pSer 202, PHF-1, and pThr231 in 
tau and that the intracellular kinase, GSK3, was activated.  GSK3 has been implicated in 
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the phosphorylation of several sites on tau, including pThr231 and pSer394/404 (PHF-1) 
(Hooper et al., 2008), and my findings are consistent with these observations.  One 
notable difference between my study and previous in vitro work was that pERK was 
found in much lower amounts (deactivated) in after infusion of ACT.  Thus in cultured 
mouse cortical neurons, adding ACT to the media increased levels of pERK in a dose 
dependent fashion (Padmanabhan et al., 2006) whereas in vivo, the opposite effect 
seemed to occur.  These results are from a pilot study of 5 mice, only 4 of which clearly 
received ACT.  This work will be followed up as a full study with more animals in 
anticipation of revealing other phosphorylation sites as well as putative kinases.  
Additionally, it is not yet known if it is the physical presence or protease inhibiting 
activity of ACT that induces these events and whether they occur from ACT interacting 
with elements on the cell surface of neurons or after endocytosis.  These possibilities 
would need to be addressed in order to determine how to best inhibit ACT-mediated tau 
phosphorylation and tangle formation. 
 ACT is of particular interest because it provides a link between the hallmark 
pathologies of AD.  It is directly involved in the fibrillization of Aβ and the formation of 
plaques and has been shown to induce tau phosphrylation by GSK-3 at sites known to be 
involved in Alzheimer’s disease (Padmanabhan et al., 2006). Therefore, inhibition or 
downregulation of ACT, which is highly upregulated during, AD may be of therapeutic 
interest.  Early observations from our lab suggest that Aβ has strong homology in the N-
terminus with both cathepsin G and chymotrypsin, both of which are serine proteases and 
known serine protease targets of ACT (Abraham and Potter, 1989).  It is therefore 
conceivable that ACT is upregulated to bind Aβ in order to sequester it from forming 
plaques or oligomers, but that ACT becomes outcompeted by the amount of substrates 
and overwhelmed in the process. 
 Historically, ridding the brain of plaques and tangles has been the major 
therapeutic goal, either through stimulation or inhibition of the innate and adaptive 
immune systems (Maccioni et al., 2009) or more direct mechanisms. The involvement of 
ACT and ApoE in the formation of amyloid plaques and concomitant activation of 
microglia and astrocytes and release of cytokines and chemokines support the theory that, 
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as in all neurodegenerative diseases, inflammation is a major aspect of AD pathogenesis.  
Whether this is a primary or secondary event to the formation of oligomers and plaques is 
uncertain, as well as whether or not it is beneficial or detrimental to have triggered an 
immunological response.  Microglia, for example, are known to release proinflammatory 
cytokines (Hanisch, 2002) and also to engulf amyloid (Herber et al., 2007).   
 In chapter 9, I describe the use of a “decoy” Aβ peptide (1-11) to reduce the 
amount of amyloid formed.  The rationale for this approach came from previous in vitro 
work from our laboratory in which the amount of Aβ fibrils was enhanced in the presence 
of ApoE and ACT, but that such catalyzed fibrilization could be attenuated by adding Aβ 
fragments 12-28 and 2-9, respectively.  These peptides include the binding regions for 
ApoE and ACT on full length Aβ and they, might block these proteins from binding Aβ 
and rendering the reaction mixture less toxic to cultured neurons, especially with 
increasing amounts of the decoy peptides (Ma et al., 1996).  In 2006, Wisniewski et al. 
published a study in which they had taken the 12-28 peptide and, with some modification, 
injected the molecule systemically into Tg2576 mice (with and without PS1 M146L).  
This treatment resulted in a significant reduction in plaque load and improved cognition 
in behavioral tasks (Sadowski et al., 2006).   The same rationale was applied in our 
attempt to interfer with the interaction of ACT and Aβ when we introduced the peptide 
fragment 1-11 (containing the 2-9 binding site of ACT on Aβ) in PS/APP mice as they 
were developing plaques.  The peptide was infused intrahippocampally into a small pilot 
of PS/APP mice, unilaterally, with aCSF to the contralateral hemisphere for direct 
comparison of plaque load.  As shown in the figures of chapter 10, the peptide not only 
significantly reduced new plaque formation, but appears to have cleared existing plaques 
as shown with both the 6E10 antibody (binds Aβ 1-16) and 4G8 antibody (binds Aβ 17-
24).  Most likely, the peptide binds to the “ACT equivalent” in the mouse or serpin A3N, 
which is identified in the plaques of these mice with anti-ACT antibodies.  The 
mechanism for the clearance is unknown, but Iba1 microglial staining is virtually absent 
from the treated hemisphere, indicating that these cells are not present or that the 
respective epitope is not accessible.  Further investigation is needed to determine the 
putative mechanisms of clearance as well as to infuse the peptide bilaterally for 
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behavioral analyses.  Ultimately, modification of the peptide to reduce immunogenicity 
and increase its half life, could allow systemic dosing and yield a potential AD therapy. 
 In another part of my dissertation research, I investigated the negative correlation 
between patients with Rheumatoid arthritis and AD.  We hypothesized that there were 
factors upregulated in the autoimmune disease that conferred neuroprotection and 
reduced if not eliminated the risk of developing AD. Although up-regulated leukocytes in 
RA could potentially enter into the brain and inhibit development of AD pathology 
and/or neuronal dysfunction, lymphocytic infiltrates into AD patient brains have not been 
reported. The lack of infiltration suggests that activation of the innate immune system 
might be responsible for preventing AD pathology in RA patients.  Originally, 3 
cytokines were identified as upregulated in RA and of potential interest: G-CSF, M-CSF, 
and GM-CSF..  These CSFs enhance the survival of their respective leukocytes and drive 
their proliferation and differentiation from monocytic precursors.  M-CSF and G-CSF 
induce specific subsets of the innate immune system, while GM-CSF induces the full 
range of innate cells.  Bolus injections of 5 μg per hemisphere showed significant plaque 
reductions after only 1 week (see chapter 11). This success led us to begin a subcutaneous 
dosing regime and performed behavioral analyses.  The improved cognitive function and 
reduced cortical amyloidosis of GM-CSF-treated Tg mice was paralleled by increased 
synaptophysin immunoreactivity in both CA1 and CA3, indicating increased synaptic 
density in these hippocampal areas.  Further investigation into GM-CSF to elucidate its 
mechanism in AD is in progress as well as the initiation of clinical trials with Leukine an 
FDA approved drug of recombinant GM-CSF currently in use for recovery from 
chemotherapy. 
It is a remarkable and unfortunate fact that despite the enourmous knowledge that 
has been acquired about ALS and AD, effective cures or even treatments for both 
diseases have been elusive.  Much debate exists on whether protein aggregation is an 
initiating factor in neurodegeneration or a side effect.  Similar debate questions whether 
activation of the immune system is beneficial or detrimental to CNS function in 
neurodegenerative diseases.  Our research suggests the former.  In AD, some reports state 
that cognition is closely linked to plaque load in the mice (Gordon et al., 2001), 
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suggesting that, even without neuron loss, the plaques cause behavioral deficits.  
Conversely, other studies show no change in plaque load with improved cognition (Costa 
et al., 2007).  Nonetheless, the studies discussed here focused primarily on the use of 
transgenic mouse models of protein aggregation and on procedures that could exacerbate 
or inhibit the effect.   The specific focus of my work was on the development of novel 
means of drug and gene delivery into transgenic mice.  The fact that certain compounds 
did not affect protein aggregation still leaves the possibility that they might have 
therapeutic potential if tested in other systems.  However, unquestionably, the delivery 
systems developed along the way, have implications that reach beyond AD and ALS as 
they can each be readily adapted for investigations with virtually all mouse models of 
neurodegenerative disease. 
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Appendix A- Lymphopenia and Spontaneous Autorosette Formation in an SOD1 
Model of ALS 
 
Oleg I. Kuzmenok a, Paul R. Sanberg a,b,d,e,f, Tammy G. Desjarlais a, Steven P. 
Bennett g, Svitlana N. Garbuzova-Davis a,b,c,d,* 
 
Abstract 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by 
motoneuron degeneration. Increasing evidence suggests immune system involvement in 
ALS pathogenesis but information about peripheral blood characteristics has been 
lacking. We evaluated hematological and morphological parameters in peripheral blood 
of G93A SOD1 mice. A significant decrease in white blood cells was found at the end 
stage of disease. The lymphocyte reduction may suggest immunodeficiency in ALS. 
Spontaneously forming rosettes with autologous erythrocytes were noted in 
approximately 28% of lymphocytes in SOD1 mice. To our knowledge, this is the first 
study characterizing hematology and revealing autorosettes in the SOD1 mouse model of 
ALS at the terminal phase of disease. 
 
 Introduction 
 
Currently, amyotrophic lateral sclerosis (ALS) is the most frequently occurring motor 
neuron disease lacking effective therapy (Mulder et al., 1986). About 10% of cases are 
dominantly inherited and about 20% of those arise from mutations in the gene for Cu/Zn 
superoxide dismutase (SOD1). The pathogenic mechanism of ALS is unknown and there  
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is no identified biological marker of disease progression that can be  monitored in ALS  
patients. In ALS spinal cord tissue, the presence of T cells (Alexianu et al., 2001), IgG 
deposits (Mohamed et al., 2002; Engelhardt and Appel, 1990), monocytes and activated 
macrophages (Henkel et al., 2004), suggests that these immune effectors are involved in  
the inflammatory process. Inflammatory response occurs in the CNS through 
mechanisms that differ from systemic inflammation (Consilvio et al., 2004), as described 
for ALS patients (McGeer and McGeer, 2002). Several transgenic mice modeling ALS  
expressing mutated human SOD1 have been created. The first and most widely used is 
the G93A mouse that overexpresses human SOD1, carrying the Gly93 Ala mutation and 
that develops an ALSlike motor neuron disease. G93A SOD1 mice show motor neuron 
pathology similar to ALS patients (Gurney et al., 1994). Still, we lack information 
regarding the hematological characteristics of both ALS patients and animals. 
Characteristics of complete blood count (CBC) and white blood cell (WBC) differential 
may therefore help elucidatethe type of pathogenic processes present during disease, very 
important for developing a treatment strategy. Previously, an increasing number of 
circulating neutrophils found in ALS patients had been described (Desport et al., 2001).  
However, statistically significant differences between the number of neutrophils in ALS 
patients and neutrophils’ normal range were not shown. The aim of the present work was 
to evaluate the complex hematological and morphological 
parameters in peripheral blood from the G93A SOD1 mouse model of ALS2.  
 
Materials and methods 
 
Mice 
 
Transgenic male mice B6SJL-TgN 1GUR (G93A) obtained from Jackson Laboratories, 
Bar Harbor, MA, overexpressing human SOD1, carrying the Gly93 to Ala mutation 
(Gurney et al., 1994), were used (n =12). Transgenic mice (BL6/SJL) carrying the normal  
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allele for human SOD1 gene (n =5, hTg) and C57BL/6 animals (n =7), matched by age 
and gender to experimental animals were used as controls. All animal experiment 
procedures were approved by the Institutional Animal Care and Use Committee at USF 
and conducted in compliance with the Guide for the Care and Use of Laboratory 
Animals. 
 
Blood samples 
 
The blood samples were obtained from G93A mice at the terminal stage of disease when 
mice developed hind limb paralysis (18–19 weeks). Samples were also obtained from 
hTg and C57BL/6 mice of the same age, 18–19 weeks. Mice were sacrificed under deep 
chloral hydrate (10%) anesthesia and about 300 Al of blood was taken transcardially and 
collected into blood collection tubes with EDTA(K3) (Sherwood Medical, MO). 
Analyses for CBC and WBC differential were performed by Antech Diagnostics. 
(NY, USA). Additionally, blood smears (3 from each animal) were taken from the tail 
vein for morphological analysis. The smears were dried for 30 min, fixed in methanol for 
7 min, then stained by Giemsa (Sigma- Aldrich, GS80, St. Louis, MO) as previously 
described (Brown and Febiger, 1993). 
 
Morphological evaluation of blood smears 
 
After staining, blood smears were rinsed several times in distilled water and cover-
slipped with Permount (Fisher Scientific, Fair Lawn, NJ). The morphology of the 
peripheral blood cells was examined under an Olympus BX-60 microscope. The images 
were analyzed by Image-Pro Plus version 4.1 for Windows software (Silver Spring, 
MD). Rosette counts were performed using the full area of the slide. 
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Statistical analysis 
 
All data on CBC count and WBC differential were analyzed by ANOVA (analysis of 
variance). The results are presented as means TSEM. Significance between the results 
for different groups was estimated using the two-tailed Student’s t-test. 
 
Results 
 
Hematological analysis 
 
The blood samples were obtained from G93A mice at the terminal stage of disease (about 
18–19 weeks of age). All G93A mice had severe disease progression (complete hind limb 
paralysis) at the time of blood collection. The main characteristics of the red and white 
blood cells from G93A and control (hTg and C57BL/6) groups of mice are presented in 
Table 1. The red blood cell counts did not differ between G93A mice and the two control 
groups. However, the platelet numbers were increased in G93A mice without statistical 
significance. In G93A mice, WBC numbers were drastically reduced (0.7_103/AL, p 
<0.001) compared to control hTg mice (2.6_103/AL) and C57BL/6 (3.8_103/AL). 
Lymphocyte density in G93A mice (0.26_103/AL) was 8.4 times lower than in hTg mice 
(2.22_103/AL) and 10 times lower than in C57BL/6 mice (2.66_103/AL). The absolute 
number of circulating monocytes and eosinophils also decreased ( p <0.05) in G93A 
mice. The basophil number was significantly increased in G93A mice compared to hTg 
mice ( p <0.05), but not to C57BL/6 mice. This dramatic reduction in the number of 
lymphocytes in peripheral blood may suggest severe immunodeficiency in ALS. 
Leukocytes are typically recruited from circulation into local sites of inflammation, 
where the cells perform their functions to reduce tissue alterations. However,  neutrophil 
levels, which can reflect acute inflammation in peripheral blood of G93A mice, did not 
significantly differ from control animals. 
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Morphological examination of the peripheral blood in SOD1 mice 
 
Routine blood smears can still be useful and informative if current views on disease 
pathogenesis are incorporated during their perusal. Morphological examination of 
peripheral blood from G93A mice showed a number of lymphocytes spontaneously 
forming rosettes with autologous erythrocytes or autorosette-forming lymphocytes 
(aRFL) (Fig. 1A,B). The mean percentage of aRFL was 27.7T3.3 in the peripheral blood  
from G93A mice. The average number of erythrocytes which formed rosettes around one 
lymphocyte in G93A mice was 8.6T3.2. A squeezed shape of erythrocytes in rosettes was 
noted. The aRFL were found in two thirds of G93A mice but not in the peripheral blood 
of C57BL/6 (Fig. 1C) or hTg (Fig. 1D,E) control animals. 
 
Discussion 
 
It has been shown that the immune system is involved in ALS in human and G93A mice 
(Alexianu et al., 2001; Mohamed et al., 2002; Engelhardt and Appel, 1990). The 
clinical significance and degree of involvement of the immune system in ALS is still 
controversial. Nyland and Naess (1978) reported that T lymphocytes in the peripheral 
blood of ALS patients were not significantly reduced. However, other clinical studies 
found decreased totals of blood lymphocytes and increased percentages of B-cells and 
IgM (Khondkarian et al., 1985) and reductions of T mu cells, which bear Fc receptor for 
IgM (Westall et al., 1983). Moreover, Provinciali et al. (1988) showed significant marked 
lymphopenia, reduction of CD2, CD8 and Leu 7 positive cells and an increase of the 
CD4/CD8 ratio in ALS patients at early disease stage. From these results, it is clear that 
immunopathological reactions in ALS are occurring and may depend upon duration, 
severity, and cause of disease. However, biological markers of this disease are still 
uncertain. Utilizing CBC and WBC differential, we were the first to find a significant  
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decrease of WBC numbers in G93A SOD1 mice at the end stage of disease. Decreased 
WBC in G93A mice was mainly due to declines in lymphocyte density, 8.4 times lower 
than in hTg mice and 10 times lower than in C57BL/6 control mice. Significantly 
decreased numbers of peripheral monocytes and eosinophils in G93A mice versus control 
animals were also noted. These findings may suggest severe immunodeficiency in these  
animals at the terminal stage of disease. Since the transgenic G93A mice have a high  
number (¨20) of copies of mutant SOD1, it is possible to suggest that peripheral blood 
results are be linked to ALS gene mutations. This SOD1-mediated toxicity may involve a 
cascade of events including depletion of peripheral lymphocytes. Also, we cannot 
exclude the possibility that ‘‘consumption’’ of these cells is extremely high, causing their 
disappearance fromperipheral blood. Monocytopenia and eosinopenia can be considered 
as prognostic features in ALS. An eosinophil is a type of phagocyte that  
produces the pro-inflammatory protein histamine, as well as nerve growth factor (NGF) 
and neurotrophin-3 (NT-3) (Kobayashi et al., 2002). Although most eosinophilic 
leukocytes are localized in mucosal tissues, perhaps these cells can migrate from blood 
into neural tissue following chemo-attraction signals, as demonstrated for T-cells (CD4, 
CD8) (Alexianu et al., 2001) and monocyte/macrophages (CD14, CD68) (Henkel et al., 
2004). Also, mucosal immune responses could be involved in ALS pathogenesis and that 
the redistribution of white cells from the blood may be mediated by mucosal chemo-kines 
(Belyakov and Berzofsky, 2004). However, the significance of mucosal immunity in the 
pathogenesis of ALS is likely linked to the possibility of viral infection. The role of 
basophils is not completely understood. Basophils circulate for a few hours in blood and 
migrate into tissues where they may reside for several weeks as mast cells. Basophilia 
commonly indicates the presence of myeloproliferative disease as opposed to leukemoid 
reaction but can be a consequence of allergy, hypersensitivity reaction, metabolic or 
endocrine disorders (Bochner and Schleimer, 2001), chronic basophilic leukemia, or 
Hodgkin’s disease (Pardanani et al., 2003). Basophils complete their differentiation in 
bone marrow and appear in the peripheral blood as mature basophils. Recently, these  
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blood cells have been shown to be important regulators of humoral immune responses by 
their influence on B cell function (Mack et al., 2005) and they can be recruited to sites of 
inflammation (Wedemeyer et al., 2000). Observed basophilia in G93A mice may reflect 
the inflammatory process in the spinal cord, involving mast cells, macrophages and T 
cells, as recently described in ALS patients (Graves et al., 2004). The link between  
basophilia and lymphopenia observed in G93A mice at end-stage disease needs further 
investigation, and we will initially focus upon possible alterations in bone marrow 
function. Interestingly, red blood cell parameters in ALS mice did not statistically differ  
from both control groups of animals. Only one hematological parameter has been 
previously noted in ALS patients, an increased number of circulating neutrophils 
correlating with hypermetabolism (Desport et al., 2001). The reason for the association 
between elevated neutrophil levels and hypermetabolism is still unknown. However, our 
data on neutrophils contained in peripheral blood of G93A mice did not support this 
neutrophil observation in patients. Additionally, the platelet numbers were increased in 
G93A mice without statistical significance. However, these results have coincident with 
recently published data (Kiktenko et al., 2005), that platelet activation was found in ALS 
patients. Platelet activation was more pronounced in ALS than in multiple sclerosis  
(Kiktenko et al., 2005). It is clear that the presence of white blood cells in the peripheral 
blood has been significantly reduced in G93A mice at end stage disease, but the 
mechanism underlying this decline is unclear. Since white blood cells ultimately originate 
from bone marrow, it is possible to suggest that production of these cells has been 
impaired. However, we cannot exclude potential involvement of secondary lymphoid 
organs such as the spleen or lymph nodes in this pathology. Presently, we are performing 
phenotypic characterization of lymphocytes in peripheral blood, primary and secondary 
lymphoid organs and degenerating areas of the brain and spinal cord in G93A mice 
modeling ALS. Correlation of lymphocyte densities among these locations is currently 
under investigation. It will also be important to determine if reductions in leukocytes, 
especially lymphocytes, in peripheral blood correlate with disease progression. Our other  
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finding was spontaneous aRFL in G93A mice at the terminal stage of disease. Rosette-
formation has been previously noted in some pathological conditions. The ability of 
lymphocytes to bind with autologous erythrocytes has been observed in patients with 
autoimmune thyroiditis and cancer (Endo et al., 1984; Tamura et al., 1984; Ichikawa et 
al., 1983). Subpopulations of T-lymphocytes (CD4) forming aRFL in peripheral blood 
from patients with thyroid diseases (Endo et al., 1984), lupus erythematous (SLE) 
(Ichikawa et al., 1983) and non-Hodgkin’s lymphomas (Tamura et al., 1984) has been 
reported. Finally, aRFL evaluation has been proposed as a criterion of autoimmune  
pathology. However, the usual protocol for aRFL evaluation includes the mitogen-
induced activation of lymphocytes in vitro by pokeweed and phytogemagglutinin 
mitogens for rosette formation (Ichikawa et al., 1983). Our results, showing aRFL in ALS 
mice without lymphocyte stimulation by mitogens or other activators, may indicate 
involvement of an autoimmune mechanism in the etiopathology of ALS. As is well 
known, autologous rosette incidence is also abnormally high in nude (congenitally 
athymic) mice. The high numbers of aRFL found after adult thymectomy can be 
normalized by injection of thymic hormones, suggesting that aRFL might be associated 
with immature T-cell precursors (Charreire and Bach, 1975). The phenomenon of 
spontaneous aRFL noted in G93A mice suggests that early precursors from thymus or 
bone marrow may be involved in forming aRFL. However, phenotypical analysis of 
lymphocyte maturation should be performed to confirm this involvement and a future 
study will include this analysis. We hypothesize that the lymphopoietic system is 
involved in ALS and that impairment of this system critically influences immune system 
function. This is the first evidence that peripheral blood of transgenic G93A mice 
contains autologous rosette-forming lymphocytes. Further investigation of autoimmunity 
and pathologically significant antigens in ALS is warranted. 
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Table 4. Complete blood cell count and white blood cell differential in SOD1 G93A 
mice  as compared to control mice 
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Figure 46. Morphological analysis of peripheral blood cells (Giemsa staining). 
Spontaneous autorosette-formations were found in G93A mice (A, B, arrows) at end 
stage of disease. A squeezed shape of erythrocytes in rosettes was noted. Normal 
morphological characteristics of peripheral blood cells were noted in C57BL/6 (C) and 
BL6/SJL (hTg) control animals (D, E). 1— autorosette forming by lymphocytes; 2—
lymphocyte, 3—platelet, 4— reticulocyte; 5—monocyte; 6—segmented neutrophil; 7—
basophil; 8—erythrocyte. Scale bar in A–E is 25 Am. 
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Supplementary Figure 1. Significant variation of amyloid plaque load between mice.  
Animals (PS/APP, all 8.8 -9.6 months, numbered sequentially according to date of birth, 
25-35 g, both genders) were anesthetized with 1-2% isoflurane, shaved and scrubbed with 
10% Betadine solution at the site of incision, and placed into a stereotaxic frame (Kopf 
Instruments, Tujunga, Ca.).  A small (3 cm) incision was made, exposing the skull, and 
curved Strabysmus surgical scissors were used to form a subcutaneous pocket along the 
animal’s back into which 2 osmotic minipumps (Alzet model 1004, average flow rate of 
0.12 µL/hour, Durect Corp., Cupertino, CA) were inserted.  Two holes were drilled into 
the skull (from Bregma -0.1 mm anterior-posterior, +/- 0.9 mm medial-lateral), and 30 
gauge catheters were inserted at a depth of 3.0 mm, corresponding to the lateral 
ventricles. Leading from the Alzet pump was a proprietary catheter system (patent 
pending - PCT/US08/73974) with the delivery tips fashioned to the contours of the skull 
rather than the commercially-available pedestal cannula. The cannulae are affixed to the 
skull using Locktite 454 adhesive (Plastics One, Roanoke, VA) and secured with 1 cm 
diameter nitrile, followed by silk sutures to close the scalp. After 2 weeks of bilateral 
intracerebroventricular infusions of M-CSF, mice were perfused, brain tissues were fixed 
in 10% neutral buffered formalin, and cryosectioned at 14 µm. Standard fluorescent 
immunohistochemistry used 6E10/Alexa 488 and Hoechst nuclear stain (blue). Bright 
green spots indicate amyloid plaques. Pictures taken at 5X. Mouse numbers 148,160,171, 
and 211 received M-CSF and mice 164, 170, 176, and 177 received aCSF.  
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Supplementary Figure 2.  Intrahippocampal injection of  M-CSF (left) and aCSF (right). 
(A) The image is a montage of ~35 5X pictures and is representative of the effects seen 
from anterior hippocampus to posterior in all 4 M-CSF-injected mice. (B) This photo 
shows enlargement of the M-CSF-injected left hemisphere, as seen following saline 
perfusion. Note the small bump at the site of injection (arrow). (C) Image shows cyst or 
tumor-like growth formed in the needle track at the site of M-CSF injection. 
Cryosectioned at 14 µm and stained with 6E10/Alexa 488 and Hoechst. Picture taken at 
20X. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix B: (Continued) 
 
 
 
 
 
 
 
 
 
 
 253 
 254 
Appendix B: (Continued) 
 
Supplementary Figure 3. Intrahippocampal injection of G-CSF (left) and aCSF (right). 
Amyloid plaques indicated as white spots.  Visual observation of amyloid plaques show a 
modest reduction of plaque in the left G-CSF-injected hemisphere. Cryosectioned at 14 
µm and stained with 6E10/Alexa546 and Hoechst nuclear stain. Images are montages of 
~35 5X pictures each. Sections numbered 1 through 6 and correspond with anterior to 
posterior.   
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Supplementary Figure 4. Intrahippocampal injection of GM-CSF(left) and aCSF(right). 
Representative sections of each mouse proximal to injection site. Tissue sections stained 
with MabTech α-Aβ/Alexa 488. White spots indicate amyloid plaque immunolabelling. 
Images are montages of about 145 pictures taken at 10X. Figures 4A-C are from 14 µm 
frozen sections, and 4D is from a 5 µm paraffin-embedded section. 
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Supplementary Figure 5. Quantification of reduced amyloid deposition in 
GM‐CSF‐injected left hemispheres versus aCSF‐injected contralateral right hemispheres.  
There were 5 sections per mouse quantified. Each montaged section contained over 140 
10X pictures and of these, 15 - 25 pictures per hemisphere were selected to quantify as 
described in Supplementary Figure 6 online. All pictures per section were taken at the 
same exposure on a Zeiss Imager.Z1 fluorescence microscope with a Zeiss Axiocam 
Mrm camera (Oberkochen, Germany) using Axiovision 4.7 software. Each figure shows 
total or average values from the 5 sections/mouse with significance per individual mouse 
and overall. Error bars are ±SEM : (a - b) plaque areas (c - d) perimeter values (e) 
average feret diameters (f) average integrated densities 
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Supplementary Figure 7. Behavioral Tasks 
 
Radial Arm Water Maze.  For the RAWM task of spatial working memory, an aluminum 
insert was placed into a 100cm circular pool to create 6 radially-distributed swim arms 
emanating from a central circular swim area. An assortment of 2-D and 3-D visual cues 
surrounded the pool. The number of errors prior to locating which one of the 6 swim 
arms contained a submerged escape platform (9cm diameter) was determined for 5 
trials/day. There was a 30-min time delay between the 4th trial (T4; final acquisition trial) 
and 5th trial (T5; memory retention trial). The platform location was changed daily to a 
different arm, with different start arms for each of the 5 trials semi-randomly selected 
from the remaining 5 swim arms. During each trial (60 s maximum), the mouse was 
returned to that trial’s start arm upon swimming into an incorrect arm and the latency 
time required to locate the submerged platform was recorded. If the mouse did not 
find the platform within a 60-s trial, it was guided to the platform for a 30-s stay. The 
numbers of errors and escape latency during trials 4 and 5 are both considered indices of  
working memory and are temporally similar to standard registration/recall testing of 
specific items used clinically in evaluating AD patients. 
 
Cognitive Interference Task. This task was designed to mimic, measure-for-measure, a 
cognitive interference task recently utilized clinically to discriminate between normal 
aged, MCI, and AD patients. The task involves two RAWM set-ups in two different 
rooms, with two sets of visual cues different from those utilized in standard RAWM 
testing. The task requires animals to remember a set of visual cues (in RAWM-A), so that 
following interference with a different set of cues (in RAWM-B), the initial set of cues 
can be recalled to successfully solve the RAWM task. Five behavioral measures were 
examined: A1-A3 (Composite three-trial recall score from first 3 trials performed in 
RAWM-A), B (proactive interference measure attained from a single trial in RAWM-B), 
A4 (retroactive interference measure attained during a single trial in RAWM-A), and A5 
(delayed-recall measure attained from a single trial in RAWM-A following a 20-min  
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delay between A4 and A5). As with the standard RAWM task, this interference task 
involves the platform location being changed daily to a different arm for both RAWM 
set-ups. For A1 and B trials, the animal is initially allowed one minute to find the 
platform on their own before being guided to the platform. Then the actual trial is 
performed in each case. As with the standard RAWM task, animals were given 60s to 
find the escape platform per trial, with the number of errors and escape latency recorded 
per trial. 
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